<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">50279</article-id><article-id pub-id-type="doi">10.7554/eLife.50279</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Common activation mechanism of class A GPCRs</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-150446"><name><surname>Zhou</surname><given-names>Qingtong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8124-3079</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-150445"><name><surname>Yang</surname><given-names>Dehua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3028-3243</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150444"><name><surname>Wu</surname><given-names>Meng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150443"><name><surname>Guo</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150442"><name><surname>Guo</surname><given-names>Wanjing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150441"><name><surname>Zhong</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150440"><name><surname>Cai</surname><given-names>Xiaoqing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150439"><name><surname>Dai</surname><given-names>Antao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167263"><name><surname>Jang</surname><given-names>Wonjo</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59609"><name><surname>Shakhnovich</surname><given-names>Eugene I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4769-2265</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104725"><name><surname>Liu</surname><given-names>Zhi-Jie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7279-2893</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104728"><name><surname>Stevens</surname><given-names>Raymond C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144772"><name><surname>Lambert</surname><given-names>Nevin A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7550-0921</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund19"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-50248"><name><surname>Babu</surname><given-names>M Madan</given-names></name><email>madanm@mrc-lmb.cam.ac.uk</email><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-150438"><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name><email>mwwang@simm.ac.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund18"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-95571"><name><surname>Zhao</surname><given-names>Suwen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5609-434X</contrib-id><email>zhaosw@shanghaitech.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">iHuman Institute</institution><institution>ShanghaiTech University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">The CAS Key Laboratory of Receptor Research</institution><institution>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">The National Center for Drug Screening</institution><institution>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">School of Life Science and Technology</institution><institution>ShanghaiTech University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Pharmacology and Toxicology, Medical College of Georgia</institution><institution>Augusta University</institution><addr-line><named-content content-type="city">Augusta</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Chemistry and Chemical Biology</institution><institution>Harvard University</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>MRC Laboratory of Molecular Biology</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">School of Pharmacy</institution><institution>Fudan University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shan</surname><given-names>Yibing</given-names></name><role>Reviewing Editor</role><aff><institution>DE Shaw Research</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Boudker</surname><given-names>Olga</given-names></name><role>Senior Editor</role><aff><institution>Weill Cornell Medicine</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>19</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e50279</elocation-id><history><date date-type="received" iso-8601-date="2019-07-17"><day>17</day><month>07</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-12-19"><day>19</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Zhou et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Zhou et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-50279-v3.pdf"/><abstract><p>Class A G-protein-coupled receptors (GPCRs) influence virtually every aspect of human physiology. Understanding receptor activation mechanism is critical for discovering novel therapeutics since about one-third of all marketed drugs target members of this family. GPCR activation is an allosteric process that couples agonist binding to G-protein recruitment, with the hallmark outward movement of transmembrane helix 6 (TM6). However, what leads to TM6 movement and the key residue level changes of this movement remain less well understood. Here, we report a framework to quantify conformational changes. By analyzing the conformational changes in 234 structures from 45 class A GPCRs, we discovered a common GPCR activation pathway comprising of 34 residue pairs and 35 residues. The pathway unifies previous findings into a common activation mechanism and strings together the scattered key motifs such as CWxP, DRY, Na<sup>+</sup> pocket, NPxxY and PIF, thereby directly linking the bottom of ligand-binding pocket with G-protein coupling region. Site-directed mutagenesis experiments support this proposition and reveal that rational mutations of residues in this pathway can be used to obtain receptors that are constitutively active or inactive. The common activation pathway provides the mechanistic interpretation of constitutively activating, inactivating and disease mutations. As a module responsible for activation, the common pathway allows for decoupling of the evolution of the ligand binding site and G-protein-binding region. Such an architecture might have facilitated GPCRs to emerge as a highly successful family of proteins for signal transduction in nature.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>allostery</kwd><kwd>GPCR</kwd><kwd>activation mechanism</kwd><kwd>genetic diseases</kwd><kwd>signal transduction</kwd><kwd>drug discovery</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC_U105185859</award-id><principal-award-recipient><name><surname>Babu</surname><given-names>M Madan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Novo Nordisk-CAS Research</institution></institution-wrap></funding-source><award-id>NNCAS-2017-1-CC</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Young Talent Program of Shanghai</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zhao</surname><given-names>Suwen</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012543</institution-id><institution>Shanghai Science and Technology Development Fund</institution></institution-wrap></funding-source><award-id>16ZR1448500</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Suwen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012543</institution-id><institution>Shanghai Science and Technology Development Fund</institution></institution-wrap></funding-source><award-id>16ZR1407100</award-id><principal-award-recipient><name><surname>Dai</surname><given-names>Antao</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>21704064</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Qingtong</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81573479</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81773792</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31971178</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Suwen</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution>National Mega R&amp;D Program for Drug Discovery</institution></institution-wrap></funding-source><award-id>2018ZX09735-001</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source><award-id>2016YFC0905900</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Suwen</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>National Mega R&amp;D Program for Drug Discovery</institution></institution-wrap></funding-source><award-id>2018ZX09711002-002-005</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Dehua</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source><award-id>2018YFA0507000</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name><name><surname>Zhao</surname><given-names>Suwen</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81872915</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Ming-Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM130142</award-id><principal-award-recipient><name><surname>Lambert</surname><given-names>Nevin A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Contrary to previous findings, class A GPCRs share a common activation pathway that directly links ligand binding to G-protein activation, as revealed by novel quantitative analysis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>As the largest and most diverse group of membrane receptors in eukaryotes, GPCRs mediate a wide variety of physiological functions (<xref ref-type="bibr" rid="bib93">Lagerström and Schiöth, 2008</xref>; <xref ref-type="bibr" rid="bib149">Rosenbaum et al., 2009</xref>; <xref ref-type="bibr" rid="bib75">Katritch et al., 2012</xref>; <xref ref-type="bibr" rid="bib181">Venkatakrishnan et al., 2013</xref>; <xref ref-type="bibr" rid="bib76">Katritch et al., 2013</xref>), including vision, olfaction, taste, neurotransmission, endocrine and immune responses via more than 800 family members, and are involved in many diseases (<xref ref-type="bibr" rid="bib142">Rana et al., 2001</xref>; <xref ref-type="bibr" rid="bib160">Smit et al., 2007</xref>; <xref ref-type="bibr" rid="bib180">Vassart and Costagliola, 2011</xref>; <xref ref-type="bibr" rid="bib174">Thompson et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Hauser et al., 2018</xref>). Therefore, GPCRs are important drug targets. There are 475 marketed drugs (~34% of all FDA-approved therapeutic agent agents) targeting 108 members of the GPCR superfamily (<xref ref-type="bibr" rid="bib52">Hauser et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Hauser et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Allen and Roth, 2011</xref>). Class A is the largest and most diverse GPCR subfamily in humans (<xref ref-type="bibr" rid="bib83">Kolakowski, 1994</xref>; <xref ref-type="bibr" rid="bib8">Bockaert and Pin, 1999</xref>; <xref ref-type="bibr" rid="bib40">Fredriksson et al., 2003</xref>; <xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>), including 388 olfactory (<xref ref-type="bibr" rid="bib86">Krautwurst et al., 1998</xref>; <xref ref-type="bibr" rid="bib164">Spehr and Munger, 2009</xref>) and 286 non-olfactory receptors (<xref ref-type="bibr" rid="bib136">Pándy-Szekeres et al., 2018</xref>; <xref ref-type="bibr" rid="bib124">Munk et al., 2019</xref>) (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). They share a seven-transmembrane (7TM) helices domain, with ligand binding pocket and G-protein-binding region located in the extracellular and intracellular ends of the helix bundle. Responding to a wide variety of extracellular signals ranged from small molecules to peptides even proteins, the extracellular facing ligand-binding pockets have evolved to be highly diverse in both shape and sequences (<xref ref-type="bibr" rid="bib181">Venkatakrishnan et al., 2013</xref>; <xref ref-type="bibr" rid="bib128">Ngo et al., 2017</xref>; <xref ref-type="bibr" rid="bib179">Vass et al., 2018</xref>). Similarly, the G-protein-binding regions are also quite diverse in sequences, modulating the activity of different signalling pathways by recruiting dozens of heterotrimeric G proteins (<xref ref-type="bibr" rid="bib143">Rasmussen et al., 2011a</xref>; <xref ref-type="bibr" rid="bib31">Du et al., 2019</xref>; <xref ref-type="bibr" rid="bib106">Liu et al., 2019a</xref>), arrestins (<xref ref-type="bibr" rid="bib42">Gainetdinov et al., 2004</xref>; <xref ref-type="bibr" rid="bib209">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib198">Yang et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Latorraca et al., 2018</xref>), GPCR kinases (<xref ref-type="bibr" rid="bib84">Komolov et al., 2017</xref>) in a ligand-specific manner. Residues that connect the ligand-binding pocket to the G-protein-coupling region are significantly more conserved (<xref ref-type="bibr" rid="bib5">Ballesteros and Weinstein, 1995</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>), with evolutionarily conserved sequence motifs (CWxP [<xref ref-type="bibr" rid="bib32">Eddy et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Filipek, 2019</xref>; <xref ref-type="bibr" rid="bib190">Wescott et al., 2016</xref>; <xref ref-type="bibr" rid="bib171">Tehan et al., 2014</xref>; <xref ref-type="bibr" rid="bib55">Holst et al., 2010</xref>; <xref ref-type="bibr" rid="bib129">Nygaard et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Hofmann et al., 2009</xref>; <xref ref-type="bibr" rid="bib176">Trzaskowski et al., 2012</xref>], PIF [<xref ref-type="bibr" rid="bib5">Ballesteros and Weinstein, 1995</xref>; <xref ref-type="bibr" rid="bib65">Ishchenko et al., 2017</xref>; <xref ref-type="bibr" rid="bib155">Schönegge et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Kato et al., 2019</xref>] Na<sup>+</sup> pocket [<xref ref-type="bibr" rid="bib32">Eddy et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Filipek, 2019</xref>; <xref ref-type="bibr" rid="bib103">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib202">Yuan et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Fenalti et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Katritch et al., 2014</xref>; <xref ref-type="bibr" rid="bib185">Vickery et al., 2018</xref>; <xref ref-type="bibr" rid="bib192">White et al., 2018</xref>; <xref ref-type="bibr" rid="bib201">Ye et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>], NPxxY [<xref ref-type="bibr" rid="bib143">Rasmussen et al., 2011a</xref>; <xref ref-type="bibr" rid="bib37">Filipek, 2019</xref>; <xref ref-type="bibr" rid="bib190">Wescott et al., 2016</xref>; <xref ref-type="bibr" rid="bib129">Nygaard et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Hofmann et al., 2009</xref>; <xref ref-type="bibr" rid="bib176">Trzaskowski et al., 2012</xref>; <xref ref-type="bibr" rid="bib155">Schönegge et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>] and DRY [<xref ref-type="bibr" rid="bib155">Schönegge et al., 2017</xref>; <xref ref-type="bibr" rid="bib2">Alhadeff et al., 2018</xref>; <xref ref-type="bibr" rid="bib69">Jacobson et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Feng et al., 2017</xref>; <xref ref-type="bibr" rid="bib151">Roth et al., 2017</xref>; <xref ref-type="bibr" rid="bib157">Shihoya et al., 2017</xref>; <xref ref-type="bibr" rid="bib203">Yuan et al., 2014</xref>]) scattered in the intracellular half of the 7TM domain (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>An increasing number of reported class A GPCR structures facilitates studies on common activation mechanism.</title><p>(<bold>a</bold>) Distribution of structures in different states in the non-olfactory class A GPCR tree as of October 1, 2018. (<bold>b</bold>) Common GPCR activation mechanism and the residue-level triggers are not well understood.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>The released class A GPCR structures (as of October 1, 2018).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-50279-fig1-data1-v3.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Disease mutations occurred in class A GPCRs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-50279-fig1-data2-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The pattern of conservation of residues and the map of number of disease-associated mutations in human class A GPCRs.</title><p>The alignment of 286 non-olfactory, class A human GPCRs were obtained from the GPCRdb (<xref ref-type="bibr" rid="bib52">Hauser et al., 2018</xref>; <xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib136">Pándy-Szekeres et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>) and sent for the sequence conservation score calculation for all residue positions by the Protein Residue Conservation Prediction (<xref ref-type="bibr" rid="bib10">Capra and Singh, 2007</xref>) tool with scoring method ‘Property Entropy” (<xref ref-type="bibr" rid="bib123">Mirny and Shakhnovich, 1999</xref>). To obtain disease-associated mutations, we performed database integration and literature investigation for all 286 non-olfactory class A GPCRs. Four commonly used databases (UniProt [<xref ref-type="bibr" rid="bib173">The UniProt Consortium, 2017</xref>], OMIM [<xref ref-type="bibr" rid="bib4">Amberger et al., 2011</xref>], Ensembl [<xref ref-type="bibr" rid="bib205">Zerbino et al., 2018</xref>] and GPCRdb) were first filtered by disease mutations and then merged. Finally, we collected 435 disease mutations from 61 class A GPCRs (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig1-figsupp1-v3.tif"/></fig></fig-group><p>GPCR activation is agonist binding induced G-protein recruitment (<xref ref-type="bibr" rid="bib32">Eddy et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Christopoulos and Kenakin, 2002</xref>; <xref ref-type="bibr" rid="bib113">Manglik et al., 2015</xref>; <xref ref-type="bibr" rid="bib166">Staus et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">DeVree et al., 2016</xref>). It is an allosteric process (<xref ref-type="bibr" rid="bib45">Gilchrist, 2007</xref>; <xref ref-type="bibr" rid="bib119">May et al., 2007</xref>; <xref ref-type="bibr" rid="bib19">Christopoulos, 2014</xref>; <xref ref-type="bibr" rid="bib97">Latorraca et al., 2017</xref>), transducing various external stimuli into cellular responses. Understanding the activation mechanism of GPCR is of paramount importance in pharmacology research and drug discovery. Tremendous previous efforts, involving sequence analysis, structural, biophysical, biochemical and computational approaches such as X-ray (<xref ref-type="bibr" rid="bib140">Popov et al., 2018</xref>; <xref ref-type="bibr" rid="bib150">Roth et al., 2008</xref>; <xref ref-type="bibr" rid="bib187">Warne et al., 2009</xref>; <xref ref-type="bibr" rid="bib11">Carpenter et al., 2016</xref>; <xref ref-type="bibr" rid="bib127">Nehmé et al., 2017</xref>; <xref ref-type="bibr" rid="bib177">Tsai et al., 2018</xref>; <xref ref-type="bibr" rid="bib144">Rasmussen et al., 2011b</xref>; <xref ref-type="bibr" rid="bib137">Pardon et al., 2014</xref>; <xref ref-type="bibr" rid="bib148">Rosenbaum et al., 2007</xref>; <xref ref-type="bibr" rid="bib80">Kobilka and Schertler, 2008</xref>; <xref ref-type="bibr" rid="bib17">Cherezov et al., 2007</xref>; <xref ref-type="bibr" rid="bib44">Ghosh et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Cherezov et al., 2004</xref>; <xref ref-type="bibr" rid="bib9">Caffrey and Cherezov, 2009</xref>; <xref ref-type="bibr" rid="bib104">Liu et al., 2013</xref>; <xref ref-type="bibr" rid="bib188">Weierstall et al., 2014</xref>; <xref ref-type="bibr" rid="bib165">Stauch and Cherezov, 2018</xref>; <xref ref-type="bibr" rid="bib206">Zhang et al., 2015</xref>), NMR (<xref ref-type="bibr" rid="bib201">Ye et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib130">Nygaard et al., 2013</xref>; <xref ref-type="bibr" rid="bib94">Lamichhane et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Isogai et al., 2016</xref>; <xref ref-type="bibr" rid="bib163">Sounier et al., 2015</xref>; <xref ref-type="bibr" rid="bib200">Ye et al., 2016</xref>; <xref ref-type="bibr" rid="bib158">Shimada et al., 2019</xref>), Cryo-EM (<xref ref-type="bibr" rid="bib102">Liang et al., 2017</xref>; <xref ref-type="bibr" rid="bib207">Zhang et al., 2017</xref>; <xref ref-type="bibr" rid="bib15">Cheng, 2018</xref>; <xref ref-type="bibr" rid="bib145">Renaud et al., 2018</xref>), labeling biosensors (<xref ref-type="bibr" rid="bib62">Irannejad et al., 2013</xref>; <xref ref-type="bibr" rid="bib175">Tian et al., 2017</xref>), FRET (<xref ref-type="bibr" rid="bib47">Gregorio et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Halls and Canals, 2018</xref>; <xref ref-type="bibr" rid="bib152">Sandhu et al., 2019</xref>), BRET (<xref ref-type="bibr" rid="bib95">Lan et al., 2012</xref>; <xref ref-type="bibr" rid="bib100">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib132">Okashah et al., 2019</xref>), DEER (<xref ref-type="bibr" rid="bib193">Wingler et al., 2019</xref>; <xref ref-type="bibr" rid="bib178">Van Eps et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Dror et al., 2015</xref>), molecular dynamic simulations (<xref ref-type="bibr" rid="bib202">Yuan et al., 2013</xref>; <xref ref-type="bibr" rid="bib30">Dror et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Dror et al., 2011a</xref>; <xref ref-type="bibr" rid="bib28">Dror et al., 2011b</xref>; <xref ref-type="bibr" rid="bib29">Dror et al., 2013</xref>; <xref ref-type="bibr" rid="bib121">Miao et al., 2013</xref>; <xref ref-type="bibr" rid="bib7">Bhattacharya and Vaidehi, 2014</xref>; <xref ref-type="bibr" rid="bib82">Kohlhoff et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Ciancetta et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Alhadeff et al., 2018</xref>), evolutionary tracing (<xref ref-type="bibr" rid="bib111">Madabushi et al., 2004</xref>; <xref ref-type="bibr" rid="bib154">Schöneberg et al., 2007</xref>; <xref ref-type="bibr" rid="bib147">Rodriguez et al., 2010</xref>), molecular docking (<xref ref-type="bibr" rid="bib88">Kufareva et al., 2011</xref>; <xref ref-type="bibr" rid="bib69">Jacobson et al., 2014</xref>; <xref ref-type="bibr" rid="bib85">Kooistra et al., 2016</xref>; <xref ref-type="bibr" rid="bib122">Miao et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Feng et al., 2017</xref>; <xref ref-type="bibr" rid="bib151">Roth et al., 2017</xref>; <xref ref-type="bibr" rid="bib110">Lyu et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Cooke et al., 2015</xref>) and mutagenesis (<xref ref-type="bibr" rid="bib155">Schönegge et al., 2017</xref>; <xref ref-type="bibr" rid="bib167">Sung et al., 2016</xref>; <xref ref-type="bibr" rid="bib116">Massink et al., 2015</xref>; <xref ref-type="bibr" rid="bib141">Ragnarsson et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Hulme, 2013</xref>) have been made to study the allosteric nature of GPCRs including but not limited to receptor activation (<xref ref-type="bibr" rid="bib190">Wescott et al., 2016</xref>; <xref ref-type="bibr" rid="bib171">Tehan et al., 2014</xref>; <xref ref-type="bibr" rid="bib176">Trzaskowski et al., 2012</xref>; <xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>; <xref ref-type="bibr" rid="bib67">Isom and Dohlman, 2015</xref>; <xref ref-type="bibr" rid="bib131">Okada et al., 2001</xref>; <xref ref-type="bibr" rid="bib59">Hunyady et al., 2003</xref>; <xref ref-type="bibr" rid="bib24">Dalton et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Lans et al., 2015</xref>), G protein activation (<xref ref-type="bibr" rid="bib176">Trzaskowski et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Flock et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Flock et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">Furness et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Glukhova et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Ilyaskina et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Inoue et al., 2019</xref>; <xref ref-type="bibr" rid="bib189">Weis and Kobilka, 2018</xref>), biased agonism (<xref ref-type="bibr" rid="bib120">McCorvy et al., 2018</xref>; <xref ref-type="bibr" rid="bib133">Onaran et al., 2014</xref>; <xref ref-type="bibr" rid="bib153">Schmid et al., 2017</xref>; <xref ref-type="bibr" rid="bib161">Smith et al., 2018</xref>; <xref ref-type="bibr" rid="bib168">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib191">Whalen et al., 2011</xref>; <xref ref-type="bibr" rid="bib195">Wootten et al., 2018</xref>; <xref ref-type="bibr" rid="bib194">Wootten et al., 2016</xref>; <xref ref-type="bibr" rid="bib118">Masureel et al., 2018</xref>), ligand efficiency (<xref ref-type="bibr" rid="bib47">Gregorio et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Furness et al., 2016</xref>; <xref ref-type="bibr" rid="bib108">Livingston et al., 2018</xref>; <xref ref-type="bibr" rid="bib162">Solt et al., 2017</xref>; <xref ref-type="bibr" rid="bib199">Yao et al., 2009</xref>), allosteric modulators (<xref ref-type="bibr" rid="bib172">Thal et al., 2018</xref>; <xref ref-type="bibr" rid="bib87">Kruse et al., 2013</xref>; <xref ref-type="bibr" rid="bib99">Leach et al., 2007</xref>; <xref ref-type="bibr" rid="bib107">Liu et al., 2019b</xref>; <xref ref-type="bibr" rid="bib109">Lu and Zhang, 2019</xref>; <xref ref-type="bibr" rid="bib146">Robertson et al., 2018</xref>; <xref ref-type="bibr" rid="bib156">Shao et al., 2019</xref>; <xref ref-type="bibr" rid="bib197">Wu et al., 2019</xref>; <xref ref-type="bibr" rid="bib208">Zheng et al., 2016</xref>; <xref ref-type="bibr" rid="bib134">Ortiz Zacarías et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Jaeger et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Hollingsworth et al., 2019</xref>; <xref ref-type="bibr" rid="bib105">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib12">Chaturvedi et al., 2018</xref>; <xref ref-type="bibr" rid="bib135">Oswald et al., 2016</xref>), and inverse agonism (<xref ref-type="bibr" rid="bib12">Chaturvedi et al., 2018</xref>; <xref ref-type="bibr" rid="bib135">Oswald et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Hori et al., 2018</xref>; <xref ref-type="bibr" rid="bib125">Nagiri et al., 2019</xref>; <xref ref-type="bibr" rid="bib139">Peng et al., 2018</xref>; <xref ref-type="bibr" rid="bib157">Shihoya et al., 2017</xref>). Starting from the first structure of a GPCR-G protein complex (β<sub>2</sub>AR-G<sub>s</sub>) (<xref ref-type="bibr" rid="bib143">Rasmussen et al., 2011a</xref>), the rapidly growing structures of receptor-G-protein complex have provided excellent opportunity to better understand receptor conformation changes upon activation. Meanwhile, mutagenesis studies on different receptors also identified functional roles of key residues in receptor activation, one good example is CXCR4 (<xref ref-type="bibr" rid="bib190">Wescott et al., 2016</xref>), where a large-scale mutagenesis study covering all 352 residues of the receptor identified 41 amino acids that are required for signalling induced by agonist CXCL12. Notably, family-wide analysis on GPCR activation with the concept of residue contacts (<xref ref-type="bibr" rid="bib181">Venkatakrishnan et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Flock et al., 2017</xref>; <xref ref-type="bibr" rid="bib78">Kayikci et al., 2018</xref>) have revealed the converged activation pathway near the G-protein-coupling region (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>) and selectivity determinants of GPCR–G-protein binding (<xref ref-type="bibr" rid="bib39">Flock et al., 2017</xref>). While these studies have provided key insights into GPCR activation mechanism for individual receptors or specific motifs, a family-wide common activation mechanism that directly connect ligand-binding pocket and G-protein-coupling region has yet to be discovered. Although it is well established that outward movement of transmembrane helix 6 (TM6) upon ligand binding is a common feature of receptor activation, the residue level changes that trigger the movement of TM6 remain less well understood (<xref ref-type="fig" rid="fig1">Figure 1b</xref>).</p><p>Receptor activation requires global reorganization of residue contacts as well as water-mediated interactions (<xref ref-type="bibr" rid="bib203">Yuan et al., 2014</xref>; <xref ref-type="bibr" rid="bib204">Yuan et al., 2016</xref>; <xref ref-type="bibr" rid="bib183">Venkatakrishnan et al., 2019</xref>). Since prior studies primarily investigated conformational changes through visual inspection (<xref ref-type="bibr" rid="bib171">Tehan et al., 2014</xref>; <xref ref-type="bibr" rid="bib176">Trzaskowski et al., 2012</xref>) or through the presence or absence of non-covalent contacts between residues (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Flock et al., 2017</xref>), we reasoned that one could gain comprehensive knowledge about mechanism of receptor activation by developing approaches that can capture not just the presence or absence of a contact but also subtle, and potentially important alterations in conformations upon receptor activation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A residue-residue contact score-based framework to characterize GPCR conformational changes</title><p>To address this, we developed an approach to rigorously quantify residue contacts in proteins structures and infer statistically significant conformational changes. We first defined a residue-residue contact score (RRCS) which is an atomic distance-based calculation that quantifies the strength of contact between residue pairs (<xref ref-type="bibr" rid="bib128">Ngo et al., 2017</xref>) by summing up all possible inter-residue heavy atom pairs (<xref ref-type="fig" rid="fig2">Figure 2a</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). We then defined ∆RRCS, which is the difference in RRCS of a residue pair between any two conformational states of a receptor that quantitatively describes the rearrangements of residue contacts (<xref ref-type="fig" rid="fig2">Figure 2b</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>). While RRCS can be 0 (no contact) or higher (stronger contact), ∆RRCS can be negative (loss in strength of residue contact), positive (gain in strength of residue contact) or 0 (no change in strength of residue contact). To capture the entirety of conformational changes in receptor structure upon activation, we computed the ∆RRCS between the active and inactive states of a receptor and defined two types of conformational changes (<xref ref-type="fig" rid="fig2">Figure 2c</xref>): (i) switching contacts: these are contacts that are present in the inactive state but lost in the active state (or vicw versa) such as loss of intra-helical contacts between D/E<sup>3×49</sup> (GPCRdb numbering [<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>]) and R<sup>3×50</sup>, and gain of inter-helical hydrophobic contacts between residues at 3×40 and 6×48 upon receptor activation; and (ii) repacking contacts: these are contacts that result in an increase or decrease in residue packing such as the decreased packing of intra-helical side-chain contacts between W<sup>6×48</sup> and F<sup>6×44</sup>, and the increase in inter-helical residue packing due to the translocation of N<sup>7×49</sup> toward D<sup>2×50</sup> upon receptor activation. In this manner, we quantified the global, local, major and subtle conformational changes in a systematic way (i.e. inter-helical and intra-helical, switching and repacking contacts).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Understanding GPCR activation mechanism by RRCS and ∆RRCS.</title><p>(<bold>a</bold>) Comparison of residue contact (RC) (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>) and residue residue contact score (RRCS) calculations. RRCS can describe the strength of residue-residue contact quantitatively in a much more accurate manner than the Boolean descriptor RC. (<bold>b</bold>) RRCS and ΔRRCS calculation for a pair of active and inactive structures can capture receptor conformational change upon activation. (<bold>c</bold>) Two types of conformational changes (i.e. switching and repacking contacts) can be defined by RRCS to quantify the global, local, major and subtle conformational changes in a systematic way. (<bold>d</bold>) Two criteria of identifying conserved residue rearrangements upon receptor activation by RRCS and ΔRRCS. Thirty-four residues pairs were identified based on the criteria (see Materials and methods, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source datas 1</xref> and <xref ref-type="supplementary-material" rid="fig2sdata2">2</xref> for details), only six of them were discovered before (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Calculated RRCS of 34 residue pairs constituting the common activation pathway for released class A GPCR structures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-50279-fig2-data1-v3.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Thirty-four residue pairs show conserved rearrangements of residue contacts upon activation.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-50279-fig2-data2-v3.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Calculation of RRCS and ΔRRCS.</title><p>(<bold>a</bold>) Workflow of RRCS calculation. (<bold>b</bold>) Examples of RRCS and ΔRRCS calculation for two residues pairs. (<bold>c</bold>) Statistics of residue contacts and contact types for six receptors (bRho, β<sub>2</sub>AR, M2R, µOR, A<sub>2A</sub>R and κ-OR) in their inactive and active states. Contact type describes physicochemical properties of two interacted amino acids that form a pair. The amino acids with hydrophobic side chains (one-letter code: A, V, I, L, M, P, F, Y, W) contribute to the majority of residue contacts, either within themselves (50.1%) or with other amino acids (37.8%).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig2-figsupp1-v3.tif"/></fig></fig-group><p>We then analyzed 234 structures of 45 class A GPCRs that were grouped into three categories (<xref ref-type="fig" rid="fig1">Figure 1a</xref>): (i) antagonist- or inverse agonist-bound (inactive; 142 structures from 38 receptors); (ii) both agonist- and G protein/G protein mimetic-bound (fully active; 27 structures from eight receptors); and (iii) agonist-bound (intermediate; 65 structures from 15 receptors). Among them, six receptors [rhodopsin (bRho) (<xref ref-type="bibr" rid="bib101">Li et al., 2004</xref>; <xref ref-type="bibr" rid="bib18">Choe et al., 2011</xref>), β<sub>2</sub>-adrenergic receptor (β<sub>2</sub>AR) (<xref ref-type="bibr" rid="bib143">Rasmussen et al., 2011a</xref>; <xref ref-type="bibr" rid="bib17">Cherezov et al., 2007</xref>), M2 muscarinic receptor (M2R) (<xref ref-type="bibr" rid="bib87">Kruse et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Haga et al., 2012</xref>), μ-opioid receptor (μOR) (<xref ref-type="bibr" rid="bib112">Manglik et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Huang et al., 2015</xref>), adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) (<xref ref-type="bibr" rid="bib11">Carpenter et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Jaakola et al., 2008</xref>) and κ-opioid receptor (κ-OR) (<xref ref-type="bibr" rid="bib196">Wu et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Che et al., 2018</xref>)] have both inactive- and active-state crystal structures available. Given that ∆RRCS can capture major and subtle conformational changes, we computed RRCS for all structures and ∆RRCS for the six pairs of receptors and investigated the existence of a common activation pathway (i.e. a common set of residue contact changes) across class A GPCRs. Two criteria (<xref ref-type="fig" rid="fig2">Figure 2d</xref>; further details in Materials and methods) were applied to identify conserved rearrangements of residue contacts: (i) equivalent residue pairs show a similar and substantial change in RRCS between the active and inactive state structures of each of the six receptors (i.e. the same sign of ∆RRCS and |∆RRCS| &gt; cut-off for all receptors) and (ii) family-wide comparison of the RRCS for the 142 inactive and 27 active state structures shows a statistically significant difference (p&lt;0.001; two sample <italic>t</italic>-test). This allowed us to reliably capture both the major rearrangements as well as subtle but conserved conformational changes at the level of individual residues in diverse GPCRs in a statistically robust and significant manner. Consistent with this, a comparison with earlier studies revealed that the RRCS based approach is able to capture a larger number of conserved large-scale and subtle changes in residues contacts (<xref ref-type="fig" rid="fig2">Figure 2d</xref>) that would have been missed by visual inspection or residue contact presence/absence criteria alone (see Materials and methods for conceptual advance of this approach and detailed comparison).</p></sec><sec id="s2-2"><title>Discovery of a common and conserved receptor activation pathway</title><p>Remarkably, for the first time, our analysis of the structures allowed the discovery of a common and conserved activation pathway that directly links ligand-binding pocket and G protein-coupling regions in class A GPCRs (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The pathway is comprised of 34 residue pairs (formed by 35 residues) with conserved rearrangement of residue contacts upon activation (<xref ref-type="fig" rid="fig2">Figure 2d</xref>), connecting several well-known but structurally and spatially disconnected motifs (CWxP, PIF, Na<sup>+</sup> pocket, NPxxY and DRY) all the way from the extracellular side (where the ligand binds) to the intracellular side (where the G-protein binds). Inspection of the rewired contacts as a ∆RRCS network reveals that the conserved receptor activation pathway is of modular nature and involves conformational changes in four layers. In layer 1, there is a conserved signal initiation step involving changes in residue contacts at the bottom of the ligand-binding pocket and Na<sup>+</sup> pocket. In layer 2, critical hydrophobic contacts are broken (<italic>i.e.</italic>, opening of the hydrophobic lock). In layer 3, microswitch residues (6×37, Y<sup>7×53</sup>) are rewired and in layer 4, the residue R<sup>3×50</sup> and G protein contacting positions are rewired, making them competent to bind to G protein on the cytosolic side (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Strikingly, recently released cryo-EM structures of four receptors (5-HT<sub>1B</sub>, rhodopsin, A<sub>1</sub>R and µOR) in complex with G<sub>i/o</sub>(<xref ref-type="bibr" rid="bib46">Glukhova et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">García-Nafría et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Kang et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Koehl et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Draper-Joyce et al., 2018</xref>; <xref ref-type="bibr" rid="bib177">Tsai et al., 2018</xref>) also support the conservation of contacts involving these 34 residue pairs (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). These observations highlight the conserved and common nature of a previously undescribed activation pathway linking ligand binding to G-protein coupling, regardless of the subtypes of intracellular effectors (<italic>i.e.</italic>, G<sub>s</sub> (<xref ref-type="bibr" rid="bib143">Rasmussen et al., 2011a</xref>; <xref ref-type="bibr" rid="bib11">Carpenter et al., 2016</xref>), G<sub>i/o</sub>(<xref ref-type="bibr" rid="bib46">Glukhova et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">García-Nafría et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Kang et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Koehl et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Draper-Joyce et al., 2018</xref>; <xref ref-type="bibr" rid="bib177">Tsai et al., 2018</xref>), arrestin (<xref ref-type="bibr" rid="bib209">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Kang et al., 2015</xref>) or G-protein mimetic nanobody/peptide (<xref ref-type="bibr" rid="bib144">Rasmussen et al., 2011b</xref>; <xref ref-type="bibr" rid="bib87">Kruse et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Choe et al., 2011</xref>; <xref ref-type="bibr" rid="bib57">Huang et al., 2015</xref>; <xref ref-type="bibr" rid="bib13">Che et al., 2018</xref>), <xref ref-type="fig" rid="fig4">Figure 4a</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Common activation pathway of class A GPCRs.</title><p>Node represents structurally equivalent residue with the GPCRdb numbering (<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>) while the width of edge is proportional to the average ∆RRCS among six receptors (bRho, β<sub>2</sub>AR, M2R, µOR, A<sub>2A</sub>R and κ-OR). Four layers were qualitatively defined based on the topology of the pathway and their roles in activation: signal initiation (layer 1), signal propagation (layer 2), microswitches rewiring (layer 3) and G-protein coupling (layer 4).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Rearrangements of ligand-residue contacts in ligand-binding pocket are not conserved, reflecting diverse ligand recognition modes.</title><p>(<bold>a</bold>) Sphere representation of antagonist- and agonist-bound receptor crystal structures. (<bold>b</bold>) Diverse LRCS and ∆LRCS reveal the repertoire of ligand recognition across class A GPCRs. The agonist or antagonist was treated as a single residue when calculating LRCS and ∆LRCS. As shown by the calculated ∆RRCS, no ligand-residue pair exhibits conserved rearrangements upon activation. (<bold>c</bold>) Conserved conformational changes were only observed at the very bottom of ligand-binding pocket (6×48, 3×40 and 6×44).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig3-figsupp1-v3.tif"/></fig></fig-group><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The common activation mechanism is the shared portion of various downstream pathways of different class A GPCRs.</title><p>(<bold>a</bold>) Intracellular binding partners used in the active state structures. (<bold>b</bold>) Comparison of RRCS for active (green) and inactive (orange) states of eight receptors with different intracellular binding partners, including four recently solved cryo-EM structures of G<sub>i/o</sub>-bound receptors (5-HT<sub>1B</sub> receptor, rhodopsin, A<sub>1</sub>R and µOR) (<xref ref-type="bibr" rid="bib177">Tsai et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">García-Nafría et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Kang et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Koehl et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Draper-Joyce et al., 2018</xref>) whose resolutions were low (usually ≥3.8 Å for the GPCR part). Nevertheless, almost all conserved residue rearrangements in the pathway can be observed from them. Three of 34 residues pairs were shown here, see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref> for the remaining 31 residue pairs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The switching conformation change is conserved upon receptor activation.</title><p>Comparison of RRCS for active (green) and inactive (orange) states of eight receptors with different intracellular binding partners, including four recently solved cryo-EM structures of G<sub>i/o</sub>-bound receptors (5-HT<sub>1B</sub> receptor, rhodopsin, A<sub>1</sub>R and µOR) whose resolutions were low (usually ≥3.8 Å for the GPCR part). Nevertheless, almost all conserved residue rearrangements in the pathway can be observed from them. Nineteen of 34 residues pairs were shown here, see <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> for the remaining residue pairs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>The repacking conformation change is conserved upon receptor activation.</title><p>Comparison of RRCS for active (green) and inactive (orange) states of eight receptors with different intracellular binding partners, including four recently solved cryo-EM structures of G<sub>i/o</sub>-bound receptors (5-HT<sub>1B</sub> receptor, rhodopsin, A<sub>1</sub>R and µOR) whose resolutions were low (usually ≥3.8 Å for the GPCR part). Nevertheless, almost all conserved residue rearrangements in the pathway can be observed from them. Twelve of 34 residues pairs were shown here, see <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for the remaining residue pairs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig4-figsupp2-v3.tif"/></fig></fig-group><p>Collectively, these findings illustrate how a combination of intra-helical and inter-helical switching contacts as well as repacking contacts underlies the common activation mechanism of GPCRs.</p></sec><sec id="s2-3"><title>Molecular insights into key steps of the common activation pathway</title><p>Receptor activation is triggered by ligand binding and is characterised by movements of different transmembrane helices. How does ligand-induced receptor activation connect the different and highly conserved motifs, rewire residue contacts and result in the observed changes in transmembrane helices? To this end, we analyzed the common activation pathway in detail and mapped, where possible, how they influence helix packing, rotation and movement (<xref ref-type="fig" rid="fig3">Figure 3</xref>). A qualitative analysis suggests the presence of four layers of residues in the pathway linking the ligand binding residues to the G-protein-binding region.</p><p>Layer 1: We did not see a single ligand-residue contact that exhibits conserved rearrangement, which accurately reflects the diverse repertoire of ligands that bind GPCRs (<xref ref-type="bibr" rid="bib75">Katritch et al., 2012</xref>; <xref ref-type="bibr" rid="bib181">Venkatakrishnan et al., 2013</xref>; <xref ref-type="bibr" rid="bib128">Ngo et al., 2017</xref>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Instead, as a first common step, extracellular binding of diverse agonists converges to trigger an identical alteration of the transmission switch (3×40, 5×51, 6×44 and 6×48) and Na<sup>+</sup> pocket (2×50, 3×39, 7×45 and 7×49). Specifically, the repacking of an intra-helical contact between residues at 6×48 and 6×44, together with the switching contacts of residue at 3×40 toward 6×48 and residue at 5×51 toward 6×44, contract the TM3-5-6 interface in this layer. This reorganization initializes the rotation of the cytoplasmic end of TM6. The collapse of Na<sup>+</sup> pocket leads to a denser repacking of the four residues (2×50, 3×39, 7×45 and 7×49), initiating the movement of TM7 toward TM3. Remarkably, a recent NMR study on A<sub>2A</sub>R (<xref ref-type="bibr" rid="bib32">Eddy et al., 2018</xref>) demonstrated the strong coupling between allosteric switch D<sup>2×50</sup> and toggle switch W<sup>6×48</sup>, which is consistent with the present observation.</p><p>Layer 2: In parallel with these movements, two residues (6×40 and 6×41) switch their contacts with residue at 3×43, and form new contacts instead with residues at 5×58 and 5×55, respectively. Residues at 3×43, 6×40 and 6×41 are mainly composed of hydrophobic amino acids and referred as hydrophobic lock (<xref ref-type="bibr" rid="bib190">Wescott et al., 2016</xref>; <xref ref-type="bibr" rid="bib171">Tehan et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Han et al., 2012</xref>; <xref ref-type="bibr" rid="bib115">Martí-Solano et al., 2014</xref>). Its opening loosens the packing of TM3-TM6 and facilitates the outward movement of the cytoplasmic end of TM6, which is necessary for receptor activation. Additionally, N<sup>7×49</sup> develops contacts with residue at 3×43 from nothing, facilitating the movement of TM7 toward TM3.</p><p>Layer 3: Upon receptor activation, Y<sup>7×53</sup> loses its inter-helical contacts (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>) with residues at 1×53 and 8×50, and forms new contacts with residues at 3×43, 3×46 and R<sup>3×50</sup>, which were closely packed with residues in TM6. Thus, the switching of contacts by Y<sup>7×53</sup> strengthens the packing of TM3-TM7, while the packing of TM3-TM6 is further loosened with the outward movement of TM6.</p><p>Layer 4: Finally, the restrains on R<sup>3×50</sup>, including more conserved, local intra-helical contacts with D(E)<sup>3×49</sup> and less conserved ionic lock with D(E)<sup>6×30</sup>, are eliminated and R<sup>3×50</sup> is released. Notably, the switching contacts between R<sup>3×50</sup> and residue at 6×37 are essential for the release of R<sup>3×50</sup>, which breaks the remaining contacts between TM3 and TM6 in the cytoplasmic end and drives the outward movement of TM6. The rewired contacts of R<sup>3×50</sup> and other G-protein contacting positions (3×53, 3×54, 5×61 and 6×33) make the receptor competent to bind to G protein on the cytosolic side.</p><p>Together, these findings demonstrate that the intra-helical/inter-helical and switching/repacking contacts between residues is not only critical to reveal the continuous and modular nature of the activation pathway, but also to link residue-level changes to transmembrane helix-level changes in the receptor.</p></sec><sec id="s2-4"><title>Common activation pathway induced changes in TM helix packing</title><p>To capture the patterns in the global movements of transmembrane helices, all inter-helical residues pairs in the common activation pathway were used to describe the inter-helical contacts between the cytoplasmic end of TM3 and TM6 as well as TM3 and TM7 (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Analysis of the RRCS<sub>TM3-TM7</sub> (X-axis) and RRCS<sub>TM3-TM6</sub> (Y-axis) for each of the 234 class A GPCR structures revealed distinct compact clusters of inactive and active states. Surprisingly, the inactive state has zero or close to zero RRCS<sub>TM3-TM7</sub> regardless of the wide distribution of RRCS<sub>TM3-TM6</sub>. In contrast, the active state has a high RRCS<sub>TM3-TM7</sub> and strictly zero RRCS<sub>TM3-TM6</sub>. Thus, receptor activation from inactive to active state occurs as a harmonious process of inter-helical contact changes: elimination of TM3-TM6 contacts, formation of TM3-TM7 contacts and repacking of TM5-TM6 (<xref ref-type="fig" rid="fig5">Figure 5b</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). In terms of global conformational changes, the binding of diverse agonists converges to trigger outward movement of the cytoplasmic end of TM6 and inward movement of TM7 toward TM3 (<xref ref-type="bibr" rid="bib143">Rasmussen et al., 2011a</xref>; <xref ref-type="bibr" rid="bib129">Nygaard et al., 2009</xref>; <xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>), thereby creating an intracellular crevice for G protein coupling (<xref ref-type="fig" rid="fig5">Figure 5b</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Common activation model of class A GPCRs reveals major changes upon GPCR activation.</title><p>(<bold>a</bold>) Active and inactive state structures form compact clusters in the 2D inter-helical contact space: RRCS<sub>TM3-TM7</sub> (X-axis) and RRCS<sub>TM3-TM6</sub> (Y-axis). GPCR activation is best described by the outward movement of TM6 and inward movement of TM7, resulting in switch in the contacts of TM3 from TM6 to TM7. (<bold>b</bold>) Common activation model for class A GPCRs. Residues are shown in circles, conserved contact rearrangements of residue pairs upon activation are denoted by lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Global conformational change upon activation.</title><p>(<bold>a</bold>) Distinct clustering of inactive- and active-state structures in two-dimentional inter-helical contact space RRCS<sub>TM5-TM6</sub> <italic>vs</italic>. RRCS<sub>TM3-TM6</sub>. (<bold>b</bold>) The inter-helical contacts comparison between inactive- and active-state structures. (<bold>c</bold>) Receptor-specific inter-helical contacts for all class A GPCR structures (inactive, intermediate and active states are colored in orange, cyan and green, respectively). These results demonstrate that receptor activation involves the elimination of TM3-TM6 contacts, formation of TM3-TM7 and TM5-TM6 contacts, reflecting the outward movement of the cytoplasmic end of TM6 away from TM3, the inward movement of TM7 towards TM3 and the repacking of TM5 and TM6.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>An inverse-agonism of class A GPCRs by preventing the collapse of Na<sup>+</sup> pocket.</title><p>(<bold>a</bold>) Comparison of binding poses of antagonist (bosentan [<xref ref-type="bibr" rid="bib157">Shihoya et al., 2017</xref>]) and inverse agonists (IRL2500 [<xref ref-type="bibr" rid="bib125">Nagiri et al., 2019</xref>], BIIL260 [<xref ref-type="bibr" rid="bib56">Hori et al., 2018</xref>] and ritanserin [<xref ref-type="bibr" rid="bib139">Peng et al., 2018</xref>]). Inverse agonists diffuse deeper in the ligand-binding pocket to touch the Na<sup>+</sup> pocket. These key residues around the Na<sup>+</sup> pocket are shown. (<bold>b</bold>) Comparison of the sum of contact scores of the conserved residue pairs around the Na<sup>+</sup> pocket (RRCS<sub>sodium_pocket</sub>) between inactive- and active-state structures. The collapse of the Na<sup>+</sup> pocket leads to a denser repacking of six residues (five residue pairs), reflected by higher RRCS<sub>sodium_pocket</sub> scores compared to that of the inactive state structures. (<bold>c</bold>) Distribution of three inverse agonist bound structures in the 2D inter-helical contact space: RRCS<sub>TM3-TM7</sub> (X-axis) and RRCS<sub>TM3-TM6</sub> (Y-axis). These inverse agonists bound structures (5×33, 6BQG and 6K1Q) located in the inactive state region with zero RRCS<sub>TM3-TM7</sub> but high RRCS<sub>TM3-TM6</sub> scores, despite deeper binding modes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig5-figsupp2-v3.tif"/></fig></fig-group><p>It is noteworthy that the common activation pathway we discovered in this study is not the only pathway that connecting extracellular ligand-binding and intracellular effector coupling for class A GPCRs ‒ it is likely to be a shared portion of various activation pathways of GPCR members belonging to this class ‒ each receptor still has its unique receptor-, ligand- and effector-specific activation pathways. In fact, research on this subject has boosted the discovery of selective and biased ligands (<xref ref-type="bibr" rid="bib120">McCorvy et al., 2018</xref>; <xref ref-type="bibr" rid="bib133">Onaran et al., 2014</xref>; <xref ref-type="bibr" rid="bib153">Schmid et al., 2017</xref>; <xref ref-type="bibr" rid="bib161">Smith et al., 2018</xref>; <xref ref-type="bibr" rid="bib168">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib191">Whalen et al., 2011</xref>; <xref ref-type="bibr" rid="bib195">Wootten et al., 2018</xref>; <xref ref-type="bibr" rid="bib194">Wootten et al., 2016</xref>).</p><p>As shown in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, collapse of the Na<sup>+</sup> pocket leads to a denser repacking of six residues (five residue pairs), reflected by higher RRCS<sub>sodium_pocket</sub> scores in active state than that in inactive state structures. Recently, the crystal structures (5X33 [<xref ref-type="bibr" rid="bib56">Hori et al., 2018</xref>], 6BQG [<xref ref-type="bibr" rid="bib139">Peng et al., 2018</xref>] and 6K1Q [<xref ref-type="bibr" rid="bib125">Nagiri et al., 2019</xref>]) whose ligand (inverse agonist) diffuses deep in ligand-binding pocket or even occupies the sodium binding pocket (below D<sup>2×50</sup>) were reported. These inverse agonists disrupt the collapse of Na<sup>+</sup> pocket by blocking the rotation of W<sup>6×48</sup> and/or taking the space of Na<sup>+</sup>, and stabilize the receptors in an inactive state. Indeed, these inactive state structures showed zero RRCS<sub>TM3-TM7</sub> but high RRCS<sub>TM3-TM6</sub> scores. The inverse agonism are not only consistent with both our activation model and mutagenesis experiments, but also supported by the NMR study of A<sub>2A</sub>R (<xref ref-type="bibr" rid="bib32">Eddy et al., 2018</xref>). This study demonstrated the role of D52<sup>2×50</sup> as an allosteric link between the orthosteric ligand-binding site and the intracellular signaling surface, revealing strong interactions with the toggle switch W246<sup>6×48</sup>.</p></sec><sec id="s2-5"><title>Experimental validation of the modular nature of the common activation pathway</title><p>Based on the knowledge of the common activation pathway, one would expect that mutations of residues in the pathway are likely to severely affect receptor activation. The two extreme consequences are constitutive activation (without agonist binding) or inactivation (abolished signalling). To experimentally test this hypothesis, we systematically designed site-directed mutagenesis for residues in the pathway on a prototypical receptor A<sub>2A</sub>R, aiming to create constitutively activating/inactivating mutations (CAM/CIM), by promoting/blocking residue and helix level conformational changes revealed in the pathway. 6/15 designed CAMs and 15/20 designed CIMs were validated by functional cAMP accumulation assays, and none of them were reported before for A<sub>2A</sub>R (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). The design of functional active/inactive mutants has been very challenging. However, the knowledge of common activation pathway of GPCRs presented here greatly improves the success rate. The mechanistic interpretation of 21 successful predicted mutants is explained below. We also discussed the 14 unsuccessful predictions in <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>. Besides, we extended mutagenesis studies to G<sub>s</sub>-coupled 5-HT<sub>7</sub> and G<sub>i</sub>-coupled 5-HT<sub>1B</sub> receptors by designing CAM/CIMs in residues at 3×40, 3×43, 6×40, 6×44, and 7×49 (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Experimental validation of the common activation mechanism.</title><p>(<bold>a</bold>) cAMP accumulation assay and (<bold>b</bold>) radioligand binding assay: both validated the common activation pathway-guided design of CAMs/CIMs for A<sub>2A</sub>R. Wildtype (WT), CAMs and CIMs are shown in black, green and orange, respectively. (<bold>c</bold>) Mechanistic interpretation of common activation pathway-guided CAMs/CIMs design. N.D.: basal activity was too high to determine an accurate EC<sub>50</sub> value.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Functional and ligand binding properties of A<sub>2A</sub>R mutations.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-50279-fig6-data1-v3.docx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Analysis of the 14 unsuccessful predictions of A<sub>2A</sub>R CAMs/CIMs.</title><p>ΔStability (&gt;0 means destabilized;&lt;0 means stabilized) is the change of receptor stability when a mutation was introduced, calculated by Residue Scanning module in BioLuminate (<xref ref-type="bibr" rid="bib6">Beard et al., 2013</xref>). WT, wild-type.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-50279-fig6-data2-v3.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Experimental validation of common activation pathway-guided CAM/CIM design for A 2A R.</title><p>(<bold>a</bold>) Cell surface expression of the WT A <sub>2A</sub>R and its mutants. WT, CAMs and CIMs are colored by black, orange and green, respectively. (<bold>b</bold>) Mapping of validated CAMs/CIMs to the common activation pathway. (<bold>c</bold>) The mechanisms of CAM/CIM design. CAMs and CIMs are in green and orange, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig6-figsupp1-v3.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Experimental validation of common activation pathway-guided CAM/CIM design for G<sub>s</sub>-coupled 5-HT<sub>7</sub> and G<sub>i</sub>-coupled 5-HT<sub>1B</sub> receptors.</title><p>(<bold>a</bold>) cAMP assay of G<sub>s</sub>-coupled 5-HT<sub>7</sub> receptor used an EPAC-based BRET cAMP sensor (n = 6). WT, CAMs and CIMs are colored by black, orange and green, respectively. (<bold>b</bold>) Trafficking assay measured WT and mutant 5-HT<sub>7</sub> receptors in the plasma membrane (PM). (<bold>c</bold>) cAMP measurement of 5-HT<sub>1B</sub> receptor. CAMs and CIMs are shown in green and orange, respectively. (<bold>d</bold>) Cell surface expression of mutant 5-HT<sub>1B</sub> receptors relative to that of WT. DHE, dihydroergotamine.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig6-figsupp2-v3.tif"/></fig></fig-group><p>In layer 1, the mutation I92<sup>3×40</sup>N likely stabilizes the active state by forming amide-π interactions with W246<sup>6×48</sup> and hydrogen bond with the backbone of C185<sup>5×461</sup>, which rewires the packing at the transmission switch and initiates the outward movement of the cytoplasmic end of TM6; this mutation elevated the basal cAMP level by sevenfold. Conversely, I92<sup>3×40</sup>A would reduce the favorable contacts with W<sup>6×48</sup> upon activation, which retards the initiation of the outward movement of TM6; this mutation resulted in a decrease in both basal cAMP level [71% of wild-type (WT)] and agonist potency (eightfold). Another example is the residue at 6×44, the mutation F242<sup>6×44</sup>R would stabilize the inactive state by forming salt bridge with D52<sup>2×50</sup>, which blocks the rotation of TM6 and thus abolishes G<sub>s</sub> coupling; indeed this mutation greatly reduced basal cAMP level (to 63% WT) and agonist potency (by 374-fold). In contrast, F242<sup>6×44</sup>A would reduce contacts with W246<sup>6×48</sup>, loosen TM3-TM6 contacts, diminish the energy barrier of TM6 release and make outward movement of TM6 easier; consistently this mutation elevated the basal cAMP level (by twofold) and increased the agonist potency (by eightfold). Mutations of residues forming the Na<sup>+</sup> pocket, such as D52<sup>2×50</sup>A and N280<sup>7×45</sup>R, would destroy the hydrogen bond network at the Na<sup>+</sup> pocket and retard the initiation of the inward movement of TM7. These mutations completely abolished agonist potency and greatly reduced the basal cAMP level (to 80% and 78% of WT, respectively).</p><p>In layer 2, the mutations L95<sup>3×43</sup>A/R and I238<sup>6×40</sup>Y would loosen the hydrophobic lock, weaken TM3-TM6 contacts, promote the outward movement of cytoplasmic end of TM6 and eventually make receptor constitutively active; this is reflected by remarkably high basal cAMP production (28-, 2- and 11-fold increase, respectively). Notably, mutations at/near the Na<sup>+</sup> pocket, L48<sup>2×46</sup>R and N284<sup>7×49</sup>K, could lock the Na<sup>+</sup> pocket at inactive packing mode by introducing salt bridge with D52<sup>2×50</sup>, thus blocking the inward movement of TM7 toward TM3. As expected, these mutations completely abolished agonist potency. The CIMs at/near the Na<sup>+</sup> pocket (from both layers 1 and 2) reflect that the subtle inward movement of TM7 towards TM3 is essential for receptor activation, which is often underappreciated and overshadowed by the movement of TM6. In line with this, two mutations on TM7, N284<sup>7×49</sup>A and Y288<sup>7×53</sup>A, attenuate the TM3-TM7 contacts upon activation and completely abolished or greatly reduced (by 16-fold) agonist potency, respectively.</p><p>In layer 3, I98<sup>3×46</sup>A likely reduces contacts with Y288<sup>7×53</sup>, weakens the packing between TM3-TM7, and retards the movement of TM7 toward TM3; similarly, L235<sup>6×37</sup>A would reduce contacts with F201<sup>5×62</sup>, weaken the packing between TM5-TM6, and makes the TM6 movement toward TM5 more difficult. In line with the interpretation, these mutations resulted in reduced basal cAMP level (72% and 71% WT, respectively) and decreased agonist potency (23- and 4-fold, respectively). These results are consistent with previous findings on vasopressin type-2 receptor (V2R) (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>).</p><p>In layer 4, D101<sup>3×49</sup>N likely diminishes its intra-helical interaction with R102<sup>3×50</sup> and thus makes the release of the latter easier, which in turn promotes G-protein recruitment. Consistent with this possibility, this mutation led to a greatly elevated basal cAMP level (eightfold).</p><p>Despite these A<sub>2A</sub>R mutants greatly affect receptor activation, our radioligand binding assay shows that they generally retain the agonist binding ability, with the exception of two CIMs: W246<sup>6×48</sup>A and N284<sup>7×45</sup>K (<xref ref-type="fig" rid="fig6">Figure 6b,c</xref> and <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). This suggests that the common activation pathway is of modular nature and that such an organization allows for a significant number of residues involved in agonist binding to be uncoupled from receptor activation/inactivation and G-protein binding.</p><p>As shown in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplements 2</xref> and 5-HT<sub>7</sub> receptor mutations F336<sup>6×44</sup>R and N380<sup>7×49</sup>K completely abolished agonist potency and greatly reduced the basal cAMP level, which is remarkably consistent with the observation on A<sub>2A</sub>R, highlighting the crucial role of the highly conserved residues F<sup>6×44</sup> and N<sup>7×49</sup>. Beyond G<sub>s</sub>-coupled A<sub>2A</sub>R and 5-HT<sub>7</sub> receptor, we also validated this mutation design in G<sub>i</sub>-coupled 5-HT<sub>1B</sub> receptor. Indeed, two CIMs, I137<sup>3×40</sup>N and F323<sup>6×44</sup>H greatly reduced receptor-mediated G<sub>i</sub> activity compared to WT, whereas three CAMs, L173<sup>3×43</sup>A in G<sub>s</sub>-coupled 5-HT<sub>7</sub> receptor, F323<sup>6×44</sup>A and I137<sup>3×40</sup>A in G<sub>i</sub>-coupled 5-HT<sub>1B</sub> receptor, were verified to promote their basal activities, consistent with the observation on CAMs (L95<sup>3×43</sup>A, F242<sup>6×44</sup>A and I92<sup>3×40</sup>A) designed for A<sub>2A</sub>R.</p></sec><sec id="s2-6"><title>The common pathway allows mechanistic interpretation of mutations</title><p>Four hundred thirty five disease-associated mutations were collected, among which 28% can be mapped to the common activation pathway, much higher than that to the ligand-binding and G-protein-binding regions (20% and 7%, respectively) (<xref ref-type="fig" rid="fig7">Figure 7a,b</xref>). Furthermore, 272 CAMs/CIMs from 41 receptors (<xref ref-type="fig" rid="fig7">Figure 7c</xref>) were mined from the literature for the 14 hub residues (i.e. residues that have more than one edges in the pathway).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Importance of the common activation pathway in pathophysiological and biological contexts.</title><p>(<bold>a</bold>) Comparison of disease-associated mutations in the common activation pathway (further decomposed into layers 1–4), ligand-binding pocket, G-protein-coupling region and other regions. Red line denotes the mean value. (<bold>b</bold>) Mapping of disease-associated mutations in class A GPCRs to the common activation pathway. (<bold>c</bold>) Key roles of the residues constituting the common activation pathway have been reported in numerous experimental studies on class A GPCRs. Two hundred seventy two (272) CAMs/CIMs from 41 receptors were mined from the literature for the 14 hub residues (i.e. residues that have more than one edges in the pathway).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Constitutively activating/inactivating mutations for the 14 hub residues in the common activation pathway.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-50279-fig7-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>The common activation pathway can be used to mechanistically interpret disease-associated mutations and CAMs/CIMs.</title><p>(<bold>a</bold>) Pathway-guided mechanistic interpretations of two disease mutations. (<bold>b</bold>) Pathway-guided mechanistic interpretations of four CAMs/CIMs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig7-figsupp1-v3.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Residues in the common activation pathway are more conserved than other functional regions of GPCR.</title><p>(<bold>a</bold>) Illustration of different functional regions of GPCR. (<bold>b-d</bold>) Sequence pattern of the G protein-coupling region (<bold>b</bold>), ligand-binding pocket (<bold>c</bold>) and the common activation pathway (<bold>d</bold>). (<bold>e</bold>) Distribution of sequence identity (left) and similarity (right) for functional regions across 286 non-olfactory class A receptors.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-fig7-figsupp2-v3.tif"/></fig></fig-group><p>The average number of disease-associated mutations in the common activation pathway is much higher than that of ligand-binding pocket, G-protein-binding site, and residues in other regions (2.5-, 3.5- and 3.5-fold, respectively), reflecting the enrichment of disease-associated mutations on the pathway (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). Within this pathway, the enrichment of disease mutations and CAMs/CIMs in layers 1 and 2 is noteworthy, which highlights the importance of signal initiation and hydrophobic lock opening, and further supports the modular and hierarchical nature of GPCR activation (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig5">5b</xref>). Notably, for certain residues, such as D<sup>2×50</sup> and Y<sup>7×53</sup>, only loss-of-function disease mutations or CIMs were observed (<xref ref-type="fig" rid="fig7">Figure 7</xref>), implying they are indispensable for receptor activation and the essential role of TM7 movement (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig5">5</xref>).</p><p>The functional consequence of these single point mutations can be rationalized by analysing if they are stabilizing/destabilizing the contacts in the common activation pathway or promoting/retarding the required helix movement upon activation (<xref ref-type="fig" rid="fig7">Figure 7b</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). For example, I130<sup>3×43</sup>N/F (layer 2) in V2R was reported as a gain-/loss-of-function mutation that causes nephrogenic syndrome of inappropriate antidiuresis (<xref ref-type="bibr" rid="bib34">Erdélyi et al., 2015</xref>) or nephrogenic diabetes insipidus (<xref ref-type="bibr" rid="bib138">Pasel, 2000</xref>), respectively. I130<sup>3×43</sup>N/F likely loosens/stabilizes the hydrophobic lock, weakens/strengthens the TM3-TM6 packing and leads to constitutively active/inactive receptors. Another example is T58<sup>1×53</sup>M in rhodopsin, which was reported as a loss-of-function mutation that causes retinitis pigmentosa 4 (<xref ref-type="bibr" rid="bib126">Napier et al., 2015</xref>). T58<sup>1×53</sup>M likely increases hydrophobic contacts with Y306<sup>7×53</sup> and P303<sup>7×50</sup>, which retards the inward movement of TM7 towards TM3 and eventually decreases G-protein recruitment. As in the case of disease-associated mutations, CAMs/CIMs that have been previously reported in the literature can also be interpreted by the framework of common activation pathway (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1b</xref>). For example, F248<sup>6×44</sup>Y in CXCR4 (<xref ref-type="bibr" rid="bib190">Wescott et al., 2016</xref>) was reported as a CIM. This residue likely forms hydrogen bond with S123<sup>3×39</sup>, which blocks the rotation of the cytoplasmic end of TM6, and decreases G-protein engagement.</p><p>Not surprisingly, the 35 residues constituting the pathway are highly conserved across class A GPCRs, dominated by physiochemically similar amino acids (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). The average sequence similarity of these positions across 286 non-olfactory class A receptors is 66.2%, significantly higher than that of ligand-binding pockets (31.9%) or signaling protein-coupling regions (35.1%). Together, these observations suggest that the modular and hierarchical nature of the activation pathway allows decoupling of the ligand-binding pocket, G-protein-binding site and the residues contributing to the common activation mechanism. Such an organization of the receptor might facilitate the uneven sequence conservation between different regions of GPCRs, confers their functional diversity in ligand recognition and G-protein binding while still retaining a common activation mechanism.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Using a novel, quantitative residue contact descriptor, RRCS, and a family-wide comparison across 234 structures from 45 class A GPCRs, we reveal a common activation pathway that directly links ligand-binding pocket and G-protein-coupling region. Key residues that connect the different modules allows for the decoupling of a large number of residues in the ligand-binding site, G-protein contacting region and residues involved in the activation pathway. Such an organization may have facilitated the rapid expansion of GPCRs through duplication and divergence, allowing them to evolve independently and bind to diverse ligands due to removal of the constraint (<italic>i.e.</italic>, between a large number of ligand-binding residues and those involved in receptor activation). This model unifies many previous important motifs and observations on GPCR activation in the literature (CWxP, PIF, Na<sup>+</sup> pocket, NPxxY, DRY and hydrophobic lock) and is consistent with numerous experimental findings.</p><p>We focused on the common activation pathway (i.e. the common part of activation mechanism shared by all class A GPCRs and various intracellular effectors) in this study. Obviously, individual class A receptor naturally has its intrinsic activation mechanism(s), as a result of the diversified sequences, ligands and physiological functions. Indeed, receptor-specific activation pathways (including mechanisms of orthosteric, positive or negative allosteric modulators, biased signaling/selectivity of downstream effectors) have been revealed by both experimental studies including biophysical (such as X-ray, cryo-EM, NMR, FRET/BRET and DEER), biochemical and computational approaches (such as evolutionary trace analysis and molecular dynamics simulations), especially for the prototypical receptors such as rhodopsin, β<sub>2</sub>-adrenergic and A<sub>2A</sub> receptors. These studies demonstrated the complexity and plasticity of signal transduction of GPCRs. The computational framework we have developed may assist us in better understanding the mechanism of allosteric modulation, G-protein selectivity and diverse activation processes via intermediate states as more GPCR structures become available. While we interpret the changes as a linear set of events, future studies aiming at understanding dynamics could provide further insights into how the common activation mechanism operates in individual receptors.</p><p>Given the common nature of this pathway, we envision that the knowledge obtained from this study can not only be used to mechanistically interpret the effect of mutations in biological and pathophysiological context but also to rationally introduce mutations in other receptors by promoting/blocking residue and helix level movements that are essential for activation. Such protein engineering approaches may enable us to make receptors in specific conformational states to accelerate structure determination studies using X-ray crystallography or electron microscopy and functional investigation in the future. The method developed here could also be readily adapted to map allosteric pathways and reveal mechanisms of action for other key biological systems such as kinases, ion channels and transcription factors.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Glossary</title><p>Transmembrane domains (TMD): the core domain exists in all GPCRs, and consists of seven-transmembrane helices (TM1–7) that are linked by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3).</p><p>GPCRdb numbering scheme: a structure-based numbering system for GPCRs (<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>), an improved version of sequence-based Ballesteros–Weinstein numbering (<xref ref-type="bibr" rid="bib5">Ballesteros and Weinstein, 1995</xref>) that considers structural distortions such as helical bulges or constrictions. The most conserved residue in a helix n is designated n×50, while other residues on the helix are numbered relative to this position.</p><p>Node: a point in a network at which lines intersect, branch or terminate. In this case, nodes represent amino acid residues.</p><p>Edge: a connection between the nodes in a network. In this case, an edge represents a residue-residue contact.</p><p>Hub: a node with two or more edges in a network.</p><p>Constitutively activating mutation (CAM): a mutant that could increase the inherent basal activity of the receptor by activating the G-protein-signaling cascade in the absence of agonist.</p><p>Constitutively inactivating mutation (CIM): a mutant completely abolishes receptor signalling.</p></sec><sec id="s4-2"><title>GPCR structure data set</title><p>As of October 1, 2018, there are 234 released structures of 45 class A GPCRs with resolution better than 3.8 Å (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), which covers 71% (203 out of 286 receptors, including 158 receptors that have no structures but share &gt;50% sequence similarity in the TMD with the 45 structure-determined receptors) of class A GPCRs (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). Based on the type of bound ligand and effector, these structures could be classified into three states: inactive state (antagonist or inverse agonist-bound, 142 structures from 38 receptors), active state (both agonist- and G protein/G protein mimetic-bound, 27 structures from eight receptors) and intermediate state (only agonist-bound, 65 structures from 15 receptors). In this study, we primarily focused on conformational comparison between inactive- and active- state structures, while also investigating the intermediate state structures. In the structure data set, seven receptors have both inactive and active structures: rhodopsin (bRho), β<sub>2</sub>-adrenergic receptor (β<sub>2</sub>AR), M2 muscarinic receptor (M2R), μ-opioid receptor (μOR), adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R), κ-opioid receptor (κ-OR) and adenosine A<sub>1A</sub> receptor (A<sub>1A</sub>R), the active state structure of which was recently determined by cryo-EM. In addition, 32 receptors have either inactive or active structures (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p></sec><sec id="s4-3"><title>Calculation of residue-residue contact score (RRCS)</title><p>We developed a much finer distance-based method (than coarse-grained Boolean descriptors such as contact map and residues contact [<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Kayikci et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Eldridge et al., 1997</xref>; <xref ref-type="bibr" rid="bib184">Verdonk et al., 2003</xref>; <xref ref-type="bibr" rid="bib186">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Adhikari and Cheng, 2016</xref>]), namely residue-residue contact score (RRCS). For a pair of residues, RRCS is calculated by summing up a plateau-linear-plateau form atomic contact score adopted from GPCR–CoINPocket (<xref ref-type="bibr" rid="bib128">Ngo et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Kufareva et al., 2011</xref>; <xref ref-type="bibr" rid="bib92">Kufareva and Abagyan, 2012</xref>; <xref ref-type="bibr" rid="bib90">Kufareva et al., 2014a</xref>; <xref ref-type="bibr" rid="bib89">Kufareva et al., 2013</xref>; <xref ref-type="bibr" rid="bib91">Kufareva et al., 2014b</xref>; <xref ref-type="bibr" rid="bib114">Marsden and Abagyan, 2004</xref>) for each possible inter-residue heavy atom pairs (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). GPCR–CoINPocket is a modified version of the hydrophobic term of ChemScore (<xref ref-type="bibr" rid="bib33">Eldridge et al., 1997</xref>; <xref ref-type="bibr" rid="bib184">Verdonk et al., 2003</xref>) that has been successfully used to describe hydrophobic contribution to binding free energy between ligand and protein. RRCS can describe the strength of residue-residue contact quantitatively in a much more accurate manner than Boolean descriptors (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Flock et al., 2017</xref>). For example, Boolean descriptors do not capture side chain repacking if the backbone atoms of the two residues are close to each other (e.g. translocation of Y<sup>7×53</sup> away from residue at 2×43 upon GPCR activation) and local contacts involving adjacent residues (residues within four/six amino acids in protein sequence) (e.g., disengagement between D/E<sup>3×49</sup> and R<sup>3×50</sup>), while both cases can be well reflected by the change of RRCS (<xref ref-type="fig" rid="fig2">Figure 2c</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>).</p><p>All RRCS data can be found in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. The computational details are described as below:</p><list list-type="order"><list-item><p>For the residue pairs between adjacent residues that are within four amino acids in protein sequence, only side chain heavy atom pairs were considered, atom pairs involving in backbone atoms (Cα, C, O, N) were excluded, since the latter seldom change during GPCR activation. For other residue pairs, all possible heavy atom pairs (including backbone atoms) were included when calculating RRCS.</p></list-item><list-item><p>Atomic contact scores are solely based on interatomic distance, and they are treated equally without weighting factors such as atom type or contact orientation. In principle, weighting of atomic contact by atom type and/or orientation would improve residue-residue contact score. However, parameterization of atom type or contact orientation is relatively arbitrary, subjective and complicated, especially considering the lipid bilayer environment surrounding GPCRs. Our preliminary study for 12 structures from six receptors (bRho, β<sub>2</sub>AR, M2R, µOR, A<sub>2A</sub>R and κ-OR) revealed that amino acids with hydrophobic side chains (one-letter code: A, V, I, L, M, P, F, Y, W) contribute to the majority (~88%) of residue pairs. Meanwhile, ionic lock opening of well-known motif DRY upon receptor activation can be adequately reflected by RRCS change between D/E<sup>3×49</sup> and R<sup>3×50</sup>. These results suggest that interatomic distance-dependent residue pair contact score may represent an acceptable approximation of actual (either hydrophobic or charge-charge) interaction energies (<xref ref-type="bibr" rid="bib128">Ngo et al., 2017</xref>) and is accurate enough for identifying conserved rearrangements of residue contacts upon receptor activation.</p></list-item><list-item><p>The quality of structures is extremely important for RRCS calculation. We adopted two criteria to exclude unreliable structures and residues: (a) crystal structures whose resolution is ≥3.8 Å. Structures in this category are: 5DGY (7.70 Å), 2I37 (4.20 Å), 2I36 (4.10 Å), 5TE5 (4.00 Å), 4GBR (4.00 Å), 5NJ6 (4.00 Å), 5V54 (3.90 Å), 2I35 (3.80 Å), 5D5B (3.80 Å), 4XT3 (3.80 Å); (b) residues whose residue-based real-space R-value (RSR [<xref ref-type="bibr" rid="bib71">Jones et al., 1991</xref>]) is greater than 0.35. RSR is measure of how well ‘observed’ and calculated electron densities agree for a residue. RSR ranges from 0 (perfect match) to 1 (no match); RSR greater than 0.4 indicates a poor fit (<xref ref-type="bibr" rid="bib159">Smart et al., 2018</xref>). Here we adopted a stricter cut-off, 0.35. Among the 234 class A GPCR structures, 156 have available RSR information (<xref ref-type="bibr" rid="bib79">Kleywegt et al., 2004</xref>) (<ext-link ext-link-type="uri" xlink:href="http://eds.bmc.uu.se">http://eds.bmc.uu.se</ext-link>), with 8.8% residues have RSR &gt;0.35 and they are omitted in our analysis. For the 35 residues that constitute the common activation pathway, 255 out of 5460 RSR data points (~4.7%, lower than 8.8% for all residues) were omitted for having RSR values &gt; 0.35.</p></list-item><list-item><p>For structures with multiple chains, RRCS were the average over all chains. For residues with multiple alternative conformations, RRCS was the sum of individual values multiplied by the weighting factor: occupancy value extracted from PDB files. Small molecule/peptide ligand, or intracellular binding partner (G protein or its mimetic) was treated as a single residue.</p></list-item><list-item><p>For the family-wide comparison of conformational changes upon activation, structurally equivalent residues are numbered by GPCRdb numbering scheme (<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>). Of the 35 residues in the common activation pathway, their GPCRdb numbering in all structures is almost identical to the Ballesteros–Weinstein numbering (<xref ref-type="bibr" rid="bib5">Ballesteros and Weinstein, 1995</xref>), the exceptions are residues at 6×37, 6×41 and 6×44 for five receptors: FFAR1, P2Y<sub>1</sub>, P2Y<sub>12</sub>, F2R and PAR2, which are all from the delta branch of class A family.</p></list-item></list></sec><sec id="s4-4"><title>Identification of conserved rearrangements of residue contacts upon activation</title><p>Using RRCS, structural information of TMD and helix eight in each structure can be decomposed into 400 ~ 500 residue pairs with positive RRCS. ∆RRCS, defined as RRCS<sub>active</sub> − RRCS<sub>inactive</sub>, reflects the change of RRCS for a residue pair from inactive- to active- state (<xref ref-type="fig" rid="fig2">Figure 2b–d</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>). To identify residue pairs with conserved conformational rearrangements upon activation across class A GPCRs, two rounds of selections (<xref ref-type="fig" rid="fig2">Figure 2d</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>) were performed: (i) identification of conserved rearrangements of residue contacts upon activation for six receptors (bRho, β<sub>2</sub>AR, M2R, μOR, A<sub>2A</sub>R and κ-OR), that is equivalent residue pairs show a similar and substantial change in RRCS between the active and inactive state structure of each of the six receptors (the same sign of ∆RRCS and |∆RRCS| &gt; 0.2 for all receptors) and (ii) family-wide RRCS comparison between the 142 inactive and 27 active state structures to identify residues pairs of statistically significant different (p&lt;0.001; two sample <italic>t</italic>-test) RRCS upon activation.</p><p>Round 1. Identification of conserved rearrangements of residue contacts. Six receptors with available inactive- and active- state structures were analyzed using ∆RRCS to identify residue pairs that share similar conformational changes. Twelve representative crystal structures (high-resolution, no mutation or one mutation in TMD without affecting receptor signalling) were chosen in this stage: six inactive state structures (PDB codes 1GZM for bRho, 2RH1 for β<sub>2</sub>AR, 3UON for M2R, 4DKL for μOR, 3EML for A<sub>2A</sub>R and 4DJH for κ-OR) and six active state structures (3PQR for bRho, 3SN6 for β<sub>2</sub>AR, 4MQS for M2R, 5C1M for μOR, 5G53 for A<sub>2A</sub>R and 6B73 for κ-OR) (<xref ref-type="fig" rid="fig2">Figure 2d</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c</xref> and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Each receptor has approximately 600 residues pairs that have positive RRCS. Roughly one quarter are newly formed during receptor activation (RRCS<sub>inactive</sub> = 0 and RRCS<sub>active</sub> &gt;0); another quarter lose their contacts upon receptor activation (RRCS<sub>inactive</sub> &gt;0 and RRCS<sub>active</sub> = 0); and the remaining appear in both the inactive- or active- state structures (RRCS<sub>inactive</sub> &gt;0 and RRCS<sub>active</sub> &gt;0), the contact rearrangement of which can only be reflected by ∆RRCS, but not Boolean descriptors.</p><p>To identify residue pairs that share conserved rearrangements of residue contacts upon activation, two steps are performed to qualify residue pairs for the next round. Firstly, residue pairs with same sign of ∆RRCS and |∆RRCS| &gt; 0.2 for all six receptors were identified. There are 32 intra-receptor residues pairs (1×49:7×50, 1×53:7×53, 1×53:7×54, 2×37:2×40, 2×42:4×45, 2×43:7×53, 2×45:4×50, 2×46:2×50, 2×50:3×39, 2×57:7×42, 3×40:6×48, 3×43:6×40, 3×43:6×41, 3×43:7×49, 3×43:7×53, 3×46:6×37, 3×46:7×53, 3×49:3×50, 3×50:3×53, 3×50:6×37, 350:7×53, 3×51:5×57, 5×51:6×44, 5×58:6×40, 5×62:6×37, 6×40:7×49, 6×44:6×48, 7×50:7×55, 7×52:7×53, 7×53:8×50, 7×54:8×50 and 7×54:8×51) and five receptor-G protein/its mimetic residue pairs (3×50:G protein, 3×53:G protein, 3×54:G protein, 5×61:G protein and 6×33:G protein) that meet this criterion. Secondly, we also investigated residue pairs with ∆RRCS that are conserved in five receptors (<italic>i.e.</italic>, with one receptor as exception). Considering there is no Na<sup>+</sup> pocket for rhodopsin, three residue pairs (2×50:7×49, 6×44:7×45 and 6×48:7×45) around Na<sup>+</sup> pocket were analyzed for five receptors but not bRho. Additionally, three residue pairs have 0 (3×46:3×50, 5×55:6×41) or negative (7×45:7×49) ∆RRCS for κ-OR but positive ∆RRCS for the other five receptors. As for 3×46:3×50, nanobody-stabilized active structures (β<sub>2</sub>AR: 3P0G, 4LDO, 4LDL, 4LDE, 4QKX; and μOR: 5C1M) generally have lower contact scores (&lt;0.4) compared with G-protein-bound active-state structures (2.17 for 3SN6 of β<sub>2</sub>AR, 2.57 for 5G53 of A<sub>2A</sub>R and 6.93 for 3PQR of bRho). For these residue pairs, we added newly determined G<sub>i</sub>-bound active A<sub>1A</sub>R and 5-HT<sub>1B</sub> receptor and found that they have positive ∆RRCS, like other five receptors (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>). Thus, these three residue pairs (3×46:3×50, 5×55:6×41 and 7×45:7×49) were retained. Totally, six residue pairs with conserved ∆RRCS in five receptors were rescued. Taken together, 38 intra-receptor residue pairs and five receptor-G protein/its mimetic residue pairs were identified to have conserved rearrangements of residue contacts upon activation.</p><p>Round 2. Family-wide conservation analysis of residue contact pattern. To investigate the conservation of residue contact pattern for the 38 intra-receptor residue pairs across these functionally diverse receptors, two-tailed unpaired <italic>t</italic>-test between inactive state (142 inactive structures from 38 receptors) and active state (27 active structures from eight receptors) groups were performed (<xref ref-type="fig" rid="fig2">Figure 2d</xref> and <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). Thirty one residue pairs have significantly different RRCS between inactive- and active-state (p&lt;10<sup>−5</sup>). As rhodopsin lacks the Na<sup>+</sup> pocket, all rhodopsin structures were neglected in the analysis of 3 residue pairs around the pocket (2×50:7×49, 6×44:7×45 and 6×48:7×45), which have good p value (&lt;10<sup>−3</sup>) for these non-rhodopsin class A GPCRs. Four residue pairs were filtered out in this round due to their poor p value, that is there are no statistically significant difference in RRCS between inactive and active states (p=0.01 for 2×37:2×40, 0.96 for 2×42:4×45, 0.02 for 2×45:4×50 and 0.014 for 2×57:7×42).</p><p>Finally, 34 intra-receptor residue pairs (<xref ref-type="fig" rid="fig2">Figure 2d</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref>) and five receptor-G-protein residue pairs were identified with conserved rearrangements of residue contacts upon activation, including all six residues pairs identified by the previous RC approaches (<xref ref-type="bibr" rid="bib182">Venkatakrishnan et al., 2016</xref>).</p></sec><sec id="s4-5"><title>Sequence analysis of class A GPCRs</title><p>The alignment of 286 non-olfactory, class A human GPCRs were obtained from the GPCRdb (<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>). The distribution of sequence similarity/identity across class A GPCRs were extracted from the sequence similarity/identity matrix for different structural regions using ‘Similarity Matrix’ tool in GPCRdb. The sequence conservation score (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) for all residue positions across 286 non-olfactory class A GPCRs were evaluated by the Protein Residue Conservation Prediction (<xref ref-type="bibr" rid="bib10">Capra and Singh, 2007</xref>) tool with scoring method 'Property Entropy' (<xref ref-type="bibr" rid="bib123">Mirny and Shakhnovich, 1999</xref>). Sequence conservation analysis (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>) were visualized by WebLogo3 (<xref ref-type="bibr" rid="bib23">Crooks et al., 2004</xref>) with sequence alignment files from GPCRdb as the input.</p></sec><sec id="s4-6"><title>CAM/CIM in class A GPCRs</title><p>For the 14 hub residues in the common activation pathway, we collected the functional mutation data from the literature and GPCRdb (<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>). Mutations with ‘more than two fold-increase in basal activity/constitutively active’ or ‘abolished effect’ compared to the wild-type receptor were selected. Together, 272 mutations from 41 class A GPCRs on the 14 hub residues were collected, including the mutations we designed and validated in this study (<xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>).</p></sec><sec id="s4-7"><title>Disease-associated mutations in class A GPCRs</title><p>To reveal the relationship between disease-associated mutations and related phenotypes of different transmembrane regions (<xref ref-type="bibr" rid="bib180">Vassart and Costagliola, 2011</xref>; <xref ref-type="bibr" rid="bib174">Thompson et al., 2014</xref>; <xref ref-type="bibr" rid="bib169">Tao, 2006</xref>; <xref ref-type="bibr" rid="bib170">Tao, 2008</xref>), we collected disease-associated mutation information for all 286 non-olfactory class A GPCRs by database integration and literature investigation. Four commonly used databases (UniProt [<xref ref-type="bibr" rid="bib173">The UniProt Consortium, 2017</xref>], OMIM [<xref ref-type="bibr" rid="bib4">Amberger et al., 2011</xref>], Ensembl [<xref ref-type="bibr" rid="bib205">Zerbino et al., 2018</xref>] and GPCRdb [<xref ref-type="bibr" rid="bib64">Isberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Isberg et al., 2015</xref>]) were first filtered by disease mutations and then merged. Totally 435 disease mutations from 61 class A GPCRs were collected (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>).</p></sec><sec id="s4-8"><title>Pathway-guided CAM/CIM design in A<sub>2A</sub>R</title><p>We designed mutations for a prototypical receptor A<sub>2A</sub>R, guided by the common activation pathway, aiming to get constitutively active/inactive receptor. Mutations that can either stabilize active or inactive state structures of A<sub>2A</sub>R or promote/block conformational changes upon activation were designed (<xref ref-type="fig" rid="fig6">Figure 6c</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) and tested by a functional cAMP accumulation assay. The inactive state structure 3EML and active state structure 5G53 were used. In silico mutagenesis was performed by Residue Scanning module in BioLuminate (<xref ref-type="bibr" rid="bib6">Beard et al., 2013</xref>). Side-chain prediction with backbone sampling and a cut-off value of 6 Å were applied during the scanning. ΔStability is the change of receptor stability when introducing a mutation. We filtered the mutations by one of the following criteria: (i) ΔStability in active and inactive structures have opposite signs; or (ii) ΔStability in active and inactive structures have the same sign, but favorable interactions such as hydrogen bonds, salt bridge or pi-pi stacking exist in only one structure that can promote/block conformational changes upon activation. Totally, 15 and 20 mutations were predicted to be CAMs and CIMs, respectively. (<xref ref-type="fig" rid="fig6">Figure 6c</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p></sec><sec id="s4-9"><title>cAMP accumulation assays</title><p>(i)A<sub>2A</sub>R. The desired mutations were introduced into amino-terminally Flag tag-labeled human A<sub>2A</sub>R in the pcDNA3.1 vector (Invitrogen, Carlsbad, CA). This construct displayed equivalent pharmacological features to that of untagged human receptor based on radioligand binding and cAMP assays (<xref ref-type="bibr" rid="bib116">Massink et al., 2015</xref>). The mutants were constructed by PCR-based site-directed mutagenesis (Muta-directTM kit, Beijing SBS Genetech Co., Ltd., China). Sequences of receptor clones were confirmed by DNA sequencing. HEK-293 cells (obtained from ATCC and confirmed as negative for mycoplasma contamination) were seeded onto 6-well cell culture plates. After overnight culture, the cells were transiently transfected with WT or mutant DNA using Lipofectamine 2000 transfection reagent (Invitrogen). After 24 hr, the transfected cells were seeded onto 384-well plates (3,000 cells per well). cAMP accumulation was measured using the LANCE cAMP kit (PerkinElmer, Boston, MA) according to the manufacturer’s instructions. Briefly, transfected cells were incubated for 40 min in assay buffer (DMEM, 1 mM 3-isobutyl-1-methylxanthine) with different concentrations of agonist [CGS21680 (179 pM to 50 μM)]. The reactions were stopped by addition of lysis buffer containing LANCE reagents. Plates were then incubated for 60 min at room temperature and time-resolved FRET signals were measured at 625 nm and 665 nm by an EnVision multilabel plate reader (PerkinElmer). The cAMP response is depicted relative to the maximal response of CGS21680 (100%) at the WT A<sub>2A</sub>R. (ii) 5-HT<sub>1B</sub> receptor. cAMP accumulation was measured using LANCE cAMP kit (PerkinElmer). Briefly, HEK293T (obtained from and certified by the Cell Bank at the Chinese Academy of Science and confirmed as negative for mycoplasma contamination) cells were transfected with plasmids bearing WT or mutant 5-HT<sub>1B</sub> receptor. Cells were collected 24 hr post-transfection and used to seed white poly-D-lysine coated 384-well plates at a density of 2,000 cells per well. Cells were incubated for a further 24 hr at 37°C. Cells were then incubated for 30 min in assay buffer (HBSS, 5 mM HEPES, 0.1% BSA, 0.5 mM 3-isobutyl-1-methylxanthine) with constant Forsklin (800 nM) and different concentrations of dihydroergotamine (DHE, 0.64 pM to 50 nM) at 37°C. The reactions were stopped by addition of lysis buffer containing LANCE reagents. Plates were then incubated for 60 min at room temperature, and time-resolved FRET signals were measured after excitation at 620 nm and 650 nm by EnVision (PerkinElmer).</p></sec><sec id="s4-10"><title>CGS21680 binding assay</title><p>CGS21680 (a specific adenosine A<sub>2A</sub> subtype receptor agonist) binding was analyzed using plasma membranes prepared from HEK-293 cells transiently expressing WT and mutant A<sub>2A</sub>Rs. Approximately 1.2×10<sup>8</sup> transfected HEK-293 cells were harvested, suspended in 10 ml ice-cold membrane buffer (50 mM Tris-HCl, pH 7.4) and centrifuged for 5 min at 700 <bold><italic>g</italic></bold>. The resulting pellet was resuspended in ice-cold membrane buffer, homogenized by Dounce Homogenizer (Wheaton, Millville, NJ) and centrifuged for 20 min at 50,000 <bold><italic>g</italic></bold>. The pellet was resuspended, homogenized, centrifuged again and the precipitate containing the plasma membranes was then suspended in the membrane buffer containing protease inhibitor (Sigma-Aldrich, St. Louis, MO) and stored at −80°C. Protein concentration was determined using a protein BCA assay kit (Pierce Biotechnology, Pittsburgh, PA). For homogeneous binding, cell membrane homogenates (10 µg protein per well) were incubated in membrane binding buffer (50 mM Tris-HCl, 10 mM NaCl, 0.1 mM EDTA, pH 7.4) with constant concentration of [<sup>3</sup>H]-CGS21680 (1 nM, PerkinElmer) and serial dilutions of unlabeled CGS21680 (0.26 nM to 100 µM) at room temperature for 3 hr. Nonspecific binding was determined in the presence of 100 µM CGS21680. Following incubation, the samples were filtered rapidly in vacuum through glass fiber filter plates (PerkinElmer). After soaking and rinsing four times with ice-cold PBS, the filters were dried and counted for radioactivity in a MicroBeta2 scintillation counter (PerkinElmer).</p></sec><sec id="s4-11"><title>Surface expression of A<sub>2A</sub>Rs</title><p>HEK293 cells were seeded into six-well plate and incubated overnight. After transient transfection with WT or mutant plasmids for 24 hr, the cells were collected and blocked with 5% BSA in PBS at room temperature for 15 min and incubated with primary anti-Flag antibody (1:100, Sigma-Aldrich) at room temperature for 1 hr. The cells were then washed three times with PBS containing 1% BSA followed by 1 hr incubation with anti-rabbit Alexa-488-conjugated secondary antibody (1:1000, Cell Signaling Technology, Danvers, MA) at 4°C in the dark. After three washes, the cells were resuspended in 200 µl of PBS containing 1% BSA for detection in a NovoCyte flow cytometer (ACEA Biosciences, San Diego, CA) utilizing laser excitation and emission wavelengths of 488 nm and 519 nm, respectively. For each assay point, approximately 15,000 cellular events were collected, and the total fluorescence intensity of positive expression cell population was calculated.</p></sec><sec id="s4-12"><title>Plasmid constructs of 5-HT<sub>7</sub> receptor</title><p>A plasmid encoding the 5-HT<sub>7</sub> receptor was obtained from PRESTO-Tango Kit produced by Addgene (Watertown, MA). 5-HT<sub>7</sub> coding sequence was amplified and ligated into the pRluc8-N1 vector to produce WT 5-HT<sub>7</sub>-Rluc8. Mutant 5-HT<sub>7</sub>-Rluc8 receptors were generated from this plasmid using the Quikchange mutagenesis kit (Agilent Technologies, Santa Clara, CA). A plasmid encoding the Nluc-EPAC-VV cAMP sensor was kindly provided by Kirill Martemyanov (The Scripps Research Institute, Jupiter, FL) and has been described previously. (<xref ref-type="bibr" rid="bib117">Masuho et al., 2015</xref>) All plasmid constructs were verified by DNA sequencing.</p></sec><sec id="s4-13"><title>Cell transfection</title><p>HEK293 cells cultured in 6-well plates were transiently transfected with the above plasmids (3.0 μg DNA) in growth medium using linear polyethyleneimine MAX (Polysciences, Warrington, PA) at an N/P ratio of 20 and used for experimentation 12–48 hr thereafter.</p></sec><sec id="s4-14"><title>BRET cAMP and trafficking assays</title><p>HEK 293 cells transiently transfected with WT or mutant 5-HT<sub>7</sub> receptor plasmids plus either the Nluc-EPAC-VV cAMP sensor (at a 15:1 ratio) or Venus-kras (at a 1:8 ratio) (<xref ref-type="bibr" rid="bib175">Tian et al., 2017</xref>) were incubated for 24 hr. After washing twice with PBS, they were transferred to opaque black 96-well plates. Steady-state BRET measurements were made using a Mithras LB940 photon-counting plate reader (Berthold Technologies GmbH, Bad Wildbad, Germany). Furimazine (NanoGlo; 1:1000, Promega) for cAMP measurement or coelenterazine h (5 µM; Nanolight, Pinetop, AZ) for trafficking assay was added followed by BRET signal detection and calculation at an emission intensity of 520–545 nm divided by that of 475–495 nm.</p></sec><sec id="s4-15"><title>Data and materials availability</title><p>The open source code is available at GitHub (<xref ref-type="bibr" rid="bib210">Zhou, 2019</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/RRCS">https://github.com/elifesciences-publications/RRCS</ext-link>). For availability of codes that were developed in-house, please contacts the corresponding authors. All data are available in the main text or the source data.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was partially supported by National Natural Science Foundation of China grants 31971178 (SZ), 81872915 (M-WW), 21704064 (QZ), 81573479 (DHY) and 81773792 (DHY), National Key R and D Program of China grants 2016YFC0905900 (SZ) and 2018YFA0507000 (SZ and M-WW), National Mega R and D Program for Drug Discovery grants 2018ZX09711002–002–005 (DHY) and 2018ZX09735–001 (M-WW), Shanghai Science and Technology Development Fund grant 16ZR1407100 (ATD), Novo Nordisk-CAS Research Fund grant NNCAS-2017–1-CC (DHY), the Medical Research Council MC_U105185859 (MMB), National Institutes of Health Grants GM130142 (NAL) and annual overhead support from ShanghaiTech University and Chinese Academy of Sciences. We thank A Sali, MA Hanson and AJ Venkatakrishnan for valuable discussions, YM Xu for technical assistance, and AP IJzerman for providing the WT A<sub>2A</sub>R plasmid.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Formal analysis, Funding acquisition, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con4"><p>Software</p></fn><fn fn-type="con" id="con5"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con7"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Funding acquisition, Validation</p></fn><fn fn-type="con" id="con9"><p>Validation</p></fn><fn fn-type="con" id="con10"><p>Provided academic support</p></fn><fn fn-type="con" id="con11"><p>Provided academic support</p></fn><fn fn-type="con" id="con12"><p>Provided academic support</p></fn><fn fn-type="con" id="con13"><p>Data curation, Validation</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Key resource table.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-50279-supp1-v3.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-50279-transrepform-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1, 2, 6 and 7.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname> <given-names>B</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Protein residue contacts and prediction methods</article-title><source>Methods in Molecular Biology</source><volume>1415</volume><fpage>463</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-3572-7_24</pub-id><pub-id pub-id-type="pmid">27115648</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhadeff</surname> <given-names>R</given-names></name><name><surname>Vorobyov</surname> <given-names>I</given-names></name><name><surname>Yoon</surname> <given-names>HW</given-names></name><name><surname>Warshel</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Exploring the free-energy landscape of GPCR activation</article-title><source>PNAS</source><volume>115</volume><fpage>10327</fpage><lpage>10332</lpage><pub-id pub-id-type="doi">10.1073/pnas.1810316115</pub-id><pub-id pub-id-type="pmid">30257944</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>JA</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Strategies to discover unexpected targets for drugs active at G protein-coupled receptors</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>51</volume><fpage>117</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010510-100553</pub-id><pub-id pub-id-type="pmid">20868273</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amberger</surname> <given-names>J</given-names></name><name><surname>Bocchini</surname> <given-names>C</given-names></name><name><surname>Hamosh</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A new face and new challenges for online mendelian inheritance in man (OMIM)</article-title><source>Human Mutation</source><volume>32</volume><fpage>564</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1002/humu.21466</pub-id><pub-id pub-id-type="pmid">21472891</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballesteros</surname> <given-names>JA</given-names></name><name><surname>Weinstein</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>[19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors</article-title><source>Methods in Neurosciences</source><volume>25</volume><fpage>366</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/S1043-9471(05)80049-7</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beard</surname> <given-names>H</given-names></name><name><surname>Cholleti</surname> <given-names>A</given-names></name><name><surname>Pearlman</surname> <given-names>D</given-names></name><name><surname>Sherman</surname> <given-names>W</given-names></name><name><surname>Loving</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e82849</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0082849</pub-id><pub-id pub-id-type="pmid">24340062</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname> <given-names>S</given-names></name><name><surname>Vaidehi</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differences in allosteric communication pipelines in the inactive and active states of a GPCR</article-title><source>Biophysical Journal</source><volume>107</volume><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2014.06.015</pub-id><pub-id pub-id-type="pmid">25028884</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockaert</surname> <given-names>J</given-names></name><name><surname>Pin</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Molecular tinkering of G protein-coupled receptors: an evolutionary success</article-title><source>The EMBO Journal</source><volume>18</volume><fpage>1723</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.7.1723</pub-id><pub-id pub-id-type="pmid">10202136</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname> <given-names>M</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystallizing membrane proteins using lipidic mesophases</article-title><source>Nature Protocols</source><volume>4</volume><fpage>706</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.31</pub-id><pub-id pub-id-type="pmid">19390528</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capra</surname> <given-names>JA</given-names></name><name><surname>Singh</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Predicting functionally important residues from sequence conservation</article-title><source>Bioinformatics</source><volume>23</volume><fpage>1875</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm270</pub-id><pub-id pub-id-type="pmid">17519246</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname> <given-names>B</given-names></name><name><surname>Nehmé</surname> <given-names>R</given-names></name><name><surname>Warne</surname> <given-names>T</given-names></name><name><surname>Leslie</surname> <given-names>AG</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of the adenosine A(2A) receptor bound to an engineered G protein</article-title><source>Nature</source><volume>536</volume><fpage>104</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nature18966</pub-id><pub-id pub-id-type="pmid">27462812</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname> <given-names>M</given-names></name><name><surname>Schilling</surname> <given-names>J</given-names></name><name><surname>Beautrait</surname> <given-names>A</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name><name><surname>Benovic</surname> <given-names>JL</given-names></name><name><surname>Shukla</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Emerging paradigm of intracellular targeting of G Protein-Coupled receptors</article-title><source>Trends in Biochemical Sciences</source><volume>43</volume><fpage>533</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2018.04.003</pub-id><pub-id pub-id-type="pmid">29735399</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Che</surname> <given-names>T</given-names></name><name><surname>Majumdar</surname> <given-names>S</given-names></name><name><surname>Zaidi</surname> <given-names>SA</given-names></name><name><surname>Ondachi</surname> <given-names>P</given-names></name><name><surname>McCorvy</surname> <given-names>JD</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Mosier</surname> <given-names>PD</given-names></name><name><surname>Uprety</surname> <given-names>R</given-names></name><name><surname>Vardy</surname> <given-names>E</given-names></name><name><surname>Krumm</surname> <given-names>BE</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Lee</surname> <given-names>MY</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>XP</given-names></name><name><surname>Strachan</surname> <given-names>RT</given-names></name><name><surname>Tribo</surname> <given-names>AR</given-names></name><name><surname>Pasternak</surname> <given-names>GW</given-names></name><name><surname>Carroll</surname> <given-names>FI</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the Nanobody-Stabilized active state of the kappa opioid receptor</article-title><source>Cell</source><volume>172</volume><fpage>55</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.011</pub-id><pub-id pub-id-type="pmid">29307491</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Lu</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Yi</surname> <given-names>C</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Frimurer</surname> <given-names>TM</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>Schwartz</surname> <given-names>TW</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Wüthrich</surname> <given-names>K</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>638</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08568-5</pub-id><pub-id pub-id-type="pmid">30733446</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single-particle cryo-EM-How did it get here and where will it go</article-title><source>Science</source><volume>361</volume><fpage>876</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1126/science.aat4346</pub-id><pub-id pub-id-type="pmid">30166484</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Peddi</surname> <given-names>A</given-names></name><name><surname>Muthusubramaniam</surname> <given-names>L</given-names></name><name><surname>Zheng</surname> <given-names>YF</given-names></name><name><surname>Caffrey</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A robotic system for crystallizing membrane and soluble proteins in lipidic mesophases</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>60</volume><fpage>1795</fpage><lpage>1807</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019109</pub-id><pub-id pub-id-type="pmid">15388926</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Rosenbaum</surname> <given-names>DM</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Choi</surname> <given-names>HJ</given-names></name><name><surname>Kuhn</surname> <given-names>P</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor</article-title><source>Science</source><volume>318</volume><fpage>1258</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1126/science.1150577</pub-id><pub-id pub-id-type="pmid">17962520</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choe</surname> <given-names>H-W</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Morizumi</surname> <given-names>T</given-names></name><name><surname>Pai</surname> <given-names>EF</given-names></name><name><surname>Krauß</surname> <given-names>N</given-names></name><name><surname>Hofmann</surname> <given-names>KP</given-names></name><name><surname>Scheerer</surname> <given-names>P</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Crystal structure of metarhodopsin II</article-title><source>Nature</source><volume>471</volume><fpage>651</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/nature09789</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Advances in G protein-coupled receptor allostery: from function to structure</article-title><source>Molecular Pharmacology</source><volume>86</volume><fpage>463</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1124/mol.114.094342</pub-id><pub-id pub-id-type="pmid">25061106</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Kenakin</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>G protein-coupled receptor allosterism and complexing</article-title><source>Pharmacological Reviews</source><volume>54</volume><fpage>323</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1124/pr.54.2.323</pub-id><pub-id pub-id-type="pmid">12037145</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancetta</surname> <given-names>A</given-names></name><name><surname>Sabbadin</surname> <given-names>D</given-names></name><name><surname>Federico</surname> <given-names>S</given-names></name><name><surname>Spalluto</surname> <given-names>G</given-names></name><name><surname>Moro</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Advances in computational techniques to study GPCR-Ligand recognition</article-title><source>Trends in Pharmacological Sciences</source><volume>36</volume><fpage>878</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2015.08.006</pub-id><pub-id pub-id-type="pmid">26538318</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname> <given-names>RM</given-names></name><name><surname>Brown</surname> <given-names>AJH</given-names></name><name><surname>Marshall</surname> <given-names>FH</given-names></name><name><surname>Mason</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structures of G protein-coupled receptors reveal new opportunities for drug discovery</article-title><source>Drug Discovery Today</source><volume>20</volume><fpage>1355</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2015.08.003</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crooks</surname> <given-names>GE</given-names></name><name><surname>Hon</surname> <given-names>G</given-names></name><name><surname>Chandonia</surname> <given-names>JM</given-names></name><name><surname>Brenner</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>WebLogo: a sequence logo generator</article-title><source>Genome Research</source><volume>14</volume><fpage>1188</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1101/gr.849004</pub-id><pub-id pub-id-type="pmid">15173120</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname> <given-names>JA</given-names></name><name><surname>Lans</surname> <given-names>I</given-names></name><name><surname>Giraldo</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantifying conformational changes in GPCRs: glimpse of a common functional mechanism</article-title><source>BMC Bioinformatics</source><volume>16</volume><elocation-id>124</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-015-0567-3</pub-id><pub-id pub-id-type="pmid">25902715</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVree</surname> <given-names>BT</given-names></name><name><surname>Mahoney</surname> <given-names>JP</given-names></name><name><surname>Vélez-Ruiz</surname> <given-names>GA</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Kuszak</surname> <given-names>AJ</given-names></name><name><surname>Edwald</surname> <given-names>E</given-names></name><name><surname>Fung</surname> <given-names>JJ</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Masureel</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Matt</surname> <given-names>RA</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Allosteric coupling from G protein to the agonist-binding pocket in GPCRs</article-title><source>Nature</source><volume>535</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature18324</pub-id><pub-id pub-id-type="pmid">27362234</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper-Joyce</surname> <given-names>CJ</given-names></name><name><surname>Khoshouei</surname> <given-names>M</given-names></name><name><surname>Thal</surname> <given-names>DM</given-names></name><name><surname>Liang</surname> <given-names>Y-L</given-names></name><name><surname>Nguyen</surname> <given-names>ATN</given-names></name><name><surname>Furness</surname> <given-names>SGB</given-names></name><name><surname>Venugopal</surname> <given-names>H</given-names></name><name><surname>Baltos</surname> <given-names>J-A</given-names></name><name><surname>Plitzko</surname> <given-names>JM</given-names></name><name><surname>Danev</surname> <given-names>R</given-names></name><name><surname>Baumeister</surname> <given-names>W</given-names></name><name><surname>May</surname> <given-names>LT</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the adenosine-bound human Adenosine A1 receptor–Gi complex</article-title><source>Nature</source><volume>558</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0236-6</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Arlow</surname> <given-names>DH</given-names></name><name><surname>Maragakis</surname> <given-names>P</given-names></name><name><surname>Mildorf</surname> <given-names>TJ</given-names></name><name><surname>Pan</surname> <given-names>AC</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Borhani</surname> <given-names>DW</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>Activation mechanism of the β2-adrenergic receptor</article-title><source>PNAS</source><volume>108</volume><fpage>18684</fpage><lpage>18689</lpage><pub-id pub-id-type="doi">10.1073/pnas.1110499108</pub-id><pub-id pub-id-type="pmid">22031696</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Pan</surname> <given-names>AC</given-names></name><name><surname>Arlow</surname> <given-names>DH</given-names></name><name><surname>Borhani</surname> <given-names>DW</given-names></name><name><surname>Maragakis</surname> <given-names>P</given-names></name><name><surname>Shan</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>Pathway and mechanism of drug binding to G-protein-coupled receptors</article-title><source>PNAS</source><volume>108</volume><fpage>13118</fpage><lpage>13123</lpage><pub-id pub-id-type="doi">10.1073/pnas.1104614108</pub-id><pub-id pub-id-type="pmid">21778406</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Green</surname> <given-names>HF</given-names></name><name><surname>Valant</surname> <given-names>C</given-names></name><name><surname>Borhani</surname> <given-names>DW</given-names></name><name><surname>Valcourt</surname> <given-names>JR</given-names></name><name><surname>Pan</surname> <given-names>AC</given-names></name><name><surname>Arlow</surname> <given-names>DH</given-names></name><name><surname>Canals</surname> <given-names>M</given-names></name><name><surname>Lane</surname> <given-names>JR</given-names></name><name><surname>Rahmani</surname> <given-names>R</given-names></name><name><surname>Baell</surname> <given-names>JB</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs</article-title><source>Nature</source><volume>503</volume><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1038/nature12595</pub-id><pub-id pub-id-type="pmid">24121438</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Mildorf</surname> <given-names>TJ</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Borhani</surname> <given-names>DW</given-names></name><name><surname>Arlow</surname> <given-names>DH</given-names></name><name><surname>Philippsen</surname> <given-names>A</given-names></name><name><surname>Villanueva</surname> <given-names>N</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Lerch</surname> <given-names>MT</given-names></name><name><surname>Hubbell</surname> <given-names>WL</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SIGNAL TRANSDUCTION. Structural basis for nucleotide exchange in heterotrimeric G proteins</article-title><source>Science</source><volume>348</volume><fpage>1361</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1126/science.aaa5264</pub-id><pub-id pub-id-type="pmid">26089515</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Duc</surname> <given-names>NM</given-names></name><name><surname>Rasmussen</surname> <given-names>SGF</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Kubiak</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Bohon</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>HR</given-names></name><name><surname>Wegrecki</surname> <given-names>M</given-names></name><name><surname>Asuru</surname> <given-names>A</given-names></name><name><surname>Jeong</surname> <given-names>KM</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Chance</surname> <given-names>MR</given-names></name><name><surname>Lodowski</surname> <given-names>DT</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Chung</surname> <given-names>KY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Assembly of a GPCR-G protein complex</article-title><source>Cell</source><volume>177</volume><fpage>1232</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.022</pub-id><pub-id pub-id-type="pmid">31080064</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname> <given-names>MT</given-names></name><name><surname>Lee</surname> <given-names>M-Y</given-names></name><name><surname>Gao</surname> <given-names>Z-G</given-names></name><name><surname>White</surname> <given-names>KL</given-names></name><name><surname>Didenko</surname> <given-names>T</given-names></name><name><surname>Horst</surname> <given-names>R</given-names></name><name><surname>Audet</surname> <given-names>M</given-names></name><name><surname>Stanczak</surname> <given-names>P</given-names></name><name><surname>McClary</surname> <given-names>KM</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Jacobson</surname> <given-names>KA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Wüthrich</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Allosteric coupling of drug binding and intracellular signaling in the A2A adenosine receptor</article-title><source>Cell</source><volume>172</volume><fpage>68</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.004</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldridge</surname> <given-names>MD</given-names></name><name><surname>Murray</surname> <given-names>CW</given-names></name><name><surname>Auton</surname> <given-names>TR</given-names></name><name><surname>Paolini</surname> <given-names>GV</given-names></name><name><surname>Mee</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Empirical scoring functions: I. the development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes</article-title><source>Journal of Computer-Aided Molecular Design</source><volume>11</volume><fpage>425</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1023/a:1007996124545</pub-id><pub-id pub-id-type="pmid">9385547</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdélyi</surname> <given-names>LS</given-names></name><name><surname>Mann</surname> <given-names>WA</given-names></name><name><surname>Morris-Rosendahl</surname> <given-names>DJ</given-names></name><name><surname>Groß</surname> <given-names>U</given-names></name><name><surname>Nagel</surname> <given-names>M</given-names></name><name><surname>Várnai</surname> <given-names>P</given-names></name><name><surname>Balla</surname> <given-names>A</given-names></name><name><surname>Hunyady</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis</article-title><source>Kidney International</source><volume>88</volume><fpage>1070</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1038/ki.2015.181</pub-id><pub-id pub-id-type="pmid">26131744</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenalti</surname> <given-names>G</given-names></name><name><surname>Giguere</surname> <given-names>PM</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Huang</surname> <given-names>X-P</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular control of δ-opioid receptor signalling</article-title><source>Nature</source><volume>506</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nature12944</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Ambia</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>KM</given-names></name><name><surname>Young</surname> <given-names>M</given-names></name><name><surname>Barth</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Computational design of ligand-binding membrane receptors with high selectivity</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2371</pub-id><pub-id pub-id-type="pmid">28459439</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipek</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular switches in GPCRs</article-title><source>Current Opinion in Structural Biology</source><volume>55</volume><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2019.03.017</pub-id><pub-id pub-id-type="pmid">31082695</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flock</surname> <given-names>T</given-names></name><name><surname>Ravarani</surname> <given-names>CNJ</given-names></name><name><surname>Sun</surname> <given-names>D</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Kayikci</surname> <given-names>M</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name><name><surname>Veprintsev</surname> <given-names>DB</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Universal allosteric mechanism for gα activation by GPCRs</article-title><source>Nature</source><volume>524</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/nature14663</pub-id><pub-id pub-id-type="pmid">26147082</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flock</surname> <given-names>T</given-names></name><name><surname>Hauser</surname> <given-names>AS</given-names></name><name><surname>Lund</surname> <given-names>N</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name><name><surname>Balaji</surname> <given-names>S</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Selectivity determinants of GPCR-G-protein binding</article-title><source>Nature</source><volume>545</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature22070</pub-id><pub-id pub-id-type="pmid">28489817</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname> <given-names>R</given-names></name><name><surname>Lagerström</surname> <given-names>MC</given-names></name><name><surname>Lundin</surname> <given-names>LG</given-names></name><name><surname>Schiöth</surname> <given-names>HB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</article-title><source>Molecular Pharmacology</source><volume>63</volume><fpage>1256</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1124/mol.63.6.1256</pub-id><pub-id pub-id-type="pmid">12761335</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furness</surname> <given-names>SGB</given-names></name><name><surname>Liang</surname> <given-names>YL</given-names></name><name><surname>Nowell</surname> <given-names>CJ</given-names></name><name><surname>Halls</surname> <given-names>ML</given-names></name><name><surname>Wookey</surname> <given-names>PJ</given-names></name><name><surname>Dal Maso</surname> <given-names>E</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ligand-Dependent modulation of G protein conformation alters drug efficacy</article-title><source>Cell</source><volume>167</volume><fpage>739</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.021</pub-id><pub-id pub-id-type="pmid">27720449</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainetdinov</surname> <given-names>RR</given-names></name><name><surname>Premont</surname> <given-names>RT</given-names></name><name><surname>Bohn</surname> <given-names>LM</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name><name><surname>Caron</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Desensitization of G protein-coupled receptors and neuronal functions</article-title><source>Annual Review of Neuroscience</source><volume>27</volume><fpage>107</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.27.070203.144206</pub-id><pub-id pub-id-type="pmid">15217328</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Nafría</surname> <given-names>J</given-names></name><name><surname>Nehmé</surname> <given-names>R</given-names></name><name><surname>Edwards</surname> <given-names>PC</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cry<sub>o</sub>-EM structure of the serotonin 5-HT<sub>1B</sub> receptor coupled t<sub>o</sub> heterotrimeric G<sub>o</sub></article-title><source>Nature</source><volume>558</volume><fpage>620</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0241-9</pub-id><pub-id pub-id-type="pmid">29925951</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname> <given-names>E</given-names></name><name><surname>Kumari</surname> <given-names>P</given-names></name><name><surname>Jaiman</surname> <given-names>D</given-names></name><name><surname>Shukla</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Methodological advances: the unsung heroes of the GPCR structural revolution</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>16</volume><fpage>69</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/nrm3933</pub-id><pub-id pub-id-type="pmid">25589408</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilchrist</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Modulating G-protein-coupled receptors: from traditional pharmacology to allosterics</article-title><source>Trends in Pharmacological Sciences</source><volume>28</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.06.012</pub-id><pub-id pub-id-type="pmid">17644194</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Draper-Joyce</surname> <given-names>CJ</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rules of engagement: gpcrs and G proteins</article-title><source>ACS Pharmacology &amp; Translational Science</source><volume>1</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.8b00026</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregorio</surname> <given-names>GG</given-names></name><name><surname>Masureel</surname> <given-names>M</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Terry</surname> <given-names>DS</given-names></name><name><surname>Juette</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Perez-Aguilar</surname> <given-names>JM</given-names></name><name><surname>Hauge</surname> <given-names>M</given-names></name><name><surname>Mathiasen</surname> <given-names>S</given-names></name><name><surname>Javitch</surname> <given-names>JA</given-names></name><name><surname>Weinstein</surname> <given-names>H</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Blanchard</surname> <given-names>SC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-molecule analysis of ligand efficacy in β<sub>2</sub>AR-G-protein activation</article-title><source>Nature</source><volume>547</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/nature22354</pub-id><pub-id pub-id-type="pmid">28607487</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname> <given-names>K</given-names></name><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Asada</surname> <given-names>H</given-names></name><name><surname>Yurugi-Kobayashi</surname> <given-names>T</given-names></name><name><surname>Shiroishi</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Okada</surname> <given-names>T</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Haga</surname> <given-names>T</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist</article-title><source>Nature</source><volume>482</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nature10753</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halls</surname> <given-names>ML</given-names></name><name><surname>Canals</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetically encoded FRET biosensors to illuminate compartmentalised GPCR signalling</article-title><source>Trends in Pharmacological Sciences</source><volume>39</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.09.005</pub-id><pub-id pub-id-type="pmid">29054309</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>X</given-names></name><name><surname>Tachado</surname> <given-names>SD</given-names></name><name><surname>Koziel</surname> <given-names>H</given-names></name><name><surname>Boisvert</surname> <given-names>WA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Leu128(3.43) (l128) and Val247(6.40) (V247) of CXCR1 are critical amino acid residues for g protein coupling and receptor activation</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e42765</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0042765</pub-id><pub-id pub-id-type="pmid">22936990</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname> <given-names>AS</given-names></name><name><surname>Attwood</surname> <given-names>MM</given-names></name><name><surname>Rask-Andersen</surname> <given-names>M</given-names></name><name><surname>Schiöth</surname> <given-names>HB</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trends in GPCR drug discovery: new agents, targets and indications</article-title><source>Nature Reviews Drug Discovery</source><volume>16</volume><fpage>829</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.178</pub-id><pub-id pub-id-type="pmid">29075003</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname> <given-names>AS</given-names></name><name><surname>Chavali</surname> <given-names>S</given-names></name><name><surname>Masuho</surname> <given-names>I</given-names></name><name><surname>Jahn</surname> <given-names>LJ</given-names></name><name><surname>Martemyanov</surname> <given-names>KA</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pharmacogenomics of GPCR drug targets</article-title><source>Cell</source><volume>172</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.033</pub-id><pub-id pub-id-type="pmid">29249361</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname> <given-names>KP</given-names></name><name><surname>Scheerer</surname> <given-names>P</given-names></name><name><surname>Hildebrand</surname> <given-names>PW</given-names></name><name><surname>Choe</surname> <given-names>HW</given-names></name><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Heck</surname> <given-names>M</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A G protein-coupled receptor at work: the rhodopsin model</article-title><source>Trends in Biochemical Sciences</source><volume>34</volume><fpage>540</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2009.07.005</pub-id><pub-id pub-id-type="pmid">19836958</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingsworth</surname> <given-names>SA</given-names></name><name><surname>Kelly</surname> <given-names>B</given-names></name><name><surname>Valant</surname> <given-names>C</given-names></name><name><surname>Michaelis</surname> <given-names>JA</given-names></name><name><surname>Mastromihalis</surname> <given-names>O</given-names></name><name><surname>Thompson</surname> <given-names>G</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Hertig</surname> <given-names>S</given-names></name><name><surname>Scammells</surname> <given-names>PJ</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Felder</surname> <given-names>CC</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryptic pocket formation underlies allosteric modulator selectivity at Muscarinic GPCRs</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3289</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11062-7</pub-id><pub-id pub-id-type="pmid">31337749</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname> <given-names>B</given-names></name><name><surname>Nygaard</surname> <given-names>R</given-names></name><name><surname>Valentin-Hansen</surname> <given-names>L</given-names></name><name><surname>Bach</surname> <given-names>A</given-names></name><name><surname>Engelstoft</surname> <given-names>MS</given-names></name><name><surname>Petersen</surname> <given-names>PS</given-names></name><name><surname>Frimurer</surname> <given-names>TM</given-names></name><name><surname>Schwartz</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>3973</fpage><lpage>3985</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.064725</pub-id><pub-id pub-id-type="pmid">19920139</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname> <given-names>T</given-names></name><name><surname>Okuno</surname> <given-names>T</given-names></name><name><surname>Hirata</surname> <given-names>K</given-names></name><name><surname>Yamashita</surname> <given-names>K</given-names></name><name><surname>Kawano</surname> <given-names>Y</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Hato</surname> <given-names>M</given-names></name><name><surname>Nakamura</surname> <given-names>M</given-names></name><name><surname>Shimizu</surname> <given-names>T</given-names></name><name><surname>Yokomizo</surname> <given-names>T</given-names></name><name><surname>Miyano</surname> <given-names>M</given-names></name><name><surname>Yokoyama</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Na<sup>+</sup>-mimicking ligands stabilize the inactive state of leukotriene B<sub>4</sub> receptor BLT1</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>262</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2547</pub-id><pub-id pub-id-type="pmid">29309055</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Laeremans</surname> <given-names>T</given-names></name><name><surname>Feinberg</surname> <given-names>EN</given-names></name><name><surname>Sanborn</surname> <given-names>AL</given-names></name><name><surname>Kato</surname> <given-names>HE</given-names></name><name><surname>Livingston</surname> <given-names>KE</given-names></name><name><surname>Thorsen</surname> <given-names>TS</given-names></name><name><surname>Kling</surname> <given-names>RC</given-names></name><name><surname>Granier</surname> <given-names>S</given-names></name><name><surname>Gmeiner</surname> <given-names>P</given-names></name><name><surname>Husbands</surname> <given-names>SM</given-names></name><name><surname>Traynor</surname> <given-names>JR</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural insights into µ-opioid receptor activation</article-title><source>Nature</source><volume>524</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/nature14886</pub-id><pub-id pub-id-type="pmid">26245379</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulme</surname> <given-names>EC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GPCR activation: a mutagenic spotlight on crystal structures</article-title><source>Trends in Pharmacological Sciences</source><volume>34</volume><fpage>67</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2012.11.002</pub-id><pub-id pub-id-type="pmid">23245528</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunyady</surname> <given-names>L</given-names></name><name><surname>Vauquelin</surname> <given-names>G</given-names></name><name><surname>Vanderheyden</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Agonist induction and conformational selection during activation of a G-protein-coupled receptor</article-title><source>Trends in Pharmacological Sciences</source><volume>24</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0165-6147(02)00050-0</pub-id><pub-id pub-id-type="pmid">12559772</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilyaskina</surname> <given-names>OS</given-names></name><name><surname>Lemoine</surname> <given-names>H</given-names></name><name><surname>Bünemann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lifetime of muscarinic receptor-G-protein complexes determines coupling efficiency and G-protein subtype selectivity</article-title><source>PNAS</source><volume>115</volume><fpage>5016</fpage><lpage>5021</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715751115</pub-id><pub-id pub-id-type="pmid">29686069</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Raimondi</surname> <given-names>F</given-names></name><name><surname>Kadji</surname> <given-names>FMN</given-names></name><name><surname>Singh</surname> <given-names>G</given-names></name><name><surname>Kishi</surname> <given-names>T</given-names></name><name><surname>Uwamizu</surname> <given-names>A</given-names></name><name><surname>Ono</surname> <given-names>Y</given-names></name><name><surname>Shinjo</surname> <given-names>Y</given-names></name><name><surname>Ishida</surname> <given-names>S</given-names></name><name><surname>Arang</surname> <given-names>N</given-names></name><name><surname>Kawakami</surname> <given-names>K</given-names></name><name><surname>Gutkind</surname> <given-names>JS</given-names></name><name><surname>Aoki</surname> <given-names>J</given-names></name><name><surname>Russell</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Illuminating G-Protein-Coupling selectivity of GPCRs</article-title><source>Cell</source><volume>177</volume><fpage>1933</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.044</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irannejad</surname> <given-names>R</given-names></name><name><surname>Tomshine</surname> <given-names>JC</given-names></name><name><surname>Tomshine</surname> <given-names>JR</given-names></name><name><surname>Chevalier</surname> <given-names>M</given-names></name><name><surname>Mahoney</surname> <given-names>JP</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>El-Samad</surname> <given-names>H</given-names></name><name><surname>Huang</surname> <given-names>B</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conformational biosensors reveal GPCR signalling from endosomes</article-title><source>Nature</source><volume>495</volume><fpage>534</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/nature12000</pub-id><pub-id pub-id-type="pmid">23515162</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isberg</surname> <given-names>V</given-names></name><name><surname>de Graaf</surname> <given-names>C</given-names></name><name><surname>Bortolato</surname> <given-names>A</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Marshall</surname> <given-names>FH</given-names></name><name><surname>Mordalski</surname> <given-names>S</given-names></name><name><surname>Pin</surname> <given-names>JP</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Vriend</surname> <given-names>G</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Generic GPCR residue numbers - aligning topology maps while minding the gaps</article-title><source>Trends in Pharmacological Sciences</source><volume>36</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.11.001</pub-id><pub-id pub-id-type="pmid">25541108</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isberg</surname> <given-names>V</given-names></name><name><surname>Mordalski</surname> <given-names>S</given-names></name><name><surname>Munk</surname> <given-names>C</given-names></name><name><surname>Rataj</surname> <given-names>K</given-names></name><name><surname>Harpsøe</surname> <given-names>K</given-names></name><name><surname>Hauser</surname> <given-names>AS</given-names></name><name><surname>Vroling</surname> <given-names>B</given-names></name><name><surname>Bojarski</surname> <given-names>AJ</given-names></name><name><surname>Vriend</surname> <given-names>G</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>GPCRdb: an information system for G protein-coupled receptors</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D356</fpage><lpage>D364</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1178</pub-id><pub-id pub-id-type="pmid">26582914</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishchenko</surname> <given-names>A</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Kapoor</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>A</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Patel</surname> <given-names>N</given-names></name><name><surname>Messerschmidt</surname> <given-names>M</given-names></name><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody</article-title><source>PNAS</source><volume>114</volume><fpage>8223</fpage><lpage>8228</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700891114</pub-id><pub-id pub-id-type="pmid">28716900</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isogai</surname> <given-names>S</given-names></name><name><surname>Deupi</surname> <given-names>X</given-names></name><name><surname>Opitz</surname> <given-names>C</given-names></name><name><surname>Heydenreich</surname> <given-names>FM</given-names></name><name><surname>Tsai</surname> <given-names>CJ</given-names></name><name><surname>Brueckner</surname> <given-names>F</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name><name><surname>Veprintsev</surname> <given-names>DB</given-names></name><name><surname>Grzesiek</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Backbone NMR reveals allosteric signal transduction networks in the β1-adrenergic receptor</article-title><source>Nature</source><volume>530</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/nature16577</pub-id><pub-id pub-id-type="pmid">26840483</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isom</surname> <given-names>DG</given-names></name><name><surname>Dohlman</surname> <given-names>HG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Buried ionizable networks are an ancient hallmark of G protein-coupled receptor activation</article-title><source>PNAS</source><volume>112</volume><fpage>5702</fpage><lpage>5707</lpage><pub-id pub-id-type="doi">10.1073/pnas.1417888112</pub-id><pub-id pub-id-type="pmid">25902551</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaakola</surname> <given-names>VP</given-names></name><name><surname>Griffith</surname> <given-names>MT</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Chien</surname> <given-names>EY</given-names></name><name><surname>Lane</surname> <given-names>JR</given-names></name><name><surname>Ijzerman</surname> <given-names>AP</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist</article-title><source>Science</source><volume>322</volume><fpage>1211</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1126/science.1164772</pub-id><pub-id pub-id-type="pmid">18832607</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>KA</given-names></name><name><surname>Costanzi</surname> <given-names>S</given-names></name><name><surname>Paoletta</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Computational studies to predict or explain G protein coupled receptor polypharmacology</article-title><source>Trends in Pharmacological Sciences</source><volume>35</volume><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.10.009</pub-id><pub-id pub-id-type="pmid">25458540</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeger</surname> <given-names>K</given-names></name><name><surname>Bruenle</surname> <given-names>S</given-names></name><name><surname>Weinert</surname> <given-names>T</given-names></name><name><surname>Guba</surname> <given-names>W</given-names></name><name><surname>Muehle</surname> <given-names>J</given-names></name><name><surname>Miyazaki</surname> <given-names>T</given-names></name><name><surname>Weber</surname> <given-names>M</given-names></name><name><surname>Furrer</surname> <given-names>A</given-names></name><name><surname>Haenggi</surname> <given-names>N</given-names></name><name><surname>Tetaz</surname> <given-names>T</given-names></name><name><surname>Huang</surname> <given-names>CY</given-names></name><name><surname>Mattle</surname> <given-names>D</given-names></name><name><surname>Vonach</surname> <given-names>JM</given-names></name><name><surname>Gast</surname> <given-names>A</given-names></name><name><surname>Kuglstatter</surname> <given-names>A</given-names></name><name><surname>Rudolph</surname> <given-names>MG</given-names></name><name><surname>Nogly</surname> <given-names>P</given-names></name><name><surname>Benz</surname> <given-names>J</given-names></name><name><surname>Dawson</surname> <given-names>RJP</given-names></name><name><surname>Standfuss</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis for allosteric ligand recognition in the human CC chemokine receptor 7</article-title><source>Cell</source><volume>178</volume><fpage>1222</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.07.028</pub-id><pub-id pub-id-type="pmid">31442409</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>TA</given-names></name><name><surname>Zou</surname> <given-names>JY</given-names></name><name><surname>Cowan</surname> <given-names>SW</given-names></name><name><surname>Kjeldgaard</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Improved methods for building protein models in electron density maps and the location of errors in these models</article-title><source>Acta Crystallographica Section a Foundations of Crystallography</source><volume>47</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1107/S0108767390010224</pub-id><pub-id pub-id-type="pmid">2025413</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Ishchenko</surname> <given-names>A</given-names></name><name><surname>Barty</surname> <given-names>A</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Yefanov</surname> <given-names>O</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>de Waal</surname> <given-names>PW</given-names></name><name><surname>Ke</surname> <given-names>J</given-names></name><name><surname>Tan</surname> <given-names>MH</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Moeller</surname> <given-names>A</given-names></name><name><surname>West</surname> <given-names>GM</given-names></name><name><surname>Pascal</surname> <given-names>BD</given-names></name><name><surname>Van Eps</surname> <given-names>N</given-names></name><name><surname>Caro</surname> <given-names>LN</given-names></name><name><surname>Vishnivetskiy</surname> <given-names>SA</given-names></name><name><surname>Lee</surname> <given-names>RJ</given-names></name><name><surname>Suino-Powell</surname> <given-names>KM</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Pal</surname> <given-names>K</given-names></name><name><surname>Ma</surname> <given-names>J</given-names></name><name><surname>Zhi</surname> <given-names>X</given-names></name><name><surname>Boutet</surname> <given-names>S</given-names></name><name><surname>Williams</surname> <given-names>GJ</given-names></name><name><surname>Messerschmidt</surname> <given-names>M</given-names></name><name><surname>Gati</surname> <given-names>C</given-names></name><name><surname>Zatsepin</surname> <given-names>NA</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>James</surname> <given-names>D</given-names></name><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Roy-Chowdhury</surname> <given-names>S</given-names></name><name><surname>Conrad</surname> <given-names>CE</given-names></name><name><surname>Coe</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Lisova</surname> <given-names>S</given-names></name><name><surname>Kupitz</surname> <given-names>C</given-names></name><name><surname>Grotjohann</surname> <given-names>I</given-names></name><name><surname>Fromme</surname> <given-names>R</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Tan</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Zheng</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Howe</surname> <given-names>N</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Standfuss</surname> <given-names>J</given-names></name><name><surname>Diederichs</surname> <given-names>K</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Potter</surname> <given-names>CS</given-names></name><name><surname>Carragher</surname> <given-names>B</given-names></name><name><surname>Caffrey</surname> <given-names>M</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Chapman</surname> <given-names>HN</given-names></name><name><surname>Spence</surname> <given-names>JC</given-names></name><name><surname>Fromme</surname> <given-names>P</given-names></name><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Gurevich</surname> <given-names>VV</given-names></name><name><surname>Griffin</surname> <given-names>PR</given-names></name><name><surname>Hubbell</surname> <given-names>WL</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser</article-title><source>Nature</source><volume>523</volume><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nature14656</pub-id><pub-id pub-id-type="pmid">26200343</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>Y</given-names></name><name><surname>Kuybeda</surname> <given-names>O</given-names></name><name><surname>de Waal</surname> <given-names>PW</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Van Eps</surname> <given-names>N</given-names></name><name><surname>Dutka</surname> <given-names>P</given-names></name><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>Bartesaghi</surname> <given-names>A</given-names></name><name><surname>Erramilli</surname> <given-names>S</given-names></name><name><surname>Morizumi</surname> <given-names>T</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>G</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Kossiakoff</surname> <given-names>AA</given-names></name><name><surname>Subramaniam</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM structure of human rhodopsin bound to an inhibitory G protein</article-title><source>Nature</source><volume>558</volume><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0215-y</pub-id><pub-id pub-id-type="pmid">29899450</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname> <given-names>HE</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Suomivuori</surname> <given-names>CM</given-names></name><name><surname>Kadji</surname> <given-names>FMN</given-names></name><name><surname>Aoki</surname> <given-names>J</given-names></name><name><surname>Krishna Kumar</surname> <given-names>K</given-names></name><name><surname>Fonseca</surname> <given-names>R</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Conformational transitions of a neurotensin receptor 1-G<sub>i1</sub> complex</article-title><source>Nature</source><volume>572</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1337-6</pub-id><pub-id pub-id-type="pmid">31243364</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diversity and modularity of G protein-coupled receptor structures</article-title><source>Trends in Pharmacological Sciences</source><volume>33</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2011.09.003</pub-id><pub-id pub-id-type="pmid">22032986</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structure-function of the G protein-coupled receptor superfamily</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>53</volume><fpage>531</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-032112-135923</pub-id><pub-id pub-id-type="pmid">23140243</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Fenalti</surname> <given-names>G</given-names></name><name><surname>Abola</surname> <given-names>EE</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Allosteric sodium in class A GPCR signaling</article-title><source>Trends in Biochemical Sciences</source><volume>39</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2014.03.002</pub-id><pub-id pub-id-type="pmid">24767681</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayikci</surname> <given-names>M</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Scott-Brown</surname> <given-names>J</given-names></name><name><surname>Ravarani</surname> <given-names>CNJ</given-names></name><name><surname>Flock</surname> <given-names>T</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Visualization and analysis of non-covalent contacts using the protein contacts atlas</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/s41594-017-0019-z</pub-id><pub-id pub-id-type="pmid">29335563</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleywegt</surname> <given-names>GJ</given-names></name><name><surname>Harris</surname> <given-names>MR</given-names></name><name><surname>Zou</surname> <given-names>JY</given-names></name><name><surname>Taylor</surname> <given-names>TC</given-names></name><name><surname>Wählby</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The Uppsala Electron-Density server</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>60</volume><fpage>2240</fpage><lpage>2249</lpage><pub-id pub-id-type="doi">10.1107/S0907444904013253</pub-id><pub-id pub-id-type="pmid">15572777</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobilka</surname> <given-names>B</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>New G-protein-coupled receptor crystal structures: insights and limitations</article-title><source>Trends in Pharmacological Sciences</source><volume>29</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.11.009</pub-id><pub-id pub-id-type="pmid">18194818</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koehl</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Maeda</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Qu</surname> <given-names>Q</given-names></name><name><surname>Paggi</surname> <given-names>JM</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Dawson</surname> <given-names>R</given-names></name><name><surname>Matile</surname> <given-names>H</given-names></name><name><surname>Schertler</surname> <given-names>GFX</given-names></name><name><surname>Granier</surname> <given-names>S</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the µ-opioid receptor-G<sub>i</sub> protein complex</article-title><source>Nature</source><volume>558</volume><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0219-7</pub-id><pub-id pub-id-type="pmid">29899455</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlhoff</surname> <given-names>KJ</given-names></name><name><surname>Shukla</surname> <given-names>D</given-names></name><name><surname>Lawrenz</surname> <given-names>M</given-names></name><name><surname>Bowman</surname> <given-names>GR</given-names></name><name><surname>Konerding</surname> <given-names>DE</given-names></name><name><surname>Belov</surname> <given-names>D</given-names></name><name><surname>Altman</surname> <given-names>RB</given-names></name><name><surname>Pande</surname> <given-names>VS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cloud-based simulations on google exacycle reveal ligand modulation of GPCR activation pathways</article-title><source>Nature Chemistry</source><volume>6</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/nchem.1821</pub-id><pub-id pub-id-type="pmid">24345941</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolakowski</surname> <given-names>LF</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>GCRDb: a G-protein-coupled receptor database</article-title><source>Receptors &amp; Channels</source><volume>2</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8081729</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komolov</surname> <given-names>KE</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Duc</surname> <given-names>NM</given-names></name><name><surname>Betz</surname> <given-names>RM</given-names></name><name><surname>Rodrigues</surname> <given-names>J</given-names></name><name><surname>Leib</surname> <given-names>RD</given-names></name><name><surname>Patra</surname> <given-names>D</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name><name><surname>Adams</surname> <given-names>CM</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Chung</surname> <given-names>KY</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Benovic</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural and functional analysis of a β<sub>2</sub>-Adrenergic Receptor Complex with GRK5</article-title><source>Cell</source><volume>169</volume><fpage>407</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.03.047</pub-id><pub-id pub-id-type="pmid">28431242</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooistra</surname> <given-names>AJ</given-names></name><name><surname>Vischer</surname> <given-names>HF</given-names></name><name><surname>McNaught-Flores</surname> <given-names>D</given-names></name><name><surname>Leurs</surname> <given-names>R</given-names></name><name><surname>de Esch</surname> <given-names>IJ</given-names></name><name><surname>de Graaf</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Function-specific virtual screening for GPCR ligands using a combined scoring method</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>28288</elocation-id><pub-id pub-id-type="doi">10.1038/srep28288</pub-id><pub-id pub-id-type="pmid">27339552</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krautwurst</surname> <given-names>D</given-names></name><name><surname>Yau</surname> <given-names>KW</given-names></name><name><surname>Reed</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Identification of ligands for olfactory receptors by functional expression of a receptor library</article-title><source>Cell</source><volume>95</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81716-X</pub-id><pub-id pub-id-type="pmid">9875846</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Ring</surname> <given-names>AM</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>K</given-names></name><name><surname>Eitel</surname> <given-names>K</given-names></name><name><surname>Hübner</surname> <given-names>H</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Valant</surname> <given-names>C</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Felder</surname> <given-names>CC</given-names></name><name><surname>Gmeiner</surname> <given-names>P</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name><name><surname>Wess</surname> <given-names>J</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activation and allosteric modulation of a muscarinic acetylcholine receptor</article-title><source>Nature</source><volume>504</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nature12735</pub-id><pub-id pub-id-type="pmid">24256733</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Rueda</surname> <given-names>M</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><collab>GPCR Dock 2010 participants</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Status of GPCR modeling and docking as reflected by community-wide GPCR dock 2010 assessment</article-title><source>Structure</source><volume>19</volume><fpage>1108</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1016/j.str.2011.05.012</pub-id><pub-id pub-id-type="pmid">21827947</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Stephens</surname> <given-names>B</given-names></name><name><surname>Gilliland</surname> <given-names>CT</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Fenalti</surname> <given-names>G</given-names></name><name><surname>Hamel</surname> <given-names>D</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><name><surname>Handel</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer</article-title><source>Methods in Molecular Biology</source><volume>1013</volume><fpage>93</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-426-5_7</pub-id><pub-id pub-id-type="pmid">23625495</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><collab>Participants of GPCR Dock 2013</collab></person-group><year iso-8601-date="2014">2014a</year><article-title>Advances in GPCR modeling evaluated by the GPCR dock 2013 assessment: meeting new challenges</article-title><source>Structure</source><volume>22</volume><fpage>1120</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1016/j.str.2014.06.012</pub-id><pub-id pub-id-type="pmid">25066135</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Stephens</surname> <given-names>BS</given-names></name><name><surname>Holden</surname> <given-names>LG</given-names></name><name><surname>Qin</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>Kawamura</surname> <given-names>T</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><name><surname>Handel</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation</article-title><source>PNAS</source><volume>111</volume><fpage>E5363</fpage><lpage>E5372</lpage><pub-id pub-id-type="doi">10.1073/pnas.1417037111</pub-id><pub-id pub-id-type="pmid">25468967</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><chapter-title>Methods of Protein Structure Comparison</chapter-title><source>Homology Modeling: Methods and Protocols</source><publisher-name>Humana Press</publisher-name><fpage>231</fpage><lpage>257</lpage></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagerström</surname> <given-names>MC</given-names></name><name><surname>Schiöth</surname> <given-names>HB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structural diversity of G protein-coupled receptors and significance for drug discovery</article-title><source>Nature Reviews Drug Discovery</source><volume>7</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nrd2518</pub-id><pub-id pub-id-type="pmid">18382464</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamichhane</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>JJ</given-names></name><name><surname>Pljevaljcic</surname> <given-names>G</given-names></name><name><surname>White</surname> <given-names>KL</given-names></name><name><surname>van der Schans</surname> <given-names>E</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Wüthrich</surname> <given-names>K</given-names></name><name><surname>Millar</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Single-molecule view of basal activity and activation mechanisms of the G protein-coupled receptor β2ar</article-title><source>PNAS</source><volume>112</volume><fpage>14254</fpage><lpage>14259</lpage><pub-id pub-id-type="doi">10.1073/pnas.1519626112</pub-id><pub-id pub-id-type="pmid">26578769</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname> <given-names>TH</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Lambert</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sensitive and high resolution localization and tracking of membrane proteins in live cells with BRET</article-title><source>Traffic</source><volume>13</volume><fpage>1450</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2012.01401.x</pub-id><pub-id pub-id-type="pmid">22816793</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lans</surname> <given-names>I</given-names></name><name><surname>Dalton</surname> <given-names>JAR</given-names></name><name><surname>Giraldo</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Helix 3 acts as a conformational hinge in class A GPCR activation: an analysis of interhelical interaction energies in crystal structures</article-title><source>Journal of Structural Biology</source><volume>192</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2015.10.019</pub-id><pub-id pub-id-type="pmid">26522273</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GPCR dynamics: structures in motion</article-title><source>Chemical Reviews</source><volume>117</volume><fpage>139</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00177</pub-id><pub-id pub-id-type="pmid">27622975</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Wang</surname> <given-names>JK</given-names></name><name><surname>Bauer</surname> <given-names>B</given-names></name><name><surname>Townshend</surname> <given-names>RJL</given-names></name><name><surname>Hollingsworth</surname> <given-names>SA</given-names></name><name><surname>Olivieri</surname> <given-names>JE</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name><name><surname>Sommer</surname> <given-names>ME</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular mechanism of GPCR-mediated arrestin activation</article-title><source>Nature</source><volume>557</volume><fpage>452</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0077-3</pub-id><pub-id pub-id-type="pmid">29720655</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname> <given-names>K</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</article-title><source>Trends in Pharmacological Sciences</source><volume>28</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.06.004</pub-id><pub-id pub-id-type="pmid">17629965</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>MH</given-names></name><name><surname>Appleton</surname> <given-names>KM</given-names></name><name><surname>Strungs</surname> <given-names>EG</given-names></name><name><surname>Kwon</surname> <given-names>JY</given-names></name><name><surname>Morinelli</surname> <given-names>TA</given-names></name><name><surname>Peterson</surname> <given-names>YK</given-names></name><name><surname>Laporte</surname> <given-names>SA</given-names></name><name><surname>Luttrell</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The conformational signature of β-arrestin2 predicts its trafficking and signalling functions</article-title><source>Nature</source><volume>531</volume><fpage>665</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/nature17154</pub-id><pub-id pub-id-type="pmid">27007854</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Edwards</surname> <given-names>PC</given-names></name><name><surname>Burghammer</surname> <given-names>M</given-names></name><name><surname>Villa</surname> <given-names>C</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Structure of bovine rhodopsin in a trigonal crystal form</article-title><source>Journal of Molecular Biology</source><volume>343</volume><fpage>1409</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2004.08.090</pub-id><pub-id pub-id-type="pmid">15491621</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>YL</given-names></name><name><surname>Khoshouei</surname> <given-names>M</given-names></name><name><surname>Radjainia</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Tarrasch</surname> <given-names>J</given-names></name><name><surname>Thal</surname> <given-names>DM</given-names></name><name><surname>Furness</surname> <given-names>SGB</given-names></name><name><surname>Christopoulos</surname> <given-names>G</given-names></name><name><surname>Coudrat</surname> <given-names>T</given-names></name><name><surname>Danev</surname> <given-names>R</given-names></name><name><surname>Baumeister</surname> <given-names>W</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Phase-plate cryo-EM structure of a class B GPCR-G-protein complex</article-title><source>Nature</source><volume>546</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1038/nature22327</pub-id><pub-id pub-id-type="pmid">28437792</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Chun</surname> <given-names>E</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Chubukov</surname> <given-names>P</given-names></name><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Roth</surname> <given-names>CB</given-names></name><name><surname>Heitman</surname> <given-names>LH</given-names></name><name><surname>IJzerman</surname> <given-names>AP</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural basis for allosteric regulation of GPCRs by sodium ions</article-title><source>Science</source><volume>337</volume><fpage>232</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1126/science.1219218</pub-id><pub-id pub-id-type="pmid">22798613</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Gati</surname> <given-names>C</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>James</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Nelson</surname> <given-names>G</given-names></name><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Barty</surname> <given-names>A</given-names></name><name><surname>Zatsepin</surname> <given-names>NA</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Messerschmidt</surname> <given-names>M</given-names></name><name><surname>Boutet</surname> <given-names>S</given-names></name><name><surname>Williams</surname> <given-names>GJ</given-names></name><name><surname>Koglin</surname> <given-names>JE</given-names></name><name><surname>Seibert</surname> <given-names>MM</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>ST</given-names></name><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Fromme</surname> <given-names>R</given-names></name><name><surname>Kupitz</surname> <given-names>C</given-names></name><name><surname>Rendek</surname> <given-names>KN</given-names></name><name><surname>Grotjohann</surname> <given-names>I</given-names></name><name><surname>Fromme</surname> <given-names>P</given-names></name><name><surname>Kirian</surname> <given-names>RA</given-names></name><name><surname>Beyerlein</surname> <given-names>KR</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Chapman</surname> <given-names>HN</given-names></name><name><surname>Caffrey</surname> <given-names>M</given-names></name><name><surname>Spence</surname> <given-names>JC</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Serial femtosecond crystallography of G protein-coupled receptors</article-title><source>Science</source><volume>342</volume><fpage>1521</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1126/science.1244142</pub-id><pub-id pub-id-type="pmid">24357322</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Ahn</surname> <given-names>S</given-names></name><name><surname>Kahsai</surname> <given-names>AW</given-names></name><name><surname>Meng</surname> <given-names>KC</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Pani</surname> <given-names>B</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Masoudi</surname> <given-names>A</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mechanism of intracellular allosteric β<sub>2</sub>AR antagonist revealed by X-ray crystal structure</article-title><source>Nature</source><volume>548</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/nature23652</pub-id><pub-id pub-id-type="pmid">28813418</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Aschauer</surname> <given-names>P</given-names></name><name><surname>Tiemann</surname> <given-names>JKS</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Hirata</surname> <given-names>K</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Guixà-González</surname> <given-names>R</given-names></name><name><surname>Mathiesen</surname> <given-names>JM</given-names></name><name><surname>Hildebrand</surname> <given-names>PW</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Structural insights into the process of GPCR-G protein complex formation</article-title><source>Cell</source><volume>177</volume><fpage>1243</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.021</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Masoudi</surname> <given-names>A</given-names></name><name><surname>Kahsai</surname> <given-names>AW</given-names></name><name><surname>Huang</surname> <given-names>LY</given-names></name><name><surname>Pani</surname> <given-names>B</given-names></name><name><surname>Staus</surname> <given-names>DP</given-names></name><name><surname>Shim</surname> <given-names>PJ</given-names></name><name><surname>Hirata</surname> <given-names>K</given-names></name><name><surname>Simhal</surname> <given-names>RK</given-names></name><name><surname>Schwalb</surname> <given-names>AM</given-names></name><name><surname>Rambarat</surname> <given-names>PK</given-names></name><name><surname>Ahn</surname> <given-names>S</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name><name><surname>Kobilka</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Mechanism of β<sub>2</sub>AR regulation by an intracellular positive allosteric modulator</article-title><source>Science</source><volume>364</volume><fpage>1283</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1126/science.aaw8981</pub-id><pub-id pub-id-type="pmid">31249059</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livingston</surname> <given-names>KE</given-names></name><name><surname>Mahoney</surname> <given-names>JP</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Traynor</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor</article-title><source>eLife</source><volume>7</volume><elocation-id>e32499</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.32499</pub-id><pub-id pub-id-type="pmid">29932421</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Small molecule allosteric modulators of G-Protein-Coupled receptors: drug-target interactions</article-title><source>Journal of Medicinal Chemistry</source><volume>62</volume><fpage>24</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01844</pub-id><pub-id pub-id-type="pmid">29457894</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Balius</surname> <given-names>TE</given-names></name><name><surname>Singh</surname> <given-names>I</given-names></name><name><surname>Levit</surname> <given-names>A</given-names></name><name><surname>Moroz</surname> <given-names>YS</given-names></name><name><surname>O'Meara</surname> <given-names>MJ</given-names></name><name><surname>Che</surname> <given-names>T</given-names></name><name><surname>Algaa</surname> <given-names>E</given-names></name><name><surname>Tolmachova</surname> <given-names>K</given-names></name><name><surname>Tolmachev</surname> <given-names>AA</given-names></name><name><surname>Shoichet</surname> <given-names>BK</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Irwin</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ultra-large library docking for discovering new chemotypes</article-title><source>Nature</source><volume>566</volume><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0917-9</pub-id><pub-id pub-id-type="pmid">30728502</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madabushi</surname> <given-names>S</given-names></name><name><surname>Gross</surname> <given-names>AK</given-names></name><name><surname>Philippi</surname> <given-names>A</given-names></name><name><surname>Meng</surname> <given-names>EC</given-names></name><name><surname>Wensel</surname> <given-names>TG</given-names></name><name><surname>Lichtarge</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>8126</fpage><lpage>8132</lpage><pub-id pub-id-type="doi">10.1074/jbc.M312671200</pub-id><pub-id pub-id-type="pmid">14660595</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Mathiesen</surname> <given-names>JM</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Pardo</surname> <given-names>L</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Granier</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Crystal structure of the µ-opioid receptor bound to a morphinan antagonist</article-title><source>Nature</source><volume>485</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nature10954</pub-id><pub-id pub-id-type="pmid">22437502</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>TH</given-names></name><name><surname>Masureel</surname> <given-names>M</given-names></name><name><surname>Altenbach</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Lerch</surname> <given-names>MT</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Hubbell</surname> <given-names>WL</given-names></name><name><surname>Prosser</surname> <given-names>RS</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural insights into the dynamic process of β2-Adrenergic receptor signaling</article-title><source>Cell</source><volume>161</volume><fpage>1101</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.043</pub-id><pub-id pub-id-type="pmid">25981665</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsden</surname> <given-names>B</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>SAD--a normalized structural alignment database: improving sequence-structure alignments</article-title><source>Bioinformatics</source><volume>20</volume><fpage>2333</fpage><lpage>2344</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bth244</pub-id><pub-id pub-id-type="pmid">15087320</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martí-Solano</surname> <given-names>M</given-names></name><name><surname>Sanz</surname> <given-names>F</given-names></name><name><surname>Pastor</surname> <given-names>M</given-names></name><name><surname>Selent</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A dynamic view of molecular switch behavior at serotonin receptors: implications for functional selectivity</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e109312</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109312</pub-id><pub-id pub-id-type="pmid">25313636</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massink</surname> <given-names>A</given-names></name><name><surname>Gutiérrez-de-Terán</surname> <given-names>H</given-names></name><name><surname>Lenselink</surname> <given-names>EB</given-names></name><name><surname>Ortiz Zacarías</surname> <given-names>NV</given-names></name><name><surname>Xia</surname> <given-names>L</given-names></name><name><surname>Heitman</surname> <given-names>LH</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>IJzerman</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sodium ion binding pocket mutations and adenosine A2A receptor function</article-title><source>Molecular Pharmacology</source><volume>87</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1124/mol.114.095737</pub-id><pub-id pub-id-type="pmid">25473121</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuho</surname> <given-names>I</given-names></name><name><surname>Ostrovskaya</surname> <given-names>O</given-names></name><name><surname>Kramer</surname> <given-names>GM</given-names></name><name><surname>Jones</surname> <given-names>CD</given-names></name><name><surname>Xie</surname> <given-names>K</given-names></name><name><surname>Martemyanov</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra123</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aab4068</pub-id><pub-id pub-id-type="pmid">26628681</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masureel</surname> <given-names>M</given-names></name><name><surname>Zou</surname> <given-names>Y</given-names></name><name><surname>Picard</surname> <given-names>LP</given-names></name><name><surname>van der Westhuizen</surname> <given-names>E</given-names></name><name><surname>Mahoney</surname> <given-names>JP</given-names></name><name><surname>Rodrigues</surname> <given-names>J</given-names></name><name><surname>Mildorf</surname> <given-names>TJ</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural insights into binding specificity, efficacy and Bias of a β<sub>2</sub>AR partial agonist</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>1059</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0145-x</pub-id><pub-id pub-id-type="pmid">30327561</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname> <given-names>LT</given-names></name><name><surname>Leach</surname> <given-names>K</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Allosteric modulation of G protein-coupled receptors</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>47</volume><fpage>1</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.47.120505.105159</pub-id><pub-id pub-id-type="pmid">17009927</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCorvy</surname> <given-names>JD</given-names></name><name><surname>Butler</surname> <given-names>KV</given-names></name><name><surname>Kelly</surname> <given-names>B</given-names></name><name><surname>Rechsteiner</surname> <given-names>K</given-names></name><name><surname>Karpiak</surname> <given-names>J</given-names></name><name><surname>Betz</surname> <given-names>RM</given-names></name><name><surname>Kormos</surname> <given-names>BL</given-names></name><name><surname>Shoichet</surname> <given-names>BK</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2527</pub-id><pub-id pub-id-type="pmid">29227473</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname> <given-names>Y</given-names></name><name><surname>Nichols</surname> <given-names>SE</given-names></name><name><surname>Gasper</surname> <given-names>PM</given-names></name><name><surname>Metzger</surname> <given-names>VT</given-names></name><name><surname>McCammon</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activation and dynamic network of the M2 muscarinic receptor</article-title><source>PNAS</source><volume>110</volume><fpage>10982</fpage><lpage>10987</lpage><pub-id pub-id-type="doi">10.1073/pnas.1309755110</pub-id><pub-id pub-id-type="pmid">23781107</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname> <given-names>Y</given-names></name><name><surname>Goldfeld</surname> <given-names>DA</given-names></name><name><surname>Moo</surname> <given-names>EV</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>McCammon</surname> <given-names>JA</given-names></name><name><surname>Valant</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor</article-title><source>PNAS</source><volume>113</volume><fpage>E5675</fpage><lpage>E5684</lpage><pub-id pub-id-type="doi">10.1073/pnas.1612353113</pub-id><pub-id pub-id-type="pmid">27601651</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirny</surname> <given-names>LA</given-names></name><name><surname>Shakhnovich</surname> <given-names>EI</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Universally conserved positions in protein folds: reading evolutionary signals about stability, folding kinetics and function</article-title><source>Journal of Molecular Biology</source><volume>291</volume><fpage>177</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1999.2911</pub-id><pub-id pub-id-type="pmid">10438614</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munk</surname> <given-names>C</given-names></name><name><surname>Mutt</surname> <given-names>E</given-names></name><name><surname>Isberg</surname> <given-names>V</given-names></name><name><surname>Nikolajsen</surname> <given-names>LF</given-names></name><name><surname>Bibbe</surname> <given-names>JM</given-names></name><name><surname>Flock</surname> <given-names>T</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Deupi</surname> <given-names>X</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An online resource for GPCR structure determination and analysis</article-title><source>Nature Methods</source><volume>16</volume><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1038/s41592-018-0302-x</pub-id><pub-id pub-id-type="pmid">30664776</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagiri</surname> <given-names>C</given-names></name><name><surname>Shihoya</surname> <given-names>W</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Kadji</surname> <given-names>FMN</given-names></name><name><surname>Aoki</surname> <given-names>J</given-names></name><name><surname>Nureki</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Crystal structure of human endothelin ET<sub>Bb</sub> receptor in complex with peptide inverse agonist IRL2500</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>236</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0482-7</pub-id><pub-id pub-id-type="pmid">31263780</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napier</surname> <given-names>ML</given-names></name><name><surname>Durga</surname> <given-names>D</given-names></name><name><surname>Wolsley</surname> <given-names>CJ</given-names></name><name><surname>Chamney</surname> <given-names>S</given-names></name><name><surname>Alexander</surname> <given-names>S</given-names></name><name><surname>Brennan</surname> <given-names>R</given-names></name><name><surname>Simpson</surname> <given-names>DA</given-names></name><name><surname>Silvestri</surname> <given-names>G</given-names></name><name><surname>Willoughby</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutational analysis of the <italic>Rhodopsin</italic> gene in sector retinitis pigmentosa</article-title><source>Ophthalmic Genetics</source><volume>36</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.3109/13816810.2014.958862</pub-id><pub-id pub-id-type="pmid">25265376</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nehmé</surname> <given-names>R</given-names></name><name><surname>Carpenter</surname> <given-names>B</given-names></name><name><surname>Singhal</surname> <given-names>A</given-names></name><name><surname>Strege</surname> <given-names>A</given-names></name><name><surname>Edwards</surname> <given-names>PC</given-names></name><name><surname>White</surname> <given-names>CF</given-names></name><name><surname>Du</surname> <given-names>H</given-names></name><name><surname>Grisshammer</surname> <given-names>R</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mini-G proteins: novel tools for studying GPCRs in their active conformation</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0175642</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0175642</pub-id><pub-id pub-id-type="pmid">28426733</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname> <given-names>T</given-names></name><name><surname>Ilatovskiy</surname> <given-names>AV</given-names></name><name><surname>Stewart</surname> <given-names>AG</given-names></name><name><surname>Coleman</surname> <given-names>JL</given-names></name><name><surname>McRobb</surname> <given-names>FM</given-names></name><name><surname>Riek</surname> <given-names>RP</given-names></name><name><surname>Graham</surname> <given-names>RM</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Smith</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Orphan receptor ligand discovery by pickpocketing pharmacological neighbors</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2266</pub-id><pub-id pub-id-type="pmid">27992882</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygaard</surname> <given-names>R</given-names></name><name><surname>Frimurer</surname> <given-names>TM</given-names></name><name><surname>Holst</surname> <given-names>B</given-names></name><name><surname>Rosenkilde</surname> <given-names>MM</given-names></name><name><surname>Schwartz</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ligand binding and micro-switches in 7tm receptor structures</article-title><source>Trends in Pharmacological Sciences</source><volume>30</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2009.02.006</pub-id><pub-id pub-id-type="pmid">19375807</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygaard</surname> <given-names>R</given-names></name><name><surname>Zou</surname> <given-names>Y</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Mildorf</surname> <given-names>TJ</given-names></name><name><surname>Arlow</surname> <given-names>DH</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Pan</surname> <given-names>AC</given-names></name><name><surname>Liu</surname> <given-names>CW</given-names></name><name><surname>Fung</surname> <given-names>JJ</given-names></name><name><surname>Bokoch</surname> <given-names>MP</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Shaw</surname> <given-names>DE</given-names></name><name><surname>Mueller</surname> <given-names>L</given-names></name><name><surname>Prosser</surname> <given-names>RS</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The dynamic process of β(2)-adrenergic receptor activation</article-title><source>Cell</source><volume>152</volume><fpage>532</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.01.008</pub-id><pub-id pub-id-type="pmid">23374348</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname> <given-names>T</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Palczewski</surname> <given-names>K</given-names></name><name><surname>Hofmann</surname> <given-names>KP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Activation of rhodopsin: new insights from structural and biochemical studies</article-title><source>Trends in Biochemical Sciences</source><volume>26</volume><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(01)01799-6</pub-id><pub-id pub-id-type="pmid">11343925</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okashah</surname> <given-names>N</given-names></name><name><surname>Wan</surname> <given-names>Q</given-names></name><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Sandhu</surname> <given-names>M</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Vaidehi</surname> <given-names>N</given-names></name><name><surname>Lambert</surname> <given-names>NA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Variable G protein determinants of GPCR coupling selectivity</article-title><source>PNAS</source><volume>116</volume><fpage>12054</fpage><lpage>12059</lpage><pub-id pub-id-type="doi">10.1073/pnas.1905993116</pub-id><pub-id pub-id-type="pmid">31142646</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onaran</surname> <given-names>HO</given-names></name><name><surname>Rajagopal</surname> <given-names>S</given-names></name><name><surname>Costa</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>What is biased efficacy? defining the relationship between intrinsic efficacy and free energy coupling</article-title><source>Trends in Pharmacological Sciences</source><volume>35</volume><fpage>639</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.09.010</pub-id><pub-id pub-id-type="pmid">25448316</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz Zacarías</surname> <given-names>NV</given-names></name><name><surname>Lenselink</surname> <given-names>EB</given-names></name><name><surname>IJzerman</surname> <given-names>AP</given-names></name><name><surname>Handel</surname> <given-names>TM</given-names></name><name><surname>Heitman</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Intracellular receptor modulation: novel approach to target GPCRs</article-title><source>Trends in Pharmacological Sciences</source><volume>39</volume><fpage>547</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.03.002</pub-id><pub-id pub-id-type="pmid">29653834</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oswald</surname> <given-names>C</given-names></name><name><surname>Rappas</surname> <given-names>M</given-names></name><name><surname>Kean</surname> <given-names>J</given-names></name><name><surname>Doré</surname> <given-names>AS</given-names></name><name><surname>Errey</surname> <given-names>JC</given-names></name><name><surname>Bennett</surname> <given-names>K</given-names></name><name><surname>Deflorian</surname> <given-names>F</given-names></name><name><surname>Christopher</surname> <given-names>JA</given-names></name><name><surname>Jazayeri</surname> <given-names>A</given-names></name><name><surname>Mason</surname> <given-names>JS</given-names></name><name><surname>Congreve</surname> <given-names>M</given-names></name><name><surname>Cooke</surname> <given-names>RM</given-names></name><name><surname>Marshall</surname> <given-names>FH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Intracellular allosteric antagonism of the CCR9 receptor</article-title><source>Nature</source><volume>540</volume><fpage>462</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nature20606</pub-id><pub-id pub-id-type="pmid">27926729</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pándy-Szekeres</surname> <given-names>G</given-names></name><name><surname>Munk</surname> <given-names>C</given-names></name><name><surname>Tsonkov</surname> <given-names>TM</given-names></name><name><surname>Mordalski</surname> <given-names>S</given-names></name><name><surname>Harpsøe</surname> <given-names>K</given-names></name><name><surname>Hauser</surname> <given-names>AS</given-names></name><name><surname>Bojarski</surname> <given-names>AJ</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GPCRdb in 2018: adding GPCR structure models and ligands</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D440</fpage><lpage>D446</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1109</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Laeremans</surname> <given-names>T</given-names></name><name><surname>Triest</surname> <given-names>S</given-names></name><name><surname>Rasmussen</surname> <given-names>SGF</given-names></name><name><surname>Wohlkönig</surname> <given-names>A</given-names></name><name><surname>Ruf</surname> <given-names>A</given-names></name><name><surname>Muyldermans</surname> <given-names>S</given-names></name><name><surname>Hol</surname> <given-names>WGJ</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A general protocol for the generation of nanobodies for structural biology</article-title><source>Nature Protocols</source><volume>9</volume><fpage>674</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.039</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasel</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families</article-title><source>Journal of Clinical Endocrinology &amp; Metabolism</source><volume>85</volume><fpage>1703</fpage><lpage>1710</lpage><pub-id pub-id-type="doi">10.1210/jc.85.4.1703</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>Y</given-names></name><name><surname>McCorvy</surname> <given-names>JD</given-names></name><name><surname>Harpsøe</surname> <given-names>K</given-names></name><name><surname>Lansu</surname> <given-names>K</given-names></name><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Popov</surname> <given-names>P</given-names></name><name><surname>Qu</surname> <given-names>L</given-names></name><name><surname>Pu</surname> <given-names>M</given-names></name><name><surname>Che</surname> <given-names>T</given-names></name><name><surname>Nikolajsen</surname> <given-names>LF</given-names></name><name><surname>Huang</surname> <given-names>XP</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Bjørn-Yoshimoto</surname> <given-names>WE</given-names></name><name><surname>Ding</surname> <given-names>K</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Jensen</surname> <given-names>AA</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Gloriam</surname> <given-names>DE</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Liu</surname> <given-names>ZJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>5-HT<sub>2C</sub> receptor structures reveal the structural basis of GPCR polypharmacology</article-title><source>Cell</source><volume>172</volume><fpage>719</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.001</pub-id><pub-id pub-id-type="pmid">29398112</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname> <given-names>P</given-names></name><name><surname>Peng</surname> <given-names>Y</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Liu</surname> <given-names>ZJ</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Computational design of thermostabilizing point mutations for G protein-coupled receptors</article-title><source>eLife</source><volume>7</volume><elocation-id>e34729</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34729</pub-id><pub-id pub-id-type="pmid">29927385</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragnarsson</surname> <given-names>L</given-names></name><name><surname>Andersson</surname> <given-names>Å</given-names></name><name><surname>Thomas</surname> <given-names>WG</given-names></name><name><surname>Lewis</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mutations in the NPxxY motif stabilize pharmacologically distinct conformational states of the α<sub>1B</sub>- and β<sub>2</sub>-adrenoceptors</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaas9485</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aas9485</pub-id><pub-id pub-id-type="pmid">30862702</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname> <given-names>BK</given-names></name><name><surname>Shiina</surname> <given-names>T</given-names></name><name><surname>Insel</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>41</volume><fpage>593</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.593</pub-id><pub-id pub-id-type="pmid">11264470</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>DeVree</surname> <given-names>BT</given-names></name><name><surname>Zou</surname> <given-names>Y</given-names></name><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Chung</surname> <given-names>KY</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Chae</surname> <given-names>PS</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Calinski</surname> <given-names>D</given-names></name><name><surname>Mathiesen</surname> <given-names>JM</given-names></name><name><surname>Shah</surname> <given-names>ST</given-names></name><name><surname>Lyons</surname> <given-names>JA</given-names></name><name><surname>Caffrey</surname> <given-names>M</given-names></name><name><surname>Gellman</surname> <given-names>SH</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2011">2011a</year><article-title>Crystal structure of the β2 adrenergic receptor-Gs protein complex</article-title><source>Nature</source><volume>477</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1038/nature10361</pub-id><pub-id pub-id-type="pmid">21772288</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Choi</surname> <given-names>HJ</given-names></name><name><surname>Fung</surname> <given-names>JJ</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Casarosa</surname> <given-names>P</given-names></name><name><surname>Chae</surname> <given-names>PS</given-names></name><name><surname>Devree</surname> <given-names>BT</given-names></name><name><surname>Rosenbaum</surname> <given-names>DM</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Schnapp</surname> <given-names>A</given-names></name><name><surname>Konetzki</surname> <given-names>I</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Gellman</surname> <given-names>SH</given-names></name><name><surname>Pautsch</surname> <given-names>A</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2011">2011b</year><article-title>Structure of a nanobody-stabilized active state of the β(2) adrenoceptor</article-title><source>Nature</source><volume>469</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nature09648</pub-id><pub-id pub-id-type="pmid">21228869</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renaud</surname> <given-names>JP</given-names></name><name><surname>Chari</surname> <given-names>A</given-names></name><name><surname>Ciferri</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>WT</given-names></name><name><surname>Rémigy</surname> <given-names>HW</given-names></name><name><surname>Stark</surname> <given-names>H</given-names></name><name><surname>Wiesmann</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-EM in drug discovery: achievements, limitations and prospects</article-title><source>Nature Reviews Drug Discovery</source><volume>17</volume><fpage>471</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.77</pub-id><pub-id pub-id-type="pmid">29880918</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>N</given-names></name><name><surname>Rappas</surname> <given-names>M</given-names></name><name><surname>Doré</surname> <given-names>AS</given-names></name><name><surname>Brown</surname> <given-names>J</given-names></name><name><surname>Bottegoni</surname> <given-names>G</given-names></name><name><surname>Koglin</surname> <given-names>M</given-names></name><name><surname>Cansfield</surname> <given-names>J</given-names></name><name><surname>Jazayeri</surname> <given-names>A</given-names></name><name><surname>Cooke</surname> <given-names>RM</given-names></name><name><surname>Marshall</surname> <given-names>FH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727</article-title><source>Nature</source><volume>553</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/nature25025</pub-id><pub-id pub-id-type="pmid">29300009</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname> <given-names>GJ</given-names></name><name><surname>Yao</surname> <given-names>R</given-names></name><name><surname>Lichtarge</surname> <given-names>O</given-names></name><name><surname>Wensel</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Evolution-guided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors</article-title><source>PNAS</source><volume>107</volume><fpage>7787</fpage><lpage>7792</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914877107</pub-id><pub-id pub-id-type="pmid">20385837</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname> <given-names>DM</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Choi</surname> <given-names>HJ</given-names></name><name><surname>Yao</surname> <given-names>XJ</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function</article-title><source>Science</source><volume>318</volume><fpage>1266</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1126/science.1150609</pub-id><pub-id pub-id-type="pmid">17962519</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbaum</surname> <given-names>DM</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The structure and function of G-protein-coupled receptors</article-title><source>Nature</source><volume>459</volume><fpage>356</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1038/nature08144</pub-id><pub-id pub-id-type="pmid">19458711</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname> <given-names>CB</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 Helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure</article-title><source>Journal of Molecular Biology</source><volume>376</volume><fpage>1305</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.12.028</pub-id><pub-id pub-id-type="pmid">18222471</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Irwin</surname> <given-names>JJ</given-names></name><name><surname>Shoichet</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of new GPCR ligands to illuminate new biology</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>1143</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2490</pub-id><pub-id pub-id-type="pmid">29045379</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname> <given-names>M</given-names></name><name><surname>Touma</surname> <given-names>AM</given-names></name><name><surname>Dysthe</surname> <given-names>M</given-names></name><name><surname>Sadler</surname> <given-names>F</given-names></name><name><surname>Sivaramakrishnan</surname> <given-names>S</given-names></name><name><surname>Vaidehi</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Conformational plasticity of the intracellular cavity of GPCR-G-protein complexes leads to G-protein promiscuity and selectivity</article-title><source>PNAS</source><volume>116</volume><fpage>11956</fpage><lpage>11965</lpage><pub-id pub-id-type="doi">10.1073/pnas.1820944116</pub-id><pub-id pub-id-type="pmid">31138704</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname> <given-names>CL</given-names></name><name><surname>Kennedy</surname> <given-names>NM</given-names></name><name><surname>Ross</surname> <given-names>NC</given-names></name><name><surname>Lovell</surname> <given-names>KM</given-names></name><name><surname>Yue</surname> <given-names>Z</given-names></name><name><surname>Morgenweck</surname> <given-names>J</given-names></name><name><surname>Cameron</surname> <given-names>MD</given-names></name><name><surname>Bannister</surname> <given-names>TD</given-names></name><name><surname>Bohn</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bias factor and therapeutic window correlate to predict safer opioid analgesics</article-title><source>Cell</source><volume>171</volume><fpage>1165</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.035</pub-id><pub-id pub-id-type="pmid">29149605</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schöneberg</surname> <given-names>T</given-names></name><name><surname>Hofreiter</surname> <given-names>M</given-names></name><name><surname>Schulz</surname> <given-names>A</given-names></name><name><surname>Römpler</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Learning from the past: evolution of GPCR functions</article-title><source>Trends in Pharmacological Sciences</source><volume>28</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.01.001</pub-id><pub-id pub-id-type="pmid">17280721</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schönegge</surname> <given-names>AM</given-names></name><name><surname>Gallion</surname> <given-names>J</given-names></name><name><surname>Picard</surname> <given-names>LP</given-names></name><name><surname>Wilkins</surname> <given-names>AD</given-names></name><name><surname>Le Gouill</surname> <given-names>C</given-names></name><name><surname>Audet</surname> <given-names>M</given-names></name><name><surname>Stallaert</surname> <given-names>W</given-names></name><name><surname>Lohse</surname> <given-names>MJ</given-names></name><name><surname>Kimmel</surname> <given-names>M</given-names></name><name><surname>Lichtarge</surname> <given-names>O</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evolutionary action and structural basis of the allosteric switch controlling β<sub>2</sub>AR functional selectivity</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>2169</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02257-x</pub-id><pub-id pub-id-type="pmid">29255305</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname> <given-names>Z</given-names></name><name><surname>Yan</surname> <given-names>W</given-names></name><name><surname>Chapman</surname> <given-names>K</given-names></name><name><surname>Ramesh</surname> <given-names>K</given-names></name><name><surname>Ferrell</surname> <given-names>AJ</given-names></name><name><surname>Yin</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Rosenbaum</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</article-title><source>Nature Chemical Biology</source><volume>15</volume><fpage>1199</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1038/s41589-019-0387-2</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shihoya</surname> <given-names>W</given-names></name><name><surname>Nishizawa</surname> <given-names>T</given-names></name><name><surname>Yamashita</surname> <given-names>K</given-names></name><name><surname>Inoue</surname> <given-names>A</given-names></name><name><surname>Hirata</surname> <given-names>K</given-names></name><name><surname>Kadji</surname> <given-names>FMN</given-names></name><name><surname>Okuta</surname> <given-names>A</given-names></name><name><surname>Tani</surname> <given-names>K</given-names></name><name><surname>Aoki</surname> <given-names>J</given-names></name><name><surname>Fujiyoshi</surname> <given-names>Y</given-names></name><name><surname>Doi</surname> <given-names>T</given-names></name><name><surname>Nureki</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>24</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3450</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname> <given-names>I</given-names></name><name><surname>Ueda</surname> <given-names>T</given-names></name><name><surname>Kofuku</surname> <given-names>Y</given-names></name><name><surname>Eddy</surname> <given-names>MT</given-names></name><name><surname>Wüthrich</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures</article-title><source>Nature Reviews Drug Discovery</source><volume>18</volume><fpage>59</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.180</pub-id><pub-id pub-id-type="pmid">30410121</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname> <given-names>OS</given-names></name><name><surname>Horský</surname> <given-names>V</given-names></name><name><surname>Gore</surname> <given-names>S</given-names></name><name><surname>Svobodová Vařeková</surname> <given-names>R</given-names></name><name><surname>Bendová</surname> <given-names>V</given-names></name><name><surname>Kleywegt</surname> <given-names>GJ</given-names></name><name><surname>Velankar</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Validation of ligands in macromolecular structures determined by X-ray crystallography</article-title><source>Acta Crystallographica Section D Structural Biology</source><volume>74</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1107/S2059798318002541</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname> <given-names>MJ</given-names></name><name><surname>Vischer</surname> <given-names>HF</given-names></name><name><surname>Bakker</surname> <given-names>RA</given-names></name><name><surname>Jongejan</surname> <given-names>A</given-names></name><name><surname>Timmerman</surname> <given-names>H</given-names></name><name><surname>Pardo</surname> <given-names>L</given-names></name><name><surname>Leurs</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>47</volume><fpage>53</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.47.120505.105126</pub-id><pub-id pub-id-type="pmid">17029567</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>JS</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name><name><surname>Rajagopal</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Biased signalling: from simple switches to allosteric microprocessors</article-title><source>Nature Reviews Drug Discovery</source><volume>17</volume><fpage>243</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.229</pub-id><pub-id pub-id-type="pmid">29302067</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solt</surname> <given-names>AS</given-names></name><name><surname>Bostock</surname> <given-names>MJ</given-names></name><name><surname>Shrestha</surname> <given-names>B</given-names></name><name><surname>Kumar</surname> <given-names>P</given-names></name><name><surname>Warne</surname> <given-names>T</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name><name><surname>Nietlispach</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Insight into partial agonism by observing multiple equilibria for ligand-bound and G<sub>s</sub>-mimetic nanobody-bound β<sub>1</sub>-adrenergic receptor</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1795</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02008-y</pub-id><pub-id pub-id-type="pmid">29176642</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sounier</surname> <given-names>R</given-names></name><name><surname>Mas</surname> <given-names>C</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Laeremans</surname> <given-names>T</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Déméné</surname> <given-names>H</given-names></name><name><surname>Granier</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Propagation of conformational changes during μ-opioid receptor activation</article-title><source>Nature</source><volume>524</volume><fpage>375</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/nature14680</pub-id><pub-id pub-id-type="pmid">26245377</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spehr</surname> <given-names>M</given-names></name><name><surname>Munger</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Olfactory receptors: g protein-coupled receptors and beyond</article-title><source>Journal of Neurochemistry</source><volume>109</volume><fpage>1570</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06085.x</pub-id><pub-id pub-id-type="pmid">19383089</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stauch</surname> <given-names>B</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Serial femtosecond crystallography of G Protein-Coupled receptors</article-title><source>Annual Review of Biophysics</source><volume>47</volume><fpage>377</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1146/annurev-biophys-070317-033239</pub-id><pub-id pub-id-type="pmid">29543504</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staus</surname> <given-names>DP</given-names></name><name><surname>Strachan</surname> <given-names>RT</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Pani</surname> <given-names>B</given-names></name><name><surname>Kahsai</surname> <given-names>AW</given-names></name><name><surname>Kim</surname> <given-names>TH</given-names></name><name><surname>Wingler</surname> <given-names>LM</given-names></name><name><surname>Ahn</surname> <given-names>S</given-names></name><name><surname>Chatterjee</surname> <given-names>A</given-names></name><name><surname>Masoudi</surname> <given-names>A</given-names></name><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Pardon</surname> <given-names>E</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Prosser</surname> <given-names>RS</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Costa</surname> <given-names>T</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation</article-title><source>Nature</source><volume>535</volume><fpage>448</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/nature18636</pub-id><pub-id pub-id-type="pmid">27409812</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname> <given-names>YM</given-names></name><name><surname>Wilkins</surname> <given-names>AD</given-names></name><name><surname>Rodriguez</surname> <given-names>GJ</given-names></name><name><surname>Wensel</surname> <given-names>TG</given-names></name><name><surname>Lichtarge</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Intramolecular allosteric communication in dopamine D2 receptor revealed by evolutionary amino acid covariation</article-title><source>PNAS</source><volume>113</volume><fpage>3539</fpage><lpage>3544</lpage><pub-id pub-id-type="doi">10.1073/pnas.1516579113</pub-id><pub-id pub-id-type="pmid">26979958</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>L</given-names></name><name><surname>Yan</surname> <given-names>W</given-names></name><name><surname>McCorvy</surname> <given-names>JD</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Biased ligands of G Protein-Coupled receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</article-title><source>Journal of Medicinal Chemistry</source><volume>61</volume><fpage>9841</fpage><lpage>9878</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00435</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>YX</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications</article-title><source>Pharmacology &amp; Therapeutics</source><volume>111</volume><fpage>949</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2006.02.008</pub-id><pub-id pub-id-type="pmid">16616374</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>YX</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics</article-title><source>Pharmacology &amp; Therapeutics</source><volume>120</volume><fpage>129</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.07.005</pub-id><pub-id pub-id-type="pmid">18768149</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tehan</surname> <given-names>BG</given-names></name><name><surname>Bortolato</surname> <given-names>A</given-names></name><name><surname>Blaney</surname> <given-names>FE</given-names></name><name><surname>Weir</surname> <given-names>MP</given-names></name><name><surname>Mason</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Unifying family A GPCR theories of activation</article-title><source>Pharmacology &amp; Therapeutics</source><volume>143</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.02.004</pub-id><pub-id pub-id-type="pmid">24561131</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname> <given-names>DM</given-names></name><name><surname>Glukhova</surname> <given-names>A</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural insights into G-protein-coupled receptor allostery</article-title><source>Nature</source><volume>559</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0259-z</pub-id><pub-id pub-id-type="pmid">29973731</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The UniProt Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>UniProt: the universal protein knowledgebase</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D158</fpage><lpage>D169</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1099</pub-id><pub-id pub-id-type="pmid">27899622</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname> <given-names>MD</given-names></name><name><surname>Hendy</surname> <given-names>GN</given-names></name><name><surname>Percy</surname> <given-names>ME</given-names></name><name><surname>Bichet</surname> <given-names>DG</given-names></name><name><surname>Cole</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>G protein-coupled receptor mutations and human genetic disease</article-title><source>Methods in Molecular Biology</source><volume>1175</volume><fpage>153</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-0956-8_8</pub-id><pub-id pub-id-type="pmid">25150870</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>H</given-names></name><name><surname>Fürstenberg</surname> <given-names>A</given-names></name><name><surname>Huber</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Labeling and Single-Molecule Methods To Monitor G Protein-Coupled Receptor Dynamics</article-title><source>Chemical Reviews</source><volume>117</volume><fpage>186</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00084</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trzaskowski</surname> <given-names>B</given-names></name><name><surname>Latek</surname> <given-names>D</given-names></name><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Ghoshdastider</surname> <given-names>U</given-names></name><name><surname>Debinski</surname> <given-names>A</given-names></name><name><surname>Filipek</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Action of molecular switches in GPCRs--theoretical and experimental studies</article-title><source>Current Medicinal Chemistry</source><volume>19</volume><fpage>1090</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.2174/092986712799320556</pub-id><pub-id pub-id-type="pmid">22300046</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname> <given-names>CJ</given-names></name><name><surname>Pamula</surname> <given-names>F</given-names></name><name><surname>Nehmé</surname> <given-names>R</given-names></name><name><surname>Mühle</surname> <given-names>J</given-names></name><name><surname>Weinert</surname> <given-names>T</given-names></name><name><surname>Flock</surname> <given-names>T</given-names></name><name><surname>Nogly</surname> <given-names>P</given-names></name><name><surname>Edwards</surname> <given-names>PC</given-names></name><name><surname>Carpenter</surname> <given-names>B</given-names></name><name><surname>Gruhl</surname> <given-names>T</given-names></name><name><surname>Ma</surname> <given-names>P</given-names></name><name><surname>Deupi</surname> <given-names>X</given-names></name><name><surname>Standfuss</surname> <given-names>J</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name><name><surname>Schertler</surname> <given-names>GFX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Crystal structure of rhodopsin in complex with a mini-G<sub>o</sub> sheds light on the principles of G protein selectivity</article-title><source>Science Advances</source><volume>4</volume><elocation-id>eaat7052</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aat7052</pub-id><pub-id pub-id-type="pmid">30255144</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Eps</surname> <given-names>N</given-names></name><name><surname>Altenbach</surname> <given-names>C</given-names></name><name><surname>Caro</surname> <given-names>LN</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Hollingsworth</surname> <given-names>SA</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Hubbell</surname> <given-names>WL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gi-and Gs-coupled GPCRs show different modes of G-protein binding</article-title><source>PNAS</source><volume>115</volume><fpage>2383</fpage><lpage>2388</lpage><pub-id pub-id-type="doi">10.1073/pnas.1721896115</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vass</surname> <given-names>M</given-names></name><name><surname>Kooistra</surname> <given-names>AJ</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Wang</surname> <given-names>MW</given-names></name><name><surname>de Graaf</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chemical Diversity in the G Protein-Coupled Receptor Superfamily</article-title><source>Trends in Pharmacological Sciences</source><volume>39</volume><fpage>494</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.02.004</pub-id><pub-id pub-id-type="pmid">29576399</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassart</surname> <given-names>G</given-names></name><name><surname>Costagliola</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>G protein-coupled receptors: mutations and endocrine diseases</article-title><source>Nature Reviews Endocrinology</source><volume>7</volume><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.20</pub-id><pub-id pub-id-type="pmid">21301490</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Deupi</surname> <given-names>X</given-names></name><name><surname>Lebon</surname> <given-names>G</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular signatures of G-protein-coupled receptors</article-title><source>Nature</source><volume>494</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nature11896</pub-id><pub-id pub-id-type="pmid">23407534</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Deupi</surname> <given-names>X</given-names></name><name><surname>Lebon</surname> <given-names>G</given-names></name><name><surname>Heydenreich</surname> <given-names>FM</given-names></name><name><surname>Flock</surname> <given-names>T</given-names></name><name><surname>Miljus</surname> <given-names>T</given-names></name><name><surname>Balaji</surname> <given-names>S</given-names></name><name><surname>Bouvier</surname> <given-names>M</given-names></name><name><surname>Veprintsev</surname> <given-names>DB</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region</article-title><source>Nature</source><volume>536</volume><fpage>484</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/nature19107</pub-id><pub-id pub-id-type="pmid">27525504</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Ma</surname> <given-names>AK</given-names></name><name><surname>Fonseca</surname> <given-names>R</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Kelly</surname> <given-names>B</given-names></name><name><surname>Betz</surname> <given-names>RM</given-names></name><name><surname>Asawa</surname> <given-names>C</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Diverse GPCRs exhibit conserved water networks for stabilization and activation</article-title><source>PNAS</source><volume>116</volume><fpage>3288</fpage><lpage>3293</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809251116</pub-id><pub-id pub-id-type="pmid">30728297</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdonk</surname> <given-names>ML</given-names></name><name><surname>Cole</surname> <given-names>JC</given-names></name><name><surname>Hartshorn</surname> <given-names>MJ</given-names></name><name><surname>Murray</surname> <given-names>CW</given-names></name><name><surname>Taylor</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Improved protein-ligand docking using GOLD</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>52</volume><fpage>609</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1002/prot.10465</pub-id><pub-id pub-id-type="pmid">12910460</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vickery</surname> <given-names>ON</given-names></name><name><surname>Carvalheda</surname> <given-names>CA</given-names></name><name><surname>Zaidi</surname> <given-names>SA</given-names></name><name><surname>Pisliakov</surname> <given-names>AV</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Zachariae</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Intracellular Transfer of Na<sup>+</sup> in an Active-State G-Protein-Coupled Receptor</article-title><source>Structure</source><volume>26</volume><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.str.2017.11.013</pub-id><pub-id pub-id-type="pmid">29249607</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Accurate de novo prediction of protein contact map by ultra-deep learning model</article-title><source>PLOS Computational Biology</source><volume>13</volume><elocation-id>e1005324</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005324</pub-id><pub-id pub-id-type="pmid">28056090</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warne</surname> <given-names>T</given-names></name><name><surname>Serrano-Vega</surname> <given-names>MJ</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Development and crystallization of a minimal thermostabilised G protein-coupled receptor</article-title><source>Protein Expression and Purification</source><volume>65</volume><fpage>204</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2009.01.014</pub-id><pub-id pub-id-type="pmid">19297694</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>James</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Spence</surname> <given-names>JC</given-names></name><name><surname>Bruce Doak</surname> <given-names>R</given-names></name><name><surname>Nelson</surname> <given-names>G</given-names></name><name><surname>Fromme</surname> <given-names>P</given-names></name><name><surname>Fromme</surname> <given-names>R</given-names></name><name><surname>Grotjohann</surname> <given-names>I</given-names></name><name><surname>Kupitz</surname> <given-names>C</given-names></name><name><surname>Zatsepin</surname> <given-names>NA</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Boutet</surname> <given-names>S</given-names></name><name><surname>Messerschmidt</surname> <given-names>M</given-names></name><name><surname>Williams</surname> <given-names>GJ</given-names></name><name><surname>Koglin</surname> <given-names>JE</given-names></name><name><surname>Marvin Seibert</surname> <given-names>M</given-names></name><name><surname>Klinker</surname> <given-names>M</given-names></name><name><surname>Gati</surname> <given-names>C</given-names></name><name><surname>Shoeman</surname> <given-names>RL</given-names></name><name><surname>Barty</surname> <given-names>A</given-names></name><name><surname>Chapman</surname> <given-names>HN</given-names></name><name><surname>Kirian</surname> <given-names>RA</given-names></name><name><surname>Beyerlein</surname> <given-names>KR</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Shah</surname> <given-names>ST</given-names></name><name><surname>Howe</surname> <given-names>N</given-names></name><name><surname>Caffrey</surname> <given-names>M</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3309</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4309</pub-id><pub-id pub-id-type="pmid">24525480</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The molecular basis of G Protein-Coupled receptor activation</article-title><source>Annual Review of Biochemistry</source><volume>87</volume><fpage>897</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060614-033910</pub-id><pub-id pub-id-type="pmid">29925258</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wescott</surname> <given-names>MP</given-names></name><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Paes</surname> <given-names>C</given-names></name><name><surname>Goodman</surname> <given-names>JR</given-names></name><name><surname>Thaker</surname> <given-names>Y</given-names></name><name><surname>Puffer</surname> <given-names>BA</given-names></name><name><surname>Berdougo</surname> <given-names>E</given-names></name><name><surname>Rucker</surname> <given-names>JB</given-names></name><name><surname>Handel</surname> <given-names>TM</given-names></name><name><surname>Doranz</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices</article-title><source>PNAS</source><volume>113</volume><fpage>9928</fpage><lpage>9933</lpage><pub-id pub-id-type="doi">10.1073/pnas.1601278113</pub-id><pub-id pub-id-type="pmid">27543332</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whalen</surname> <given-names>EJ</given-names></name><name><surname>Rajagopal</surname> <given-names>S</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Therapeutic potential of β-arrestin- and G protein-biased agonists</article-title><source>Trends in Molecular Medicine</source><volume>17</volume><fpage>126</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2010.11.004</pub-id><pub-id pub-id-type="pmid">21183406</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>KL</given-names></name><name><surname>Eddy</surname> <given-names>MT</given-names></name><name><surname>Gao</surname> <given-names>ZG</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Lian</surname> <given-names>T</given-names></name><name><surname>Deary</surname> <given-names>A</given-names></name><name><surname>Patel</surname> <given-names>N</given-names></name><name><surname>Jacobson</surname> <given-names>KA</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural connection between activation microswitch and allosteric sodium site in GPCR signaling</article-title><source>Structure</source><volume>26</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.str.2017.12.013</pub-id><pub-id pub-id-type="pmid">29395784</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wingler</surname> <given-names>LM</given-names></name><name><surname>Elgeti</surname> <given-names>M</given-names></name><name><surname>Hilger</surname> <given-names>D</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Lerch</surname> <given-names>MT</given-names></name><name><surname>Staus</surname> <given-names>DP</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Hubbell</surname> <given-names>WL</given-names></name><name><surname>Lefkowitz</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Angiotensin analogs with divergent Bias stabilize distinct receptor conformations</article-title><source>Cell</source><volume>176</volume><fpage>468</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.005</pub-id><pub-id pub-id-type="pmid">30639099</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Reynolds</surname> <given-names>CA</given-names></name><name><surname>Smith</surname> <given-names>KJ</given-names></name><name><surname>Mobarec</surname> <given-names>JC</given-names></name><name><surname>Koole</surname> <given-names>C</given-names></name><name><surname>Savage</surname> <given-names>EE</given-names></name><name><surname>Pabreja</surname> <given-names>K</given-names></name><name><surname>Simms</surname> <given-names>J</given-names></name><name><surname>Sridhar</surname> <given-names>R</given-names></name><name><surname>Furness</surname> <given-names>SGB</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Thompson</surname> <given-names>PE</given-names></name><name><surname>Miller</surname> <given-names>LJ</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism</article-title><source>Cell</source><volume>165</volume><fpage>1632</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.023</pub-id><pub-id pub-id-type="pmid">27315480</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootten</surname> <given-names>D</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name><name><surname>Marti-Solano</surname> <given-names>M</given-names></name><name><surname>Babu</surname> <given-names>MM</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of signalling and biased agonism in G protein-coupled receptors</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>19</volume><fpage>638</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0049-3</pub-id><pub-id pub-id-type="pmid">30104700</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Mileni</surname> <given-names>M</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Vardy</surname> <given-names>E</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Huang</surname> <given-names>XP</given-names></name><name><surname>Carroll</surname> <given-names>FI</given-names></name><name><surname>Mascarella</surname> <given-names>SW</given-names></name><name><surname>Westkaemper</surname> <given-names>RB</given-names></name><name><surname>Mosier</surname> <given-names>PD</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structure of the human κ-opioid receptor in complex with JDTic</article-title><source>Nature</source><volume>485</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/nature10939</pub-id><pub-id pub-id-type="pmid">22437504</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Tong</surname> <given-names>J</given-names></name><name><surname>Ding</surname> <given-names>K</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><chapter-title>GPCR Allosteric Modulator Discovery</chapter-title><source>Protein Allostery in Drug Discovery</source><publisher-name>Springer</publisher-name><fpage>225</fpage><lpage>251</lpage></element-citation></ref><ref id="bib198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Xiao</surname> <given-names>P</given-names></name><name><surname>Qu</surname> <given-names>CX</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>LY</given-names></name><name><surname>Liu</surname> <given-names>ZX</given-names></name><name><surname>He</surname> <given-names>QT</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>JY</given-names></name><name><surname>Li</surname> <given-names>RR</given-names></name><name><surname>Li</surname> <given-names>MJ</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Guo</surname> <given-names>XZ</given-names></name><name><surname>Yang</surname> <given-names>ZY</given-names></name><name><surname>He</surname> <given-names>DF</given-names></name><name><surname>Yi</surname> <given-names>F</given-names></name><name><surname>Ruan</surname> <given-names>K</given-names></name><name><surname>Shen</surname> <given-names>YM</given-names></name><name><surname>Yu</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>JP</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Allosteric mechanisms underlie GPCR signaling to SH3-domain proteins through arrestin</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>876</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0115-3</pub-id><pub-id pub-id-type="pmid">30120361</pub-id></element-citation></ref><ref id="bib199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>XJ</given-names></name><name><surname>Vélez Ruiz</surname> <given-names>G</given-names></name><name><surname>Whorton</surname> <given-names>MR</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>DeVree</surname> <given-names>BT</given-names></name><name><surname>Deupi</surname> <given-names>X</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Kobilka</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex</article-title><source>PNAS</source><volume>106</volume><fpage>9501</fpage><lpage>9506</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811437106</pub-id><pub-id pub-id-type="pmid">19470481</pub-id></element-citation></ref><ref id="bib200"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>L</given-names></name><name><surname>Van Eps</surname> <given-names>N</given-names></name><name><surname>Zimmer</surname> <given-names>M</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Prosser</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activation of the A2A adenosine G-protein-coupled receptor by conformational selection</article-title><source>Nature</source><volume>533</volume><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/nature17668</pub-id><pub-id pub-id-type="pmid">27144352</pub-id></element-citation></ref><ref id="bib201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>L</given-names></name><name><surname>Neale</surname> <given-names>C</given-names></name><name><surname>Sljoka</surname> <given-names>A</given-names></name><name><surname>Lyda</surname> <given-names>B</given-names></name><name><surname>Pichugin</surname> <given-names>D</given-names></name><name><surname>Tsuchimura</surname> <given-names>N</given-names></name><name><surname>Larda</surname> <given-names>ST</given-names></name><name><surname>Pomès</surname> <given-names>R</given-names></name><name><surname>García</surname> <given-names>AE</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Prosser</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanistic insights into allosteric regulation of the A<sub>2A</sub>Adenosine G protein-coupled receptor by physiological cations</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>1372</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-03314-9</pub-id><pub-id pub-id-type="pmid">29636462</pub-id></element-citation></ref><ref id="bib202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Vogel</surname> <given-names>H</given-names></name><name><surname>Filipek</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of water and sodium ions in the activation of the μ-opioid receptor</article-title><source>Angewandte Chemie International Edition</source><volume>52</volume><fpage>10112</fpage><lpage>10115</lpage><pub-id pub-id-type="doi">10.1002/anie.201302244</pub-id><pub-id pub-id-type="pmid">23904331</pub-id></element-citation></ref><ref id="bib203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Filipek</surname> <given-names>S</given-names></name><name><surname>Palczewski</surname> <given-names>K</given-names></name><name><surname>Vogel</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4733</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5733</pub-id><pub-id pub-id-type="pmid">25203160</pub-id></element-citation></ref><ref id="bib204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>S</given-names></name><name><surname>Filipek</surname> <given-names>S</given-names></name><name><surname>Vogel</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A gating mechanism of the serotonin 5-HT3 receptor</article-title><source>Structure</source><volume>24</volume><fpage>816</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.03.019</pub-id><pub-id pub-id-type="pmid">27112600</pub-id></element-citation></ref><ref id="bib205"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbino</surname> <given-names>DR</given-names></name><name><surname>Achuthan</surname> <given-names>P</given-names></name><name><surname>Akanni</surname> <given-names>W</given-names></name><name><surname>Amode</surname> <given-names>MR</given-names></name><name><surname>Barrell</surname> <given-names>D</given-names></name><name><surname>Bhai</surname> <given-names>J</given-names></name><name><surname>Billis</surname> <given-names>K</given-names></name><name><surname>Cummins</surname> <given-names>C</given-names></name><name><surname>Gall</surname> <given-names>A</given-names></name><name><surname>Girón</surname> <given-names>CG</given-names></name><name><surname>Gil</surname> <given-names>L</given-names></name><name><surname>Gordon</surname> <given-names>L</given-names></name><name><surname>Haggerty</surname> <given-names>L</given-names></name><name><surname>Haskell</surname> <given-names>E</given-names></name><name><surname>Hourlier</surname> <given-names>T</given-names></name><name><surname>Izuogu</surname> <given-names>OG</given-names></name><name><surname>Janacek</surname> <given-names>SH</given-names></name><name><surname>Juettemann</surname> <given-names>T</given-names></name><name><surname>To</surname> <given-names>JK</given-names></name><name><surname>Laird</surname> <given-names>MR</given-names></name><name><surname>Lavidas</surname> <given-names>I</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Loveland</surname> <given-names>JE</given-names></name><name><surname>Maurel</surname> <given-names>T</given-names></name><name><surname>McLaren</surname> <given-names>W</given-names></name><name><surname>Moore</surname> <given-names>B</given-names></name><name><surname>Mudge</surname> <given-names>J</given-names></name><name><surname>Murphy</surname> <given-names>DN</given-names></name><name><surname>Newman</surname> <given-names>V</given-names></name><name><surname>Nuhn</surname> <given-names>M</given-names></name><name><surname>Ogeh</surname> <given-names>D</given-names></name><name><surname>Ong</surname> <given-names>CK</given-names></name><name><surname>Parker</surname> <given-names>A</given-names></name><name><surname>Patricio</surname> <given-names>M</given-names></name><name><surname>Riat</surname> <given-names>HS</given-names></name><name><surname>Schuilenburg</surname> <given-names>H</given-names></name><name><surname>Sheppard</surname> <given-names>D</given-names></name><name><surname>Sparrow</surname> <given-names>H</given-names></name><name><surname>Taylor</surname> <given-names>K</given-names></name><name><surname>Thormann</surname> <given-names>A</given-names></name><name><surname>Vullo</surname> <given-names>A</given-names></name><name><surname>Walts</surname> <given-names>B</given-names></name><name><surname>Zadissa</surname> <given-names>A</given-names></name><name><surname>Frankish</surname> <given-names>A</given-names></name><name><surname>Hunt</surname> <given-names>SE</given-names></name><name><surname>Kostadima</surname> <given-names>M</given-names></name><name><surname>Langridge</surname> <given-names>N</given-names></name><name><surname>Martin</surname> <given-names>FJ</given-names></name><name><surname>Muffato</surname> <given-names>M</given-names></name><name><surname>Perry</surname> <given-names>E</given-names></name><name><surname>Ruffier</surname> <given-names>M</given-names></name><name><surname>Staines</surname> <given-names>DM</given-names></name><name><surname>Trevanion</surname> <given-names>SJ</given-names></name><name><surname>Aken</surname> <given-names>BL</given-names></name><name><surname>Cunningham</surname> <given-names>F</given-names></name><name><surname>Yates</surname> <given-names>A</given-names></name><name><surname>Flicek</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ensembl 2018</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D754</fpage><lpage>D761</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1098</pub-id><pub-id pub-id-type="pmid">29155950</pub-id></element-citation></ref><ref id="bib206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Unal</surname> <given-names>H</given-names></name><name><surname>Gati</surname> <given-names>C</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Zatsepin</surname> <given-names>NA</given-names></name><name><surname>James</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Nelson</surname> <given-names>G</given-names></name><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>Sawaya</surname> <given-names>MR</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Messerschmidt</surname> <given-names>M</given-names></name><name><surname>Williams</surname> <given-names>GJ</given-names></name><name><surname>Boutet</surname> <given-names>S</given-names></name><name><surname>Yefanov</surname> <given-names>OM</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Ishchenko</surname> <given-names>A</given-names></name><name><surname>Tirupula</surname> <given-names>KC</given-names></name><name><surname>Desnoyer</surname> <given-names>R</given-names></name><name><surname>Coe</surname> <given-names>J</given-names></name><name><surname>Conrad</surname> <given-names>CE</given-names></name><name><surname>Fromme</surname> <given-names>P</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Karnik</surname> <given-names>SS</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structure of the angiotensin receptor revealed by serial femtosecond crystallography</article-title><source>Cell</source><volume>161</volume><fpage>833</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.011</pub-id><pub-id pub-id-type="pmid">25913193</pub-id></element-citation></ref><ref id="bib207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Feng</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Chu</surname> <given-names>M</given-names></name><name><surname>Qu</surname> <given-names>Q</given-names></name><name><surname>Tarrasch</surname> <given-names>JT</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Sun Kobilka</surname> <given-names>T</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Skiniotis</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein</article-title><source>Nature</source><volume>546</volume><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/nature22394</pub-id><pub-id pub-id-type="pmid">28538729</pub-id></element-citation></ref><ref id="bib208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Qin</surname> <given-names>L</given-names></name><name><surname>Zacarías</surname> <given-names>NV</given-names></name><name><surname>de Vries</surname> <given-names>H</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Gustavsson</surname> <given-names>M</given-names></name><name><surname>Dabros</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>Cherney</surname> <given-names>RJ</given-names></name><name><surname>Carter</surname> <given-names>P</given-names></name><name><surname>Stamos</surname> <given-names>D</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>IJzerman</surname> <given-names>AP</given-names></name><name><surname>Heitman</surname> <given-names>LH</given-names></name><name><surname>Tebben</surname> <given-names>A</given-names></name><name><surname>Kufareva</surname> <given-names>I</given-names></name><name><surname>Handel</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists</article-title><source>Nature</source><volume>540</volume><fpage>458</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1038/nature20605</pub-id><pub-id pub-id-type="pmid">27926736</pub-id></element-citation></ref><ref id="bib209"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>de Waal</surname> <given-names>PW</given-names></name><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>Kang</surname> <given-names>Y</given-names></name><name><surname>Van Eps</surname> <given-names>N</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Pal</surname> <given-names>K</given-names></name><name><surname>Goswami</surname> <given-names>D</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Barty</surname> <given-names>A</given-names></name><name><surname>Latorraca</surname> <given-names>NR</given-names></name><name><surname>Chapman</surname> <given-names>HN</given-names></name><name><surname>Hubbell</surname> <given-names>WL</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Gurevich</surname> <given-names>VV</given-names></name><name><surname>Griffin</surname> <given-names>PR</given-names></name><name><surname>Ernst</surname> <given-names>OP</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors</article-title><source>Cell</source><volume>170</volume><fpage>457</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.07.002</pub-id></element-citation></ref><ref id="bib210"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>RRCS (Residue-residue contact score)</data-title><source>GitHub</source><version designator="2f9a555">2f9a555</version><ext-link ext-link-type="uri" xlink:href="https://github.com/zhaolabSHT/RRCS">https://github.com/zhaolabSHT/RRCS</ext-link></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.50279.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Shan</surname><given-names>Yibing</given-names></name><role>Reviewing Editor</role><aff><institution>DE Shaw Research</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript reports the structural analysis of class A GPCR activation mechanism by developing a novel residue-residue contact score (RRCS) and comparing this score between the active and inactive class A GPCR structures. From this analysis, the authors propose an activation pathway from extracellular ligand binding to the intracellular coupling of signal transducers like G proteins. The proposed pathway involves four clusters (layers) of residues. This proposed activation mechanism is supported by the accompanying mutagenesis experiments.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Universal activation mechanism of class A GPCRs&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Olga Boudker as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) There are more than 800 different GPCRs in human body, 45 structures were resolved in class A, and only 4 pairs of single static structures have been analyzed in details in this report. While the analysis aiming to reveal a shared GPCR activation mechanism is a meaningful attempt, it is premature to claim a &quot;universal&quot; activation mechanism. It would be surprising if the activation elements involved in Gs coupling and Gi coupling receptors are entirely conserved, given that the dramatic difference in the outward movement in the cytoplasmic end of TM6 and that the coupling of GPCRs with different intracellular transducers is subjected to different conformational changes. At best we can hope that the proposed mechanism provides a framework and a common language for future structural/mechanistic analysis of GPCRs, and different GPCRs (especially GPCRs of the A family) may to variously degrees and in different aspects resemble proposed mechanism. The entire manuscript, especially the title and the Abstract, needs revision in recognition of this understanding.</p><p>2) Within this four detailed analyzed structure, RHO actually doesn't have agonist. It is not justified to include RHO as an example for analysis.</p><p>3) Can the authors based on their proposal provide explanation of the basis for GPCR coupling to different G proteins using the RRCS analysis?</p><p>4) The author always assumed that ligand binding is located above the highly conserved W6.48, but there are more and more new structures indicated that the ligand could actually diffuse as deep as below D2.50. This is represented by the structure of LTB4 receptor (Nat. Chem. Biol. 14: 262-269) as well as several others. The revision should discuss how a deeper ligand binding would affect their conclusion.</p><p>5) Many non-orthosteric ligand binding site have been captured in crystal structures (Sci Rep. 2019; 9: 6180; Front Pharmacol. 2018; 9: 128). How does the proposed activation mechanism provides new insight to these non-orthosteric ligand bindings.</p><p>6) The activation mechanism and G protein specificity have been extensively discussed previously (e.g. Nature Structural and Molecular Biology 25(2):185-194 (2018); Nature 545: 317-322 (2017); Nature 536: 484-487 (2016); Nature Chemical Biology 14: 1059-1066(2018); Chem. Rev.20171171139-155). A summary of these discussions should be provided in an expanded Introduction, and the proposed mechanism should be contextualized with respect to the current understanding. Related, the citation of 19 references in one stroke is highly unconventional; this should be revised with a more nuanced account of the current structural understanding of GPCRs.</p><p>7) Certain aspects of the proposed model have already been reported, and the authors in the revision should make a special effort in making sure that these reports are properly cited.</p><p>8) The description for the four layer elements in the activation pathway as &quot;modular&quot; is quite misleading. &quot;Modular&quot; means isolated and functionally independent, like classic DNA-binding domain and transcriptional activation domain in transcription factors, which can function separately and can be exchanged between transcriptional factors. In this paper, the modality of the four layers in GPCR activation has not been demonstrated. It is not clear whether layer elements can be exchanged between different receptors.</p><p>9) Compared to the diverse residue types in the Class A GPCR activation pathways, residues involved in class B GPCR activation appeared to be much more conserved as presented in the recent PTH1R receptor. Discussing the difference and similarity of class A and class B GPCR activation will broaden the interests and impact of the paper.</p><p>10) The authors introduced biological mutation experiment to support their ideas. It should be made clear that a positive result can only show the involvement of the mutated residue in GPCR activation, but cannot confirm a residue-residue interaction. With this in mind, the claims associated with the mutation data should be re-calibrated.</p><p>11) The paper will be much strengthened if the mutagenesis experiments performed on A2aR are also performed for one of representative Gi coupled receptors. (Probably not the whole set of mutants but the representative CAM and CIM for a Gi coupled receptor.)</p><p>12) To confirm the predicted residue-residue interactions, it would be highly desirable to use NMR to show correlated signal changes of the residue pairs.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.50279.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) There are more than 800 different GPCRs in human body, 45 structures were resolved in class A, and only 4 pairs of single static structures have been analyzed in details in this report. While the analysis aiming to reveal a shared GPCR activation mechanism is a meaningful attempt, it is premature to claim a &quot;universal&quot; activation mechanism. It would be surprising if the activation elements involved in Gs coupling and Gi coupling receptors are entirely conserved, given that the dramatic difference in the outward movement in the cytoplasmic end of TM6 and that the coupling of GPCRs with different intracellular transducers is subjected to different conformational changes. At best we can hope that the proposed mechanism provides a framework and a common language for future structural/mechanistic analysis of GPCRs, and different GPCRs (especially GPCRs of the A family) may to variously degrees and in different aspects resemble proposed mechanism. The entire manuscript, especially the title and the Abstract, needs revision in recognition of this understanding.</p></disp-quote><p>We thank the reviewers for the comments. In the revised manuscript, we have reworked on the title, the Abstract and related contents to ensure the accuracy and clarity.</p><p>We discuss possible misunderstandings of our work below:</p><p>First, we analyzed 6 inactive <italic>vs</italic>. fully active pairs of structures in detail (listed in <xref ref-type="table" rid="resptable1">Author response table 1</xref>, inactive state is in orange) but not 4 pairs, as shown in Figure 2D, Figure 2—figure supplement 1, and Results paragraph two. These structures were picked based on their high quality. That is, they are all of high-resolution, no mutation or only one mutation in the transmembrane domain which is known not to affect receptor signaling. These 6 pairs were also selected for analysis by the previous research [Venkatakrishnan, et al. Nature 536.7617 (2016): 484.].</p><table-wrap id="resptable1" position="float"><label>Author response table 1.</label><caption><title>List of twelve structures of six receptors.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>GPCR</th><th>PDB code</th><th>Resolution (Å)</th><th>Ligand <break/>G protein/G protein memetic</th><th>State</th><th>Mutation in the TM region</th></tr></thead><tbody><tr><td rowspan="2">bRho</td><td>1GZM</td><td>2.7</td><td>11-cis-retinal (inverse agonist, covalently bound)</td><td>Inactive</td><td>No mutation</td></tr><tr><td>3PQR</td><td>2.9</td><td>All-trans-retinal (agonist, covalently bound) <break/>GαCT2 (G protein peptide)</td><td>Active</td><td>No mutation</td></tr><tr><td>β<sub>2</sub>AR</td><td>2RH1</td><td>2.4</td><td>Carazolol (inverse agonist)</td><td>Inactive</td><td>No mutation</td></tr><tr><td>3SN6</td><td>3.2</td><td>BI-167107 (agonist) <break/>G<sub>s</sub> (G protein)</td><td>Active</td><td>No mutation</td></tr><tr><td rowspan="2">M2R</td><td>3UON</td><td>3.0</td><td>3-quinuclidinyl-benzilate (antagonist)</td><td>Inactive</td><td>No mutation</td></tr><tr><td>4MQS</td><td>3.5</td><td>Iperoxo (agonist) <break/>Nb9-8 (nanobody)</td><td>Active</td><td>No mutation</td></tr><tr><td rowspan="2">μOR</td><td>4DKL</td><td>2.8</td><td>β-funaltrexamine (antagonist)</td><td>Inactive</td><td>No mutation</td></tr><tr><td>5C1M</td><td>2.1</td><td>BU72 (agonist) <break/>Nb39 (nanobody)</td><td>Active</td><td>No mutation</td></tr><tr><td>A<sub>2A</sub>R</td><td>3EML</td><td>2.6</td><td>ZM241385 (antagonist)</td><td>Inactive</td><td>No mutation</td></tr><tr><td>5G53</td><td>3.4</td><td>NECA (agonist) <break/>Mini-G<sub>s</sub> (engineered G protein)</td><td>Active</td><td>No mutation</td></tr><tr><td rowspan="2">κOR</td><td>4DJH</td><td>2.9</td><td>JDTic (antagonist)</td><td>Inactive</td><td>I135L (3×29)</td></tr><tr><td>6B73</td><td>3.1</td><td>MP1104 (agonist) <break/>Nb39 (nanobody)</td><td>Active</td><td>I135L (3×29)</td></tr></tbody></table></table-wrap><p>More importantly, beyond the analysis on the six receptors, we performed a class-wide RRCS comparison between the 142 inactive and 27 active state class A GPCR structures to identify residue pairs showing statistically significant different RRCS scores (P&lt;0.001; two sample <italic>t</italic>-test) upon activation (Figure 2D, Figure 2—source data 2, Materials and methods). The combination of such an analysis and the across-class comparison could take the full advantage of tremendous successes of GPCR structural biology in the past decade, and only this exercise would give us the confidence to claim what we discovered are common to diverse class A GPCRs.</p><p>Second, the common activation pathway we discovered is a shared portion among G<sub>s</sub>, G<sub>i</sub>, and arrestin activation pathways of various receptors stimulated by various agonists. At the same time, receptors that do have their own receptor-, agonist-, and effector-specific pathways are not the focus of this study. Therefore, we totally agree that activation elements involved in G<sub>s</sub> and G<sub>i</sub> coupling are NOT entirely conserved (<italic>i.e.</italic>, biased signaling), and we had avoided to use this term in the manuscript.</p><disp-quote content-type="editor-comment"><p>2) Within this four detailed analyzed structure, RHO actually doesn't have agonist. It is not justified to include RHO as an example for analysis.</p></disp-quote><p>We agree with the reviewers on the importance of structure selection to study receptor activation.</p><p>As listed in the <xref ref-type="table" rid="resptable1">Author response table 1</xref>, we used a high quality (2.9 Å resolution) structure (PDB: 3PQR) as the fully active state structure of Rho, which has all-trans-retinal (i.e., agonist) covalently bound.</p><p>In fact, we did investigate a low resolution (4.5 Å for the overall complex, in local resolution map, the receptor part has even a lower resolution) cryo-EM structure of the Rho-G<sub>i</sub> complex (PDB: 6CMO), in which agonist is missing. It serves as a negative control for our analysis. We noticed that 6CMO has 8 pairs of residues that do not match the common activation pathway (<italic>i.e.</italic>, 8 outliers out of 34 residues pairs), and we attributed these mismatches to the rather low resolution of the structure and probably the missing of agonist. The positive control is a 3.1 Å crystal structure of the Rho-mini-G<sub>o</sub> complex (PDB: 6FUF), for which no outliers were observed (Figure 4, Figure 4—figure supplement 1 and Figure 4—figure supplement 2). These results reflect that our RRCS approach is dependent on the high-quality structures.</p><disp-quote content-type="editor-comment"><p>3) Can the authors based on their proposal provide explanation of the basis for GPCR coupling to different G proteins using the RRCS analysis?</p></disp-quote><p>This is a good question. After we developed the RRCS analysis, we have been trying to find possible applications for this method. In theory, this method could be used to analyze any system that have big or subtle but significant conformational changes. The limit is that it really relies on the accuracy of side chain conformations, thus high-resolution structures are the key.</p><p>We did apply the RRCS analysis to study G protein selectivity and failed to reach any meaningful conclusions. This may be caused by following reasons:</p><p>a) Lack of high resolution GPCR-G protein complex structures. <xref ref-type="table" rid="resptable2">Author response table 2</xref> lists all available GPCR-G protein complexes to date (14 structures from 10 receptors). However, 6 of them have poor resolution (lines in gray) thus are not qualified for the RRCS analysis. For the other cryo-EM structures, carefully checking the local resolution for the GPCR-G protein interface but not directly use the overall resolution of the whole complex is need before doing any RRCS calculation, since in general, large G<sub>β</sub> protein has the highest resolution in the complex. Hopefully, with more high-resolution complexes determined, RRCS analysis may help answer the question of G protein selectivity.</p><table-wrap id="resptable2" position="float"><label>Author response table 2.</label><caption><title>List of GPCR-G protein complex structures.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Receptor</th><th>PDB code</th><th>Method</th><th>Resolution (Å)</th><th>Ligand + G protein/G protein memetic</th></tr></thead><tbody><tr><td>A<sub>2A</sub>R</td><td>5G53</td><td>X-ray</td><td>3.4</td><td>NECA + Mini-G<sub>s</sub></td></tr><tr><td>A<sub>2A</sub>R</td><td>6GDG</td><td>cryo-EM</td><td>4.1</td><td>NECA + Mini-G<sub>s</sub></td></tr><tr><td>β<sub>2</sub>AR</td><td>3SN6</td><td>X-ray</td><td>3.2</td><td>BI-167107 + G<sub>s</sub></td></tr><tr><td>β<sub>2</sub>AR</td><td>6E67</td><td>X-ray</td><td>3.7</td><td>BI-167107 + Fused G<sub>s</sub> C-terminal</td></tr><tr><td>Rho</td><td>6CMO</td><td>cryo-EM</td><td>4.5</td><td>G<sub>i</sub></td></tr><tr><td>Rho</td><td>6FUF</td><td>X-ray</td><td>3.1</td><td>all-trans-retinal +Mini-G<sub>o</sub></td></tr><tr><td>μOR</td><td>6DDE/6DDF</td><td>cryo-EM</td><td>3.5</td><td>DAMGO + G<sub>i</sub></td></tr><tr><td>A<sub>1A</sub>R</td><td>6D9H</td><td>cryo-EM</td><td>3.6</td><td>Adenosine + G<sub>i2</sub></td></tr><tr><td>5-HT<sub>1B</sub></td><td>6G79</td><td>cryo-EM</td><td>3.8</td><td>Donitriptan + G<sub>o</sub></td></tr><tr><td>CB1</td><td>6N4B</td><td>cryo-EM</td><td>3.0</td><td>MDMB-Fubinaca + G<sub>i</sub></td></tr><tr><td>NTSR1</td><td>6OSA</td><td>cryo-EM</td><td>3.0</td><td>JMV449 + G<sub>i1</sub> (NC state)</td></tr><tr><td>NTSR1</td><td>6OS9</td><td>cryo-EM</td><td>3.0</td><td>JMV449 + G<sub>i1</sub> (C state)</td></tr><tr><td>M2R</td><td>6OIK</td><td>cryo-EM</td><td>3.6</td><td>Iperoxo + LY2119620 +G<sub>oA</sub></td></tr><tr><td>M1R</td><td>6OIJ</td><td>cryo-EM</td><td>3.3</td><td>Iperoxo + G<sub>11</sub></td></tr></tbody></table></table-wrap><p>b) It is known that G-protein activation is a complex process<sup>1, 2</sup> which may have several states. Taking NTSR1–G<sub>i1</sub> complexes for example, a canonical-state and a non-canonical state of G protein were determined showing different hNTSR1–G<sub>i1</sub> interfaces. The complexity of this dynamic process also increases the difficulty of RRCS analysis.</p><p>c) The G protein coupling region is much more diverse in sequence compared to intracellular half of the TM domain in which our common activation pathway locates. Thus, different receptors may recognize different positions of the G-protein through distinct residues, like multiple keys (receptors) opening the same lock (G protein) using non-identical cuts, as a previous study pointed out.<sup>3</sup></p><disp-quote content-type="editor-comment"><p>4) The author always assumed that ligand binding is located above the highly conserved W6.48, but there are more and more new structures indicated that the ligand could actually diffuse as deep as below D2.50. This is represented by the structure of LTB4 receptor (Nat. Chem. Biol. 14: 262-269) as well as several others. The revision should discuss how a deeper ligand binding would affect their conclusion.</p></disp-quote><p>We thank the reviewers for providing the valuable insights. We took this suggestion and added analysis for several crystal structures (PDB: 5X33, 6K1Q and 6BQH, <xref ref-type="table" rid="resptable3">Author response table 3</xref>), the ligand of which diffuses as deep as below D<sup>2.50</sup>. These ligands are all inverse agonists that touch/occupy the Na<sup>+</sup> pocket. By taking the space of the Na<sup>+</sup>, they prevented the collapse of Na<sup>+</sup> pocket, as well as blocking the rotation of W<sup>6.48</sup>, leading to lock the receptors to an inactive state.</p><table-wrap id="resptable3" position="float"><label>Author response table 3.</label><caption><title>List of three inverse agonist-bound structures.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>GPCR</th><th>PDB code</th><th>Ligand</th><th>Ligand type</th><th>Na<sup>+</sup> mimic group in ligand</th><th>Occupying Na<sup>+</sup> pocket</th></tr></thead><tbody><tr><td>BLT1</td><td>5X33</td><td>BIIL260</td><td>Inverse agonist</td><td>Yes</td><td>Yes</td></tr><tr><td>ET<sub>B</sub></td><td>6K1Q</td><td>IRL2500</td><td>Inverse agonist</td><td>No</td><td>Yes</td></tr><tr><td>5-HT<sub>2C</sub></td><td>6BQH</td><td>Ritanserin</td><td>Inverse agonist</td><td>No</td><td>No</td></tr></tbody></table></table-wrap><p>These observations are consistent with our activation model and functional study of A<sub>2A</sub>R mutants. As shown in Figure 6, Figure 6—source data 1, Figure 6—source data 2 and Figure 6—figure supplement 1, three mutations of A<sub>2A</sub>R (L48<sup>2x46</sup>R, N280<sup>7x45</sup>R and N284<sup>7x49</sup>K) that form slat bridges with D<sup>2.50</sup> and stabilize the inactive state were shown to abolish cAMP accumulation as expected.</p><p>Interestingly, for D<sup>2.50</sup>, only loss-of-function disease mutations (Figure 7B) or constitutively inactivating mutations (Figure 7C) were observed for 24 receptors, implying that D<sup>2.50</sup> is indispensable for receptor activation. These finding are also supported by the NMR study of A<sub>2A</sub>R<sup>4</sup>, which demonstrated the role of D52<sup>2.50</sup> as an allosteric link between the orthosteric drug binding site and the intracellular signaling surface<sup>4</sup>.</p><disp-quote content-type="editor-comment"><p>5) Many non-orthosteric ligand binding site have been captured in crystal structures (Sci Rep. 2019; 9: 6180; Front Pharmacol. 2018; 9: 128). How does the proposed activation mechanism provides new insight to these non-orthosteric ligand bindings.</p></disp-quote><p>We thank the reviewers for raising this point. Exactly as the recommended literature revealed, allosteric modulation of GPCR provides a promising potential of pharmacological intervention, due to the diversity in location, mechanism, and selectivity of allosteric ligands.</p><p>A list of reported allosteric modulators among determined structures of class A GPCRs are listed in <xref ref-type="table" rid="resptable4">Author response table 4</xref>, with PAMs labeled in green.</p><table-wrap id="resptable4" position="float"><label>Author response table 4.</label><caption><title>List of allosteric modulators among determined structures of class A GPCRs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Location of binding site</th><th>Receptor</th><th>Ligand</th><th>Ligand type</th><th>PDB code</th></tr></thead><tbody><tr><td rowspan="3">Intracellular pocket</td><td>β<sub>2</sub>AR</td><td>CMPD-15PA</td><td>Negative allosteric modulator</td><td>5X7D</td></tr><tr><td>CCR9</td><td>Vercirnon</td><td>Antagonist</td><td>5LWE</td></tr><tr><td>CCR2</td><td>CCR2-RA-[R]</td><td>Antagonist</td><td>5T1A</td></tr><tr><td rowspan="8">Extra-helical binding site</td><td>C5aR</td><td>NDT9513727</td><td>Inverse agonist</td><td>5O9H</td></tr><tr><td>C5aR</td><td>avacopan</td><td>Allosteric antagonist</td><td>6C1R</td></tr><tr><td>C5aR</td><td>NDT9513727</td><td>Allosteric antagonist</td><td>6C1Q</td></tr><tr><td>β<sub>2</sub>AR</td><td>compound-6FA</td><td>Positive allosteric modulator</td><td>6N48</td></tr><tr><td>P2Y1</td><td>BPTU</td><td>antagonist</td><td>4XNV</td></tr><tr><td>GPR40</td><td>AP8</td><td>Full allosteric agonists (agoPAM)</td><td>5TZY</td></tr><tr><td>GPR40</td><td>Compound 1</td><td>Full agonist</td><td>5KW2</td></tr><tr><td>PAR2</td><td>AZ3451</td><td>Antagonist</td><td>5NDZ</td></tr><tr><td rowspan="3">Non-canonical binding pocket</td><td>GPR40</td><td>TAK-875</td><td>Ago-allosteric modulator</td><td>4PHU</td></tr><tr><td>GPR40</td><td>MK-8666</td><td>Ago-allosteric modulator</td><td>5TZR</td></tr><tr><td>PAR2</td><td>AZ8838</td><td>antagonist</td><td>5NDD</td></tr><tr><td>Extracellular vestibule above the orthosteric site</td><td>M2</td><td>LY2119620</td><td>Positive allosteric modulator</td><td>4MQT</td></tr></tbody></table></table-wrap><p>As we can see, the locations of binding site are quite diverse for GPCR allosteric modulators, and so do the mechanisms as one can expect.</p><p>Here is our brief analysis of the possible mechanisms. A) Directly altering the common activation pathway. For example, for allosteric modulators bound to the intracellular pocket of their receptor (PDB: 5X7D, 5LWE and 5T1A), they exert antagonism by preventing G protein coupling. B) Having receptor-, ligand-, and effector-specific pathways. An example is compound-6FA (in PDB 6N58), which binds to the extrahelical surface of β<sub>2</sub>AR, but also directly interacts with G protein. C) A mixture of the above two mechanisms.</p><disp-quote content-type="editor-comment"><p>6) The activation mechanism and G protein specificity have been extensively discussed previously (e.g. Nature Structural and Molecular Biology 25(2):185-194 (2018); Nature 545: 317-322 (2017); Nature 536: 484-487 (2016); Nature Chemical Biology 14: 1059-1066(2018); Chem. Rev.20171171139-155). A summary of these discussions should be provided in an expanded Introduction, and the proposed mechanism should be contextualized with respect to the current understanding. Related, the citation of 19 references in one stroke is highly unconventional; this should be revised with a more nuanced account of the current structural understanding of GPCRs.</p></disp-quote><p>We thank the reviewer for the comments. We significantly rewrote the Introduction part to reflect the previous understanding of GPCR activation. Many more references are cited now.</p><disp-quote content-type="editor-comment"><p>7) Certain aspects of the proposed model have already been reported, and the authors in the revision should make a special effort in making sure that these reports are properly cited.</p></disp-quote><p>We thank the reviewer for this comment. We have greatly increased the citation and number of references to reflect previous findings on GPCR activation mechanism.</p><disp-quote content-type="editor-comment"><p>8) The description for the four layer elements in the activation pathway as &quot;modular&quot; is quite misleading. &quot;Modular&quot; means isolated and functionally independent, like classic DNA-binding domain and transcriptional activation domain in transcription factors, which can function separately and can be exchanged between transcriptional factors. In this paper, the modality of the four layers in GPCR activation has not been demonstrated. It is not clear whether layer elements can be exchanged between different receptors.</p></disp-quote><p>We changed the word modular to modular nature, we meant each layer has different function and can be activated/inactivated in a rather independent manner, as shown in our mutagenesis study (Figure 6B).</p><p>Analyzing residue pairs in each layer of the common activation pathway for intermediate structures (<italic>i.e.</italic>, only agonist but not G protein bound structures) also supports the modular nature of the common activation pathway. As shown in <xref ref-type="fig" rid="respfig1">Author response image 1</xref>, β<sub>2</sub>AR (3PDS) only has layer 4 in the active state; 5-HT<sub>2B</sub> (6DS0) has layers 2 and 3 partially activated, while leaving layers 1 and 4 not activated; A<sub>2A</sub>R (2YDV) and LPA<sub>6</sub> (5XSZ) have layers 1-3 all partially activated, while leaving layer 4 untouched; and US28 (4XT1) has layers 2-4 in fully active state, while layer 1 is largely inactivated.</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>Receptor activation process via intermediate structures (i.e., only agonist but not G protein bound structures) are in receptor- and ligand-specific manner, thereby highlighting the modular nature and complexity of the activation pathways.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-resp-fig1-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>9) Compared to the diverse residue types in the Class A GPCR activation pathways, residues involved in class B GPCR activation appeared to be much more conserved as presented in the recent PTH1R receptor. Discussing the difference and similarity of class A and class B GPCR activation will broaden the interests and impact of the paper.</p></disp-quote><p>We thank the reviewers for this suggestion. Actually, the idea of applying RRCS on other allosteric systems including class B GPCRs is on our to-do-list. However, we have not done so due to the following reasons:</p><p>a) Different from class A GPCRs, only one receptor (GLP-1R) has been determined with both inactive and fully active state structures, while other receptors only have either antagonist-bound inactive structures or G protein-bound active structures.</p><table-wrap id="resptable5" position="float"><label>Author response table 5.</label><caption><title>List of available class B GPCRs structures.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Receptor</th><th>PDB code</th><th>Method</th><th>Resolution (Å)</th><th>Ligand + G protein/G protein memetic</th><th valign="top">States</th></tr></thead><tbody><tr><td>CRF1R</td><td>4K5Y</td><td>X-ray</td><td>2.9</td><td>Antagonist CP-376395</td><td valign="top">Inactive</td></tr><tr><td>CRF1R</td><td>4Z9G</td><td>X-ray</td><td>3.2</td><td>Antagonist CP-376395</td><td valign="top">Inactive</td></tr><tr><td>CTR</td><td>6NIY</td><td>cryo-EM</td><td>3.3</td><td>Peptide ligand + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td>CTR</td><td>5UZ7</td><td>cryo-EM</td><td>4.1</td><td>Peptide ligand + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td>CGRP</td><td>6E3Y</td><td>cryo-EM</td><td>3.3</td><td>CGRP + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td>GCGR</td><td>4L6R</td><td>X-ray</td><td>3.3</td><td>No ligand was seen</td><td valign="top">Inactive</td></tr><tr><td>GCGR</td><td>5EE7</td><td>X-ray</td><td>2.5</td><td>Antagonist MK-0893</td><td valign="top">Inactive</td></tr><tr><td>GCGR</td><td>5YQZ</td><td>X-ray</td><td>3.0</td><td>Partial agonist NNC1702</td><td valign="top">Intermediate</td></tr><tr><td>GCGR</td><td>5XEZ</td><td>X-ray</td><td>3.0</td><td>Negative allosteric modulator NNC0640</td><td valign="top">Inactive</td></tr><tr><td>GCGR</td><td>5XF1</td><td>X-ray</td><td>3.2</td><td>Negative allosteric modulator NNC0640</td><td valign="top">Inactive</td></tr><tr><td>GLP-1R</td><td>5VAI</td><td>cryo-EM</td><td>4.1</td><td>human GLP-1 + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td valign="top">GLP-1R</td><td>6B3J</td><td>cryo-EM</td><td>3.3</td><td>Exendin-P5 + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td valign="top">GLP-1R</td><td>5NX2</td><td valign="top">X-ray</td><td>3.7</td><td>Truncated peptide agonist</td><td valign="top">Intermediate</td></tr><tr><td valign="top">GLP-1R</td><td>5VEW</td><td valign="top">X-ray</td><td>2.7</td><td>PF-06372222</td><td valign="top">Inactive</td></tr><tr><td valign="top">GLP-1R</td><td>5VEX</td><td valign="top">X-ray</td><td>3.0</td><td>NNC0640</td><td valign="top">Inactive</td></tr><tr><td>PTH1R</td><td>6FJ3</td><td>X-ray</td><td>2.5</td><td>Peptide agonist ePTH</td><td valign="top">Intermediate</td></tr><tr><td>PTH1R</td><td>6NBH</td><td valign="top">cryo-EM</td><td>3.5</td><td>A long-acting PTH analog + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td>PTH1R</td><td>6NBI</td><td valign="top">cryo-EM</td><td>4.0</td><td>A long-acting PTH analog + G<sub>s</sub></td><td valign="top">Active</td></tr><tr><td>PTH1R</td><td>6NBF</td><td valign="top">cryo-EM</td><td>3.0</td><td>A long-acting PTH analog + G<sub>s</sub></td><td valign="top">Active</td></tr></tbody></table></table-wrap><p>b) The active state structures of class B GPCRs are all EM structures, their resolutions are generally low compared to that of crystal structures. As mentioned before, the RRCS analysis highly relies on the quality of side chain conformations. More class B structures with resolution higher than 3.0 Å are needed.</p><p>c) The primary results of RRCS on class B GPCRs revealed that RRCS could describe the well-known conformational changes including the HETX motif (Nature. 2017;546(7657):248-253<sup>5</sup>) very well (<xref ref-type="fig" rid="respfig2">Author response image 2</xref>).</p><fig id="respfig2"><label>Author response image 2.</label><caption><title>Calculated RRCS for the HETX motif in class B GPCRs.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-50279-resp-fig2-v3.tif"/></fig><p>The comparison of the activation mechanism between classes A and B GPCRs have been frequently discussed<sup>6</sup>. The most notable conformational change in class B GPCRs is the sharp kink and unwinding in the middle of TM6, as observed for GLP-1R<sup>5</sup>/CTR<sup>7</sup>/CGRP<sup>8</sup>/PTH1R<sup>9</sup>. Another notable difference is the signal initiation and transduction pathway: class A has PIF/CWxP/Na<sup>+</sup> pocket/DRY/NPxxY motifs, while class B has totally different conserved motifs. Despite these differences, they both couple G protein in similar orientation, highlighting the converge of signal transduction in the cytoplasmic region.</p><disp-quote content-type="editor-comment"><p>10) The authors introduced biological mutation experiment to support their ideas. It should be made clear that a positive result can only show the involvement of the mutated residue in GPCR activation, but cannot confirm a residue-residue interaction. With this in mind, the claims associated with the mutation data should be re-calibrated.</p></disp-quote><p>Thank the reviewer for raising this point. We were very careful when making mechanistic interpretations of the successfully predicted mutants, we always used the words “likely”, “would”, and “probably” to avoid any confirmation of residue-residue interactions, unless such interactions were reported by NMR studies.</p><disp-quote content-type="editor-comment"><p>11) The paper will be much strengthened if the mutagenesis experiments performed on A2aR are also performed for one of representative Gi coupled receptors. (Probably not the whole set of mutants but the representative CAM and CIM for a Gi coupled receptor.)</p></disp-quote><p>Thank the reviewer for the suggestion. We expanded our mutagenesis studies to two additional receptors: G<sub>s</sub>-coupled 5-HT<sub>7</sub> and G<sub>i</sub>-coupled 5-HT<sub>1B</sub>. The three mutations on the G<sub>s</sub>-coupled 5-HT<sub>7</sub> were designed and validated by Dr. Nevin Lambert (who designed the mutations by directly following our designs on A<sub>2A</sub>R reported in the preprint of this manuscript. We did not interact with each other before this paper was submitted to the preprint server). The four mutations on the G<sub>i</sub>-coupled 5-HT<sub>1B</sub> were validated by ourselves. All the mutations are remarkably consistent with what we discovered in A<sub>2A</sub>R. We added a new figure (Figure 6—figure supplement 2) to show the new mutagenesis data.</p><disp-quote content-type="editor-comment"><p>12) To confirm the predicted residue-residue interactions, it would be highly desirable to use NMR to show correlated signal changes of the residue pairs.</p></disp-quote><p>This is an excellent suggestion. Exactly, NMR study could provide comprehensive and precise information on residue contacts changes upon receptor activation. Although we were unable to perform NMR study due to 2-month time limit and lack of expertise, we collected and analyzed published NMR data, which covered several regions in the common activation pathway, including residues at 5.57, 3.40, 5.58, 7.53, the Na<sup>+</sup> pocket, TM6 and DRY motif. The following is a brief summary of our analysis.</p><p>Isogai et al. in the NMR study of turkey β<sub>1</sub>-adrenergic receptor (β<sub>1</sub>AR)<sup>10</sup> demonstrated that chemical shifts of the labeled V226<sup>5.57</sup> correlate linearly with ligand efficacies of the G protein pathway, thereby proving the involvement of residue 5.57 in receptor activation. The same NMR study also showed the participation of three residues (V129<sup>3.40</sup>, A227<sup>5.58</sup>, and L343<sup>7.53</sup>) in receptor activation through NMR response to ligand binding and point mutations (V129<sup>3.40</sup>I, A227<sup>5.58</sup>Y, and L343<sup>7.53</sup>Y) These results provide experimental evidence at high resolution of an extensive signal transduction network that connects the ligand binding site to the intracellular sides of TM5, TM6, and TM7.</p><p>Notably, 5.57, 3.40, 5.58 and 7.53 are nodes in our common activation pathway. Exactly as shown in Figure 5 and Figure 5—figure supplement 1, receptor activation involves the elimination of TM3-TM6 contacts, formation of TM3-TM7 and TM5-TM6 contacts, reflecting the outward movement of the cytoplasmic end of TM6 away from TM3, the inward movement of TM7 towards TM3 and the repacking of TM5 and TM6.</p><p>By using stable isotope NMR study for A<sub>2A</sub> adenosine receptor (A<sub>2A</sub>R)<sup>4</sup>,Eddy et al. observed the interplay of the ‘‘toggle switch’’ W246<sup>6.48</sup> with the allosteric center at D52<sup>2.50</sup>. The observation is modelled in Figures 3 and 5 of our manuscript.</p><p><bold>References</bold></p><p>1. Kato, H. E.; Zhang, Y.; Hu, H.; Suomivuori, C. M.; Kadji, F. M. N.; Aoki, J.; Krishna Kumar, K.; Fonseca, R.; Hilger, D.; Huang, W.; Latorraca, N. R.; Inoue, A.; Dror, R. O.; Kobilka, B. K.; Skiniotis, G., Conformational transitions of a neurotensin receptor 1-Gi1 complex. Nature 2019, 572 (7767), 80-85.</p><p>2. Liu, X.; Xu, X.; Hilger, D.; Aschauer, P.; Tiemann, J. K. S.; Du, Y.; Liu, H.; Hirata, K.; Sun, X.; Guixa-Gonzalez, R.; Mathiesen, J. M.; Hildebrand, P. W.; Kobilka, B. K., Structural Insights into the Process of GPCR-G Protein Complex Formation. Cell 2019, 177 (5), 1243-1251 e12.</p><p>3. Flock, T.; Hauser, A. S.; Lund, N.; Gloriam, D. E.; Balaji, S.; Babu, M. M., Selectivity determinants of GPCR-G-protein binding. Nature 2017, 545 (7654), 317-322.</p><p>4. Eddy, M. T.; Lee, M. Y.; Gao, Z. G.; White, K. L.; Didenko, T.; Horst, R.; Audet, M.; Stanczak, P.; McClary, K. M.; Han, G. W.; Jacobson, K. A.; Stevens, R. C.; Wuthrich, K., Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor. Cell 2018, 172 (1-2), 68-80 e12.</p><p>5. Zhang, Y.; Sun, B.; Feng, D.; Hu, H.; Chu, M.; Qu, Q.; Tarrasch, J. T.; Li, S.; Sun Kobilka, T.; Kobilka, B. K.; Skiniotis, G., Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 2017, 546 (7657), 248-253.</p><p>6. Jazayeri, A.; Rappas, M.; Brown, A. J. H.; Kean, J.; Errey, J. C.; Robertson, N. J.; Fiez-Vandal, C.; Andrews, S. P.; Congreve, M.; Bortolato, A.; Mason, J. S.; Baig, A. H.; Teobald, I.; Dore, A. S.; Weir, M.; Cooke, R. M.; Marshall, F. H., Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 2017, 546 (7657), 254-258.</p><p>7. Liang, Y. L.; Khoshouei, M.; Radjainia, M.; Zhang, Y.; Glukhova, A.; Tarrasch, J.; Thal, D. M.; Furness, S. G. B.; Christopoulos, G.; Coudrat, T.; Danev, R.; Baumeister, W.; Miller, L. J.; Christopoulos, A.; Kobilka, B. K.; Wootten, D.; Skiniotis, G.; Sexton, P. M., Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 2017, 546 (7656), 118-123.</p><p>8. Liang, Y. L.; Khoshouei, M.; Deganutti, G.; Glukhova, A.; Koole, C.; Peat, T. S.; Radjainia, M.; Plitzko, J. M.; Baumeister, W.; Miller, L. J.; Hay, D. L.; Christopoulos, A.; Reynolds, C. A.; Wootten, D.; Sexton, P. M., Cryo-EM structure of the active, G(s)- protein complexed, human CGRP receptor. Nature 2018, 561 (7724), 492-+.</p><p>9. Zhao, L. H.; Ma, S.; Sutkeviciute, I.; Shen, D. D.; Zhou, X. E.; de Waal, P. W.; Li, C. Y.; Kang, Y.; Clark, L. J.; Jean-Alphonse, F. G.; White, A. D.; Yang, D.; Dai, A.; Cai, X.; Chen, J.; Li, C.; Jiang, Y.; Watanabe, T.; Gardella, T. J.; Melcher, K.; Wang, M. W.; Vilardaga, J. P.; Xu, H. E.; Zhang, Y., Structure and dynamics of the active human parathyroid hormone receptor-1. Science 2019, 364 (6436), 148-153.</p><p>10. Isogai, S.; Deupi, X.; Opitz, C.; Heydenreich, F. M.; Tsai, C. J.; Brueckner, F.; Schertler, G. F.; Veprintsev, D. B.; Grzesiek, S., Backbone NMR reveals allosteric signal transduction networks in the beta1-adrenergic receptor. Nature 2016, 530 (7589), 237-41.</p></body></sub-article></article>